



L4 ANSWER 42 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1987:459057 CAPLUS
 DN 107:59057
 TI Diphenyloxadiazinones as miticides and nematocides
 IN Dekeyser, Mark A.; Mishra, Anupama; Moore, Richard C.
 PA Uniroyal Chemical Co., Inc., USA
 SO Fr. Demande, 39 pp.
 CODEN: FRXXBL
 DT Patent
 LA French
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2580643	A1	19861024	FR 1986-5639	19860418
	US 4670555	A	19870602	US 1985-725029	19850419
	US 4782066	A	19881101	US 1987-18252	19870224
PRAI	US 1985-725029		19850419		
OS	CASREACT 107:59057				
GI					




AB The title compds. [I; R1, R2 = H, alkyl, halo, etc.; R3, R4 = H, halo, alkyl, alkoxy, arylsulfonyl, alkylsulfonyl, etc.], useful as miticides and nematocides, are prep'd. p-MeC₆H₄COCl was added to a soln. of p-H₂NNHC₆H₄Me.HCl in pyridine and the resulting mixt. stirred at ambient temp. for 3 h to give p-MeC₆H₄NHNHCOC₆H₄Me-p. This was refluxed with ClCH₂COCl in MeCOEt for 4 h, the reaction mixt. cooled to ambient temp., K₂CO₃ added, and the resulting mixt. refluxed for 4 h to give I (R1 = R3 = H, R2 = R4 = p-Me) (II). II at 1000 ppm showed 100% control of mites.
 IT 109462-69-3P 109462-75-1P 109462-76-2P
 109462-77-3P 109462-78-4P 109462-93-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as miticide and nematocide)
 RN 109462-69-3 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-chlorophenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-75-1 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-iodophenyl)-4-phenyl- (9CI) (CA
INDEX
NAME)




RN 109462-76-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-methylphenyl)-4-phenyl- (9CI) (CA
INDEX NAME)




RN 109462-77-3 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3-methylphenyl)-4-phenyl- (9CI) (CA
INDEX NAME)



RN 109462-78-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-phenyl- (9CI) (CA
INDEX NAME)




RN 109462-93-3 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methoxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)




IT 109462-65-9P 109462-66-0P 109462-67-1P
 109462-68-2P 109462-69-3P 109462-70-6P
 109462-71-7P 109462-72-8P 109462-73-9P
 109462-74-0P 109462-75-1P 109462-76-2P
 109462-77-3P 109462-78-4P 109462-79-5P
 109462-80-8P 109462-81-9P 109462-82-0P
 109462-83-1P 109462-84-2P 109462-85-3P
 109462-86-4P 109462-87-5P 109462-88-6P
 109462-89-7P 109462-90-0P 109462-91-1P
 109462-92-2P 109462-93-3P 109462-94-4P
 109462-95-5P 109462-96-6P 109462-97-7P
 109462-98-8P 109462-99-9P 109463-00-5P
 109463-01-6P 109463-02-7P 109463-03-8P
 109463-04-9P 109463-05-0P 109463-06-1P
 109463-07-2P 109463-08-3P 109463-09-4P
 109463-10-7P 109463-11-8P 109463-12-9P
 109463-13-0P 109463-14-1P 109463-15-2P
 109463-16-3P 109463-17-4P 109463-18-5P
 109463-19-6P 109463-20-9P 109463-21-0P
 109463-22-1P 109463-23-2P 109463-24-3P
 109491-75-0P 109491-76-1P 109491-77-2P
 109491-78-3P 109491-79-4P 109491-80-7P
 109491-81-8P 109491-82-9P 109491-83-0P
 109491-84-1P 109491-85-2P 109491-86-3P
 109491-87-4P 109491-88-5P 109491-89-6P
 109491-90-9P 109491-91-0P 109491-92-1P
 109491-93-2P 109491-94-3P 109491-95-4P
 109491-96-5P 109491-97-6P 109491-98-7P
 109491-99-8P 109492-00-4P 109492-01-5P
 109492-02-6P 109492-03-7P 109492-04-8P
 109492-05-9P 109492-06-0P 109492-07-1P
 109525-24-8P 109551-08-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as nematocide and miticide)


RN 109462-65-9 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2,4-diphenyl- (9CI) (CA INDEX NAME)




RN 109462-66-0 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-fluorophenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-67-1 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3-fluorophenyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 109462-68-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-fluorophenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-69-3 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-chlorophenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-70-6 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3-chlorophenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-71-7 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-chlorophenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-72-8 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-bromophenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-73-9 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-iodophenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-74-0 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3-iodophenyl)-4-phenyl- (9CI) (CA
INDEX
NAME)




RN 109462-75-1 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-iodophenyl)-4-phenyl- (9CI) (CA
INDEX
NAME)




RN 109462-76-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-methylphenyl)-4-phenyl- (9CI) (CA
INDEX NAME)




RN 109462-77-3 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3-methylphenyl)-4-phenyl- (9CI) (CA
INDEX NAME)




RN 109462-78-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-79-5 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-ethylphenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-80-8 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-butylphenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-81-9 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[4-(1,1-dimethylethyl)phenyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-82-0 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[2-(phenylmethyl)phenyl]- (9CI)
(CA INDEX NAME)




RN 109462-83-1 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[3-(phenylmethyl)phenyl]- (9CI)
(CA INDEX NAME)



RN 109462-84-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[4-(phenylmethyl)phenyl]- (9CI)
(CA INDEX NAME)




RN 109462-85-3 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 109462-86-4 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[3-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)




RN 109462-87-5 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[4-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)




RN 109462-88-6 CAPLUS

CN Benzoic acid, 2-(5,6-dihydro-5-oxo-4-phenyl-4H-1,3,4-oxadiazin-2-yl)-, propyl ester (9CI) (CA INDEX NAME)




RN 109462-89-7 CAPLUS

CN Benzoic acid, 2-(5,6-dihydro-5-oxo-4-phenyl-4H-1,3,4-oxadiazin-2-yl)-, phenyl ester (9CI) (CA INDEX NAME)



RN 109462-90-0 CAPLUS


CN Benzoic acid, 2-(5,6-dihydro-5-oxo-4-phenyl-4H-1,3,4-oxadiazin-2-yl)-, sodium salt (9CI) (CA INDEX NAME)



● Na


RN 109462-91-1 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-methoxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-92-2 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3-methoxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-93-3 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methoxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-94-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-ethoxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-95-5 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-ethoxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-96-6 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-butoxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-97-7 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[3-(pentyloxy)phenyl]-4-phenyl- (9CI)
(CA INDEX NAME)




RN 109462-98-8 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[2-(phenylmethoxy)phenyl]- (9CI)
 (CA INDEX NAME)




RN 109462-99-9 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[4-(methylthio)phenyl]-4-phenyl- (9CI)
 (CA INDEX NAME)




RN 109463-00-5 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[4-(ethylthio)phenyl]-4-phenyl- (9CI)
 (CA INDEX NAME)




RN 109463-01-6 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[3-(phenylthio)phenyl]- (9CI)
 (CA INDEX NAME)




RN 109463-02-7 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[4-(methylsulfinyl)phenyl]-4-phenyl-
(9CI)
(CA INDEX NAME)




RN 109463-03-8 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3,4-dichlorophenyl)-4-phenyl- (9CI)
(CA
INDEX NAME)




RN 109463-04-9 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2,6-dichlorophenyl)-4-phenyl- (9CI)
(CA
INDEX NAME)




RN 109463-05-0 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3,5-dichlorophenyl)-4-phenyl- (9CI)
(CA
INDEX NAME)




RN 109463-06-1 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3-fluoro-4-methylphenyl)-4-phenyl-
(9CI)
(CA INDEX NAME)




RN 109463-07-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3,4-dimethylphenyl)-4-phenyl- (9CI)
(CA
INDEX NAME)



RN 109463-08-3 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3,5-dimethylphenyl)-4-phenyl- (9CI)
(CA
INDEX NAME)



RN 109463-09-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3,4-dimethoxyphenyl)-4-phenyl- (9CI)
(CA
INDEX NAME)




RN 109463-10-7 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3,5-dimethoxyphenyl)-4-phenyl- (9CI)

(CA

INDEX NAME)




RN 109463-11-8 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methoxy-3-methylphenyl)-4-phenyl-


(9CI)

(CA INDEX NAME)



RN 109463-12-9 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-methylphenyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 109463-13-0 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-fluorophenyl)-4-(4-methylphenyl)- (9CI)


(CA INDEX NAME)




RN 109463-14-1 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-chlorophenyl)-4-(4-methylphenyl)-
(9CI)
(CA INDEX NAME)




RN 109463-15-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-iodophenyl)-4-(4-methylphenyl)- (9CI)
(CA INDEX NAME)




RN 109463-16-3 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methoxyphenyl)-4-(4-methylphenyl)-
(9CI) (CA INDEX NAME)



RN 109463-17-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-butoxyphenyl)-4-(4-methylphenyl)-
(9CI)
(CA INDEX NAME)




RN 109463-18-5 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[4-(ethylthio)phenyl]-4-(4-
methylphenyl)-
(9CI) (CA INDEX NAME)



RN 109463-19-6 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2,4-bis(4-methylphenyl)- (9CI) (CA INDEX


NAME)



RN 109463-20-9 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-ethylphenyl)-4-(4-methylphenyl)-(9CI)

(CA INDEX NAME)




RN 109463-21-0 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3,4-dichlorophenyl)-4-(4-methylphenyl)-(9CI) (CA INDEX NAME)



RN 109463-22-1 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3,4-dimethylphenyl)-4-(4-methylphenyl)-(9CI) (CA INDEX NAME)



RN 109463-23-2 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-methylphenyl)-2-(4-methylphenyl)-(9CI)


(CA INDEX NAME)



RN 109463-24-3 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-[2-

(phenylmethyl)phenyl] - (9CI) (CA INDEX NAME)




RN 109491-75-0 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3,4-dimethylphenyl)-2-(4-methylphenyl)-(9CI) (CA INDEX NAME)




RN 109491-76-1 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-methoxyphenyl)-2-(4-methylphenyl)-(9CI) (CA INDEX NAME)




RN 109491-77-2 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-methoxyphenyl)-2-(4-methylphenyl)-(9CI) (CA INDEX NAME)




RN 109491-78-3 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-bromophenyl)-2-(4-methylphenyl)-(9CI) (CA INDEX NAME)




RN 109491-79-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-fluorophenyl)-2-(4-methylphenyl)-
(9CI)
(CA INDEX NAME)




RN 109491-80-7 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-fluorophenyl)-2-(4-methylphenyl)-
(9CI)
(CA INDEX NAME)




RN 109491-81-8 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-bromophenyl)-2-(4-methylphenyl)-
(9CI)
(CA INDEX NAME)



RN 109491-82-9 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2,5-dichlorophenyl)-2-(4-methylphenyl)-
(9CI) (CA INDEX NAME)




RN 109491-83-0 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2,6-dichlorophenyl)-2-(4-methylphenyl)-
(9CI) (CA INDEX NAME)




RN 109491-84-1 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3,4-dichlorophenyl)-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 109491-85-2 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-chloro-4-methylphenyl)-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 109491-86-3 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-[2-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 109491-87-4 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[1,1'-biphenyl]-2-yl-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 109491-88-5 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-[4-


(methylsulfonyl)phenyl] - (9CI) (CA INDEX NAME)



RN 109491-89-6 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-ethylphenyl)-2-(4-methylphenyl)-(9CI)


(CA INDEX NAME)



RN 109491-90-9 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[4-(dimethylamino)phenyl]-4-phenyl-(9CI)


(CA INDEX NAME)



RN 109491-91-0 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[3-(diethylamino)phenyl]-4-phenyl- (9CI)


(CA INDEX NAME)




RN 109491-92-1 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[4-(diethylamino)phenyl]-4-phenyl- (9CI)


(CA INDEX NAME)




RN 109491-93-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-aminophenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109491-94-3 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3,4-dichlorophenyl)-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 109491-95-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3,4-dichlorophenyl)-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 109491-96-5 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-chloro-4-methylphenyl)-2-(3,4-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 109491-97-6 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 109491-98-7 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-butoxyphenyl)-4-(3-chloro-4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 109491-99-8 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-aminophenyl)-2-(4-methylphenyl)- (9CI)
(CA INDEX NAME)




RN 109492-00-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-aminophenyl)-2-(4-methylphenyl)- (9CI)
(CA INDEX NAME)




RN 109492-01-5 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-methoxyphenyl)-2-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 109492-02-6 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2,4-bis(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 109492-03-7 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-methylphenyl)-2-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 109492-04-8 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-chloro-4-methylphenyl)-2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 109492-05-9 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3-methoxyphenyl)-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 109492-06-0 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2,4-bis(4-bromophenyl)- (9CI) (CA INDEX NAME)



RN 109492-07-1 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2,4-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 109525-24-8 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-fluorophenyl)-2-(4-methylphenyl)- (9CI)

(CA INDEX NAME)




RN 109551-08-8 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 58 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1970:445478 CAPLUS
 DN 73:45478
 TI Pyrimidine derivatives and related compounds. LXVI. Reactions of dialkyl acylphosphonates with 1,3,4-thiadiazolium derivatives
 AU Takamizawa, Akira; Sato, Hisao
 CS Shionogi Res. Lab., Shionogi and Co., Ltd., Osaka, Japan
 SO Chem. Pharm. Bull. (1970), 18(6), 1201-10
 CODEN: CPBTAL
 DT Journal
 LA English
 AB The novel reaction of 1,3,4-thiadiazolium halides with dialkyl acylphosphonates in the presence of Et₃N to give 1,3,4-thiadiazine derivs., accompanied by ring expansion, was described. In some of the reactions, 10a-(1-dialkylphosphoroyl)benzyl (or -ethyl)-10,10a-dihydro-5H-pyrimido[4,5-d]-1,3,4-thiadiazolo[3,2-a]pyrimidines were isolated as the intermediates. Neutral and alk. hydrolysis of these are described.
 IT 25626-39-5P 25626-41-9P 26734-74-7P
 26734-75-8P 26734-76-9P 26734-77-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 25626-39-5 CAPLUS
 CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-2,6-diphenyl- (8CI) (CA INDEX NAME)



RN 25626-41-9 CAPLUS
 CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-6-methyl-2-phenyl- (8CI) (CA INDEX NAME)




RN 26734-74-7 CAPLUS
 CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-methyl-2,6-diphenyl- (8CI, 9CI) (CA INDEX NAME)




RN 26734-75-8 CAPLUS

CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4,6-dimethyl-2-phenyl- (8CI) (CA INDEX NAME)




RN 26734-76-9 CAPLUS

CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-benzyl-2,6-diphenyl- (8CI) (CA INDEX NAME)



RN 26734-77-0 CAPLUS

CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-benzyl-6-methyl-2-phenyl- (8CI) (CA INDEX NAME)



L4 ANSWER 49 OF 61 CAPLUS COPYRIGHT 2002 ACS

10 ~

AN 1978:563556 CAPLUS

DN 89:163556

TI 6-Substituted 2,4-diphenyl-1,3,4-oxadiazin-5-ones

AU Westphal, Guenter; Mueller, Thomas

CS Sekt. Chem., Humboldt-Univ., Berlin, E. Ger.


SO J. Prakt. Chem. (1978), 320(3), 452-6

CODEN: JPCEAO; ISSN: 0021-8383

DT Journal

LA German

GI




AB The oxadiazinone I (R = Cl) was obtained in 46.3% yield by treating Cl₂CHCOCl with PhNNHBz and cyclizing Cl₂CHCONPhNHBz with base. I (R = Cl) was aminated to give I (R = phthalimido, succinimido). I (R = NHCH₂Ph, NNH₂) were obtained by treating I (R = phthalimido) with the appropriate amines.

IT 67947-71-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and amination of)

RN 67947-71-1 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 6-chloro-2,4-diphenyl- (9CI) (CA INDEX NAME)




IT 67947-72-2P 67947-73-3P 67947-74-4P

67947-75-5P 67947-76-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 67947-72-2 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-(5,6-dihydro-5-oxo-2,4-diphenyl-4H-1,3,4-oxadiazin-6-yl)- (9CI) (CA INDEX NAME)




RN 67947-73-3 CAPLUS


CN 2,5-Pyrrolidinedione, 1-(5,6-dihydro-5-oxo-2,4-diphenyl-4H-1,3,4-oxadiazin-6-yl)- (9CI) (CA INDEX NAME)



RN 67947-74-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2,4-diphenyl-6-[(phenylmethyl)amino]-
(9CI)
(CA INDEX NAME)




RN 67947-75-5 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2,4-diphenyl-6-[(phenylmethyl)amino]-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 67947-76-6 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 6-hydrazino-2,4-diphenyl- (9CI) (CA INDEX
NAME)




L4 ANSWER 51 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1976:494324 CAPLUS
 DN 85:94324
 TI Competing cycloadditions in the reaction of acetylazobenzene with diphenylketene
 AU Sommer, Sven
 CS Org.-Chem. Inst., Tech. Univ. Muenchen, Munich, Ger.
 SO Angew. Chem. (1976), 88(13), 449
 CODEN: ANCEAD
 DT Journal
 LA German
 GI




AB Reaction of Ph₂C:CO with PhN:NAc gave the diazetidinones I and II by [2+2]-cycloaddn., the oxadiazine III by [4+2]-cycloaddn., and the cinnoline IV by [4+2]-cycloaddn. followed by 1,3-H shift, the ratio of the product being 60:26:10:4.


IT 59231-02-6P
 RL: PREP (Preparation)
 (by cycloaddn. of diphenylketene with acetylazobenzene)
 RN 59231-02-6 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-methyl-4,6,6-triphenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 55 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1974:552058 CAPLUS
 DN 81:152058
 TI New compounds. 4-Substituted 5,6-dihydro-2-o-hydroxyphenyl-4H-1,3,4-oxadiazine-5-ones, potential psychopharmacological drugs
 AU Sicardi, Susana M.; Lamdan, Samuel; Gaozza, Carlos H.
 CS Fac. Farm. Bioquim., Univ. Buenos Aires, Buenos Aires, Argent.
 SO J. Pharm. Sci. (1974), 63(8), 1336-7
 CODEN: JPMSAE
 DT Journal
 LA English
 GI For diagram(s), see printed CA Issue.
 AB 1,3,4-Oxadiazines I ($n = 2, 3$, R = H, Cl, pyrrolidino, piperidino, morpholino; $n = 2$, R = NMe₂, NEt₂, OPh, OC₆-H₄Cl-p, OC₆H₄Me-p; $n = 1$, R = Ph) were prep'd. by 4-alkylation and reaction with a secondary amine.
 IT **53995-34-9P 53995-35-0P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and reaction of, with amines)
 RN 53995-34-9 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-chloroethyl)-2-(2-hydroxyphenyl)-(9CI) (CA INDEX NAME)




RN 53995-35-0 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-chloropropyl)-2-(2-hydroxyphenyl)-(9CI) (CA INDEX NAME)




IT **53995-32-7P 53995-33-8P 53995-36-1P**
53995-37-2P 53995-38-3P 53995-39-4P
53995-40-7P 53995-41-8P 53995-42-9P
53995-43-0P 53995-44-1P 53995-45-2P
53995-46-3P 53995-47-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 53995-32-7 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-ethyl-2-(2-hydroxyphenyl)-(9CI) (CA INDEX NAME)




RN 53995-33-8 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)




RN 53995-36-1 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 53995-37-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)




RN 53995-38-3 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[2-(4-chlorophenoxy)ethyl]-2-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 53995-39-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[2-(4-methylphenoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 53995-40-7 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[2-(dimethylamino)ethyl]-2-(2-hydroxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 53995-41-8 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[2-(diethylamino)ethyl]-2-(2-hydroxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 53995-42-9 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 53995-43-0 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[2-(1-piperidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 53995-44-1 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[2-(4-morpholinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 53995-45-2 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[3-(1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 53995-46-3 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[3-(1-piperidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 53995-47-4 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[3-(4-morpholinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


L4 ANSWER 57 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1970:477209 CAPLUS
 DN 73:77209
 TI Intramolecular cyclization of N'-chloroacetyl salicylhydrazide
 AU Gaozza, Carlos H.; Lamdan, Samuel
 CS Fac. Farm. Bioquim., Univ. Buenos Aires, Buenos Aires, Argent.
 SO J. Heterocycl. Chem. (1970), 7(4), 927-30 CODEN: JHTCAD
 DT Journal
 LA English
 AB Treatment of N'-chloroacetyl salicylhydrazide with NaOH in DMF gives an intramol. cyclization to give 5,6-dihydro-2-(.omicron.-hydroxyphenyl)-4H-1,3,4-oxadiazin-5-one. No 1,4,5-benzoxadiazocin-3,6-dione is detected.
 IT 28669-15-0P 28669-16-1P 28669-23-0P 28669-25-2P
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)
 RN 28669-15-0 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 28669-16-1 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(hydroxymethyl)-2-(o-hydroxyphenyl)- (8CI) (CA INDEX NAME)




RN 28669-23-0 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(o-hydroxyphenyl)-4-methyl-, acetate (ester) (8CI) (CA INDEX NAME)



RN 28669-25-2 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(o-hydroxyphenyl)-4-methyl- (8CI) (CA INDEX NAME)




L4 ANSWER 48 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1979:168552 CAPLUS
 DN 90:168552
 TI Synthesis and structure of dihydro-1,2,4-triazin-6(1H)-ones
 AU Camparini, Alfredo; Celli, Angela Maria; Ponticelli, Fabio; Tedeschi, Piero
 CS Ist. Chim. Org., Univ. Siena, Siena, Italy
 SO J. Heterocycl. Chem. (1978), 15(8), 1271-6
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 GI




AB Reactions of the imino esters (I; R, R1 = Ph, Ph; Ph, Me; Me, Ph) with hydrazine or (NHMe)2 gave 4,5-dihydro-II (R2 = H) or 2,5-dihydro-1,2,4-triazin-6(1H)-ones III (R2 = R3 = Me), resp. When NH2NHMe was employed, 1-methyl-4,5-dihydro-II (R2 = Me) and 2-methyl-2,5-dihydro-1,2,4-triazin-6(1H)-ones III (R2 = Me, R3 = H) (IV) were obtained. IV exist as zwitterions in the solid state and in polar aprotic solvents.

IT 60206-70-4P 60206-72-6P 60206-74-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and oxidn. of)


RN 60206-70-4 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1-methyl-3,5-diphenyl- (9CI) (CA INDEX NAME)




RN 60206-72-6 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1,5-dimethyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 60206-74-8 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1,3-dimethyl-5-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 58 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1970:445478 CAPLUS
 DN 73:45478
 TI Pyrimidine derivatives and related compounds. LXVI. Reactions of dialkyl acylphosphonates with 1,3,4-thiadiazolium derivatives
 AU Takamizawa, Akira; Sato, Hisao
 CS Shionogi Res. Lab., Shionogi and Co., Ltd., Osaka, Japan
 SO Chem. Pharm. Bull. (1970), 18(6), 1201-10
 CODEN: CPBTAL
 DT Journal
 LA English
 AB The novel reaction of 1,3,4-thiadiazolium halides with dialkyl acylphosphonates in the presence of Et₃N to give 1,3,4-thiadiazine derivs., accompanied by ring expansion, was described. In some of the reactions, 10a-(1-dialkylphosphoroyl)benzyl (or -ethyl)-10,10a-dihydro-5H-pyrimido[4,5-d]-1,3,4-thiadiazolo[3,2-a]pyrimidines were isolated as the intermediates. Neutral and alk. hydrolysis of these are described.
 IT 25626-39-5P 25626-41-9P 26734-74-7P
 26734-75-8P 26734-76-9P 26734-77-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 25626-39-5 CAPLUS
 CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-2,6-diphenyl- (8CI) (CA INDEX NAME)




RN 25626-41-9 CAPLUS
 CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-6-methyl-2-phenyl- (8CI) (CA INDEX NAME)




RN 26734-74-7 CAPLUS
 CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-methyl-2,6-diphenyl- (8CI, 9CI) (CA INDEX NAME)




RN 26734-75-8 CAPLUS
CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4,6-dimethyl-2-phenyl- (8CI) (CA INDEX NAME)



RN 26734-76-9 CAPLUS
CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-benzyl-2,6-diphenyl- (8CI) (CA INDEX NAME)




RN 26734-77-0 CAPLUS
CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-benzyl-6-methyl-2-phenyl- (8CI) (CA INDEX NAME)




L4 ANSWER 55 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1974:552058 CAPLUS
 DN 81:152058
 TI New compounds. 4-Substituted 5,6-dihydro-2-o-hydroxyphenyl-4H-1,3,4-oxadiazine-5-ones, potential psychopharmacological drugs
 AU Sicardi, Susana M.; Lamdan, Samuel; Gaozza, Carlos H.
 CS Fac. Farm. Bioquim., Univ. Buenos Aires, Buenos Aires, Argent.
 SO J. Pharm. Sci. (1974), 63(8), 1336-7
 CODEN: JPMSAE
 DT Journal
 LA English
 GI For diagram(s), see printed CA Issue.
 AB 1,3,4-Oxadiazines I ($n = 2, 3$, R = H, Cl, pyrrolidino, piperidino, morpholino; $n = 2$, R = NMe₂, NET₂, OPh, OC₆-H₄Cl-p, OC₆H₄Me-p; $n = 1$, R = Ph) were prep'd. by 4-alkylation and reaction with a secondary amine.
 IT **53995-34-9P 53995-35-0P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and reaction of, with amines)

RN 53995-34-9 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-chloroethyl)-2-(2-hydroxyphenyl)-(9CI) (CA INDEX NAME)




RN 53995-35-0 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-chloropropyl)-2-(2-hydroxyphenyl)-(9CI) (CA INDEX NAME)



IT **53995-32-7P 53995-33-8P 53995-36-1P**
53995-37-2P 53995-38-3P 53995-39-4P
53995-40-7P 53995-41-8P 53995-42-9P
53995-43-0P 53995-44-1P 53995-45-2P
53995-46-3P 53995-47-4P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)

RN 53995-32-7 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-ethyl-2-(2-hydroxyphenyl)-(9CI) (CA INDEX NAME)



RN 53995-40-7 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[2-(dimethylamino)ethyl]-2-(2-hydroxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 53995-41-8 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[2-(diethylamino)ethyl]-2-(2-hydroxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 53995-42-9 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 53995-43-0 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[2-(1-piperidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 53995-44-1 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[2-(4-morpholinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 53995-45-2 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[3-(1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 53995-46-3 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[3-(1-piperidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 53995-47-4 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[3-(4-morpholinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


L4 ANSWER 57 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1970:477209 CAPLUS
 DN 73:77209
 TI Intramolecular cyclization of N'-chloroacetylsalicylhydrazide
 AU Gaozza, Carlos H.; Lamdan, Samuel
 CS Fac. Farm. Bioquim., Univ. Buenos Aires, Buenos Aires, Argent.
 SO J. Heterocycl. Chem. (1970), 7(4), 927-30 CODEN: JHTCAD
 DT Journal
 LA English
 AB Treatment of N'-chloroacetylsalicylhydrazide with NaOH in DMF gives an intramol. cyclization to give 5,6-dihydro-2-(.omicron.-hydroxyphenyl)-4H-1,3,4-oxadiazin-5-one. No 1,4,5-benzoxadiazocin-3,6-dione is detected.
 IT 28669-15-0P 28669-16-1P 28669-23-0P 28669-25-2P
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)
 RN 28669-15-0 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-phenyl- (8CI) (CA INDEX NAME)




RN 28669-16-1 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(hydroxymethyl)-2-(o-hydroxyphenyl)- (8CI) (CA INDEX NAME)



RN 28669-23-0 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(o-hydroxyphenyl)-4-methyl-, acetate (ester) (8CI) (CA INDEX NAME)



RN 28669-25-2 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(o-hydroxyphenyl)-4-methyl- (8CI) (CA INDEX NAME)



L4 ANSWER 49 OF 61 CAPLUS COPYRIGHT 2002 ACS

AN 1978:563556 CAPLUS

DN 89:163556

TI 6-Substituted 2,4-diphenyl-1,3,4-oxadiazin-5-ones

AU Westphal, Guenter; Mueller, Thomas

CS Sekt. Chem., Humboldt-Univ., Berlin, E. Ger.


SO J. Prakt. Chem. (1978), 320(3), 452-6

CODEN: JPCEAO; ISSN: 0021-8383

DT Journal

LA German

GI



I


AB The oxadiazinone I (R = Cl) was obtained in 46.3% yield by treating Cl₂CHCOCl with PhHNHBz and cyclizing Cl₂CHCONPhNHBz with base. I (R = Cl) was aminated to give I (R = phthalimido, succinimido). I (R = NHCH₂Ph, NHNH₂) were obtained by treating I (R = phthalimido) with the appropriate amines.

IT 67947-71-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and amination of)

RN 67947-71-1 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 6-chloro-2,4-diphenyl- (9CI) (CA INDEX NAME)




IT 67947-72-2P 67947-73-3P 67947-74-4P

67947-75-5P 67947-76-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 67947-72-2 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-(5,6-dihydro-5-oxo-2,4-diphenyl-4H-1,3,4-oxadiazin-6-yl)- (9CI) (CA INDEX NAME)




RN 67947-73-3 CAPLUS


CN 2,5-Pyrrolidinedione, 1-(5,6-dihydro-5-oxo-2,4-diphenyl-4H-1,3,4-oxadiazin-

6-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1976:494324 CAPLUS
 DN 85:94324
 TI Competing cycloadditions in the reaction of acetylazobenzene with diphenylketene
 AU Sommer, Sven
 CS Org.-Chem. Inst., Tech. Univ. Muenchen, Munich, Ger.
 SO Angew. Chem. (1976), 88(13), 449
 CODEN: ANCEAD
 DT Journal
 LA German
 GI



AB Reaction of Ph₂C:CO with PhN:NAc gave the diazetidinones I and II by [2+2]-cycloaddn., the oxadiazine III by [4+2]-cycloaddn., and the cinnoline IV by [4+2]-cycloaddn. followed by 1,3-H shift, the ratio of the product being 60:26:10:4.
 IT 59231-02-6P
 RL: PREP (Preparation)
 (by cycloaddn. of diphenylketene with acetylazobenzene)
 RN 59231-02-6 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-methyl-4,6,6-triphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 48 OF 61 CAPLUS COPYRIGHT 2002 ACS

AN 1979:168552 CAPLUS

DN 90:168552

TI Synthesis and structure of dihydro-1,2,4-triazin-6(1H)-ones

AU Camparini, Alfredo; Celli, Angela Maria; Ponticelli, Fabio; Tedeschi, Piero

CS Ist. Chim. Org., Univ. Siena, Siena, Italy




SO J. Heterocycl. Chem. (1978), 15(8), 1271-6

CODEN: JHTCAD; ISSN: 0022-152X

DT Journal

LA English

GI




AB Reactions of the imino esters (I; R, R₁ = Ph, Ph; Ph, Me; Me, Ph) with hydrazine or (NHMe)₂ gave 4,5-dihydro-II (R₂ = H) or 2,5-dihydro-1,2,4-triazin-6(1H)-ones III (R₂ = R₃ = Me), resp. When NH₂NHMe was employed, 1-methyl-4,5-dihydro-II (R₂ = Me) and 2-methyl-2,5-dihydro-1,2,4-triazin-6(1H)-ones III (R₂ = Me, R₃ = H) (IV) were obtained. IV exist as zwitterions in the solid state and in polar aprotic solvents.

IT 60206-70-4P 60206-72-6P 60206-74-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and oxidn. of)


RN 60206-70-4 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1-methyl-3,5-diphenyl- (9CI) (CA INDEX NAME)




RN 60206-72-6 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1,5-dimethyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 60206-74-8 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1,3-dimethyl-5-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 43 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1984:551816 CAPLUS
 DN 101:151816
 TI 2-[Hydroxy(dialkyl)methyl]-4-aryl-6,6-disubstituted 4,5-dihydro-6H-
 1,3,4-oxadiazin-5-ones
 AU Glushkov, V. A.; Berdinskii, I. S.
 CS Perm. Gos. Univ., Perm, 614600, USSR
 SO Khim. Geterotsikl. Soedin. (1984), (7), 896-7
 CODEN: KGSSAQ; ISSN: 0453-8234
 DT Journal
 LA Russian
 GI




I


AB The title compds. I ($R_1 = H, 3\text{-Me}, 4\text{-Me}, 4\text{-F}, 4\text{-Cl}, 4\text{-Br}, 4\text{-MeO}$, $R_2 = Et, Pr, Bu, \text{isopentyl, C}_7H_{15}$, $R_3 = Ph, Me, H$) were prepd. in 31-80% yields by cyclocondensation of $RC_6H_4NHNHCOC(OH)R_22$ with $R_3^2CXCOC_1$ ($X = Cl, Br$).
 IT 92176-03-9P 92176-04-0P 92176-05-1P
 92176-06-2P 92176-07-3P 92176-08-4P
 92176-09-5P 92176-10-8P 92176-11-9P
 92176-12-0P 92176-13-1P 92176-14-2P
92176-15-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prep. of)
 RN 92176-03-9 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(1-ethyl-1-hydroxypropyl)-4,6,6-triphenyl-
 (9CI) (CA INDEX NAME)




RN 92176-04-0 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(1-hydroxy-1-propylbutyl)-4,6,6-triphenyl-
 (9CI) (CA INDEX NAME)




RN 92176-05-1 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(1-butyl-1-hydroxypentyl)-4,6,6-triphenyl- (9CI) (CA INDEX NAME)




RN 92176-06-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[1-hydroxy-4-methyl-1-(3-methylbutyl)pentyl]-4,6,6-triphenyl- (9CI) (CA INDEX NAME)



RN 92176-07-3 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(1-heptyl-1-hydroxyoctyl)-4,6,6-triphenyl- (9CI) (CA INDEX NAME)




RN 92176-08-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(1-butyl-1-hydroxypentyl)-4-(3-methylphenyl)-6,6-diphenyl- (9CI) (CA INDEX NAME)




RN 92176-09-5 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(1-butyl-1-hydroxypentyl)-4-(4-methylphenyl)-6,6-diphenyl- (9CI) (CA INDEX NAME)




RN 92176-10-8 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(1-butyl-1-hydroxypentyl)-4-(4-fluorophenyl)-6,6-diphenyl- (9CI) (CA INDEX NAME)




RN 92176-11-9 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(1-butyl-1-hydroxypentyl)-4-(4-chlorophenyl)-6,6-diphenyl- (9CI) (CA INDEX NAME)




RN 92176-12-0 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-bromophenyl)-2-(1-butyl-1-hydroxypentyl)-6,6-diphenyl- (9CI) (CA INDEX NAME)




RN 92176-13-1 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(1-butyl-1-hydroxypentyl)-4-(4-methoxyphenyl)-6,6-diphenyl- (9CI) (CA INDEX NAME)




RN 92176-14-2 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(1-butyl-1-hydroxypentyl)-6,6-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 92176-15-3 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(1-butyl-1-hydroxypentyl)-4-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 44 OF 61 CAPLUS COPYRIGHT 2002 ACS

AN 1982:406264 CAPLUS

DN 97:6264

TI Synthesis and reactions of 1,3-diphenyl-as-triazin-6-one

AU Badr, M. Z. A.; Aly, M. M.; Khalil, Z. H.; Attalla, A. A.

CS Fac. Sci., Assiut Univ., Assiut, Egypt

SO Indian J. Chem., Sect. B (1982), 21B(2), 115-19


CODEN: IJSBDB; ISSN: 0376-4699

DT Journal

LA English

OS CASREACT 97:6264

GI




AB 1,3-Diphenyl-as-triazin-6-one was prep'd. by condensing hippuric acid
with PhNNH₂. Condensing this triazinone with arom. aldehydes or ketones
gave 5-arylidene-as-triazinones, which reacted as .alpha.,.beta.-unsatd.
carbonyl compds. to give tetrahydropyrazolo[4,3-e]-as-triazines, e.g. I
(X = NPh), with hydrazines, oxopentaazaspiro[4,5]-1,8-decadienes, e.g. II,
with diazoalkanes, tetrahydroisooxazolo[4,3-e]-as-triazines, e.g. I (X = O)
with HONH₂ and aminothiatetraazaspiro[4,5]-2,8-decadienes, e.g. III,
with thiourea.

IT 82059-55-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and condensation with arom. aldehydes and ketones)

RN 82059-55-0 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1,3-diphenyl- (9CI) (CA INDEX
NAME)



L4 ANSWER 44 OF 61 CAPLUS COPYRIGHT 2002 ACS

AN 1982:406264 CAPLUS

DN 97:6264

TI Synthesis and reactions of 1,3-diphenyl-as-triazin-6-one

AU Badr, M. Z. A.; Aly, M. M.; Khalil, Z. H.; Attalla, A. A.

CS Fac. Sci., Assiut Univ., Assiut, Egypt

SO Indian J. Chem., Sect. B (1982), 21B(2), 115-19


CODEN: IJSBDB; ISSN: 0376-4699

DT Journal

LA English

OS CASREACT 97:6264

GI




AB 1,3-Diphenyl-as-triazin-6-one was prep'd. by condensing hippuric acid
with PhNNHNH₂. Condensing this triazinone with arom. aldehydes or ketones
gave 5-arylidene-as-triazinones, which reacted as .alpha.,.beta.-unsatd.
carbonyl compds. to give tetrahydropyrazolo[4,3-e]-as-triazines, e.g. I
(X = NPh), with hydrazines, oxopentaazaspido[4,5]-1,8-decadienes, e.g. II,
with diazoalkanes, tetrahydroisooxazolo[4,3-e]-as-triazines, e.g. I (X = O)
with HONH₂ and aminothiatetraazaspido[4,5]-2,8-decadienes, e.g. III,
with thiourea.

IT 82059-55-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and condensation with arom. aldehydes and ketones)

RN 82059-55-0 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1,3-diphenyl- (9CI) (CA INDEX
NAME)



L4 ANSWER 45 OF 61 CAPLUS COPYRIGHT 2002 ACS

ANSWER TO H-1000

AN 1981.1750
DN 94-175019

TI Formation of thiazoles, thiazines, and thiadiazines from phthalazin-1-vlthiosemicarbazides as potential anticonvulsants

All rights reserved. ISSN 0008-6813 © 1997 Blackwell Science Ltd, *Journal of Clinical Pharmacy and Therapeutics*, 22, 431–436

Fac. Pharm., Univ. Alexandria, Alexandria, Egypt.


SO J. Pharm. Sci. (1981). 70(1). 94-6

CODEN: JPMSAE ISSN: 0022-3549

CODEN: DT Journal

Bilingual English

IA
GT



AB Phthalazinylhydrazones I and thiadiazines II ($R = Et, Bu, allyl, Ph, PhCH_2, cyclohexyl; X = CH_2, CHMe, CH_2CH_2$) were prepd. by cyclizing thiosemicarbazides III with $BrCH_2CO_2Et$, $MeCHBrCO_2Et$, and $BrCH_2CH_2CO_2Et$, resp. Some I and II showed weak to moderate anticonvulsant activity.


IT 77407-71-7P

RL: BAC (Biological activity or effector, except adverse); SPN
(Synthetic

preparation); BIOL (Biological study); PREP (prepn. and anticonvulsant activity of)

RN 77407-71-7 CAPLUS

CN 4H-1,3,4-Thiadiazin-5(6H)-one, 2-(ethylamino)-4-(1-phthalazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




HCl

IT **77407-72-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 77407-72-8 CAPLUS

CN 4H-1,3,4-Thiadiazin-5(6H)-one, 2-[(phenylmethyl)amino]-4-(1-phthalazinyl)-
, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 46 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1979:203920 CAPLUS
 DN 90:203920
 TI Photochemical rearrangement of isoxazol-5-ylhyrazines and
 N-(3-methyl-4-phenylisoxazol-5-yl)acetamidine
 AU Adembri, G.; Camparini, A.; Donati, D.; Ponticelli, F.; Tedeschi, P.
 CS Ist. Chim. Org., Univ. Siena, Siena, Italy
 SO Tetrahedron Lett. (1978), (45), 4439-42
 CODEN: TELEAY; ISSN: 0040-4039
 DT Journal
 LA English
 GI




AB Photochem. rearrangement of isoxazoles I ($R = H$, $R1 = NH_2$; $R = Me$, $R1 = NH_2$, $NHMe$) gave 5-19% pyrazolones II ($R = H$, Me , $R1 = H$; $R = R1 = Me$, resp.), together with 4-amino-2-pyrazolinones and/or tetrahydro-1,2,4-triazin-6-ones previously obtained (A. et al., 1977) by thermal rearrangement. The formation of pyrazolones II involves a 1,2-shift of the 3-Me group to the isoxazole ring N to give ketenimine intermediates which undergo intramol. attack from the .beta.-hydrazinic N atom.


Irradn.
 of I [$RR1 = C(NH_2)Me$] gave 17% pyrimidine III and 43% imidazole IV.
 IT 60206-74-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 60206-74-8 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1,3-dimethyl-5-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 47 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1979:186884 CAPLUS
 DN 90:186884
 TI Reactions of phenyl(trichloromethyl)carbinol with substituted thioureas,
 thiobenzhydrazide, and amino thiols to form heterocyclic compounds
 AU Reeve, Wilkins; Coley, W. Robert, III
 CS Chem. Dep., Univ. Maryland, College Park, Md., USA
 SO Can. J. Chem. (1979), 57(4), 444-9
 CODEN: CJCHAG; ISSN: 0008-4042
 DT Journal
 LA English
 AB HOCHPhCCl₃ reacts with bifunctional reagents contg. nucleophilic sulfur
 such as thioureas, thiobenzhydrazide, o-aminothiophenol, etc., in a
 series
 of steps involving an initial attack of the S anion on the intermediate
 epoxide followed by ring closure to a heterocyclic compd.
 Thiazolidinones, thiadiazinones, benzothiazinones, and thiomorpholinones
 are obtained in 20-57% yields. Monosubstituted ureas are actually in
 the
 aminothiazolone form with considerable zwitterionic character.
 1,3-Disubstituted ureas do not give heterocyclic products. The reaction
 works particularly well with those nucleophiles which are stable to
 base,
 contain a S nucleophilic center for the initial step of the reaction and
 an amino or imino group properly positioned for the final ring closure
 to
 the heterocyclic compd. NH₂OH forms .alpha.-
 oximinophenylacetohydroxamic
 acid, an oxidn.-redn. reaction having occurred. PhSH forms PhSCHPhCO₂H
 in
 nearly quant. yield.
 IT 26734-74-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 26734-74-7 CAPLUS
 CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-methyl-2,6-diphenyl- (8CI, 9CI) (CA
 INDEX NAME)




L4 ANSWER 48 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1979:168552 CAPLUS
 DN 90:168552
 TI Synthesis and structure of dihydro-1,2,4-triazin-6(1H)-ones
 AU Camparini, Alfredo; Celli, Angela Maria; Ponticelli, Fabio; Tedeschi, Piero
 CS Ist. Chim. Org., Univ. Siena, Siena, Italy
 SO J. Heterocycl. Chem. (1978), 15(8), 1271-6
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 GI




AB Reactions of the imino esters (I; R, R1 = Ph, Ph; Ph, Me; Me, Ph) with hydrazine or (NHMe)2 gave 4,5-dihydro-II (R2 = H) or 2,5-dihydro-1,2,4-triazin-6(1H)-ones III (R2 = R3 = Me), resp. When NH2NHMe was employed, 1-methyl-4,5-dihydro-II (R2 = Me) and 2-methyl-2,5-dihydro-1,2,4-triazin-6(1H)-ones III (R2 = Me, R3 = H) (IV) were obtained. IV exist as zwitterions in the solid state and in polar aprotic solvents.


IT 60206-70-4P 60206-72-6P 60206-74-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and oxidn. of)
 RN 60206-70-4 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1-methyl-3,5-diphenyl- (9CI) (CA INDEX NAME)



RN 60206-72-6 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1,5-dimethyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 60206-74-8 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1,3-dimethyl-5-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 49 OF 61 CAPLUS COPYRIGHT 2002 ACS

AN 1978:563556 CAPLUS

DN 89:163556

TI 6-Substituted 2,4-diphenyl-1,3,4-oxadiazin-5-ones

AU Westphal, Guenter; Mueller, Thomas

CS Sekt. Chem., Humboldt-Univ., Berlin, E. Ger.


SO J. Prakt. Chem. (1978), 320(3), 452-6

CODEN: JPCEAO; ISSN: 0021-8383

DT Journal

LA German

GI




AB The oxadiazinone I ($R = Cl$) was obtained in 46.3% yield by treating $Cl_2CHCOCl$ with $PhHNHBz$ and cyclizing $Cl_2CHCONPhNHBz$ with base. I ($R = Cl$) was aminated to give I ($R = p$ thalimido, succinimido). I ($R = NHCH_2Ph$, $NHNH_2$) were obtained by treating I ($R = p$ thalimido) with the appropriate amines.

IT **67947-71-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prep. and amination of)

RN 67947-71-1 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 6-chloro-2,4-diphenyl- (9CI) (CA INDEX NAME)




IT **67947-72-2P 67947-73-3P 67947-74-4P**

67947-75-5P 67947-76-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prep. of)


RN 67947-72-2 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-(5,6-dihydro-5-oxo-2,4-diphenyl-4H-1,3,4-oxadiazin-6-yl)- (9CI) (CA INDEX NAME)




RN 67947-73-3 CAPLUS

CN 2,5-Pyrrolidinedione, 1-(5,6-dihydro-5-oxo-2,4-diphenyl-4H-1,3,4-oxadiazin-6-yl)- (9CI) (CA INDEX NAME)




RN 67947-74-4 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2,4-diphenyl-6-[(phenylmethyl)amino]- (9CI)
(CA INDEX NAME)



RN 67947-75-5 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2,4-diphenyl-6-[(phenylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 67947-76-6 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 6-hydrazino-2,4-diphenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 50 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1978:170106 CAPLUS
 DN 88:170106
 TI Electron deficient heteroaromatic ammonioamidates, XIV. The synthesis
 and some reactions of 9,10-dimethoxy-2H[1,3,4]-thiadiazino[3,2,-
 c]quinazolin-5-ium-3-olates
 AU Lempert-Sreter, M.; Lempert, K.; Bruck, P.; Toth, G.
 CS Dep. Org. Chem., Eotvos Lorand Univ., Budapest, Hung.
 SO Acta Chim. Acad. Sci. Hung. (1977), 94(4), 391-401
 CODEN: ACASA2; ISSN: 0001-5407
 DT Journal
 LA English
 GI For diagram(s), see printed CA Issue.
 AB Ring closure of thiadiazinones I (R = NHAc, NHBz; R1 = H) gave electron
 deficient heteroarom. ammonioamidates II (R2 = Me, Ph). Alk. hydrolysis
 of II (R2 = Me) gave, in addn. to minor amts. of I (R = NHAc, R1 = H)
 and III (Y = O, R3 = NH2), the mercaptoquinazolinone IV, which was in equil.
 with its ring chain tautomer V. Photolysis of II (R2 = Me) gave III (Y
 = S, R3 = H) and minor amts. of III (Y = S, R3 = NHAc).
 IT 66299-60-3P 66299-62-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prep. of)
 RN 66299-60-3 CAPLUS
 CN Acetamide, N-[2-(4-acetyl-5,6-dihydro-5-oxo-4H-1,3,4-thiadiazin-2-yl)-
 4,5-
 dimethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 66299-62-5 CAPLUS
 CN Benzamide, N-[2-(4-acetyl-5,6-dihydro-5-oxo-4H-1,3,4-thiadiazin-2-yl)-
 4,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 51 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1976:494324 CAPLUS
 DN 85:94324
 TI Competing cycloadditions in the reaction of acetylazobenzene with diphenylketene
 AU Sommer, Sven
 CS Org.-Chem. Inst., Tech. Univ. Muenchen, Munich, Ger.
 SO Angew. Chem. (1976), 88(13), 449
 CODEN: ANCEAD
 DT Journal
 LA German
 GI




AB Reaction of Ph₂C:CO with PhN:NAc gave the diazetidinones I and II by [2+2]-cycloaddn., the oxadiazine III by [4+2]-cycloaddn., and the cinnoline IV by [4+2]-cycloaddn. followed by 1,3-H shift, the ratio of the product being 60:26:10:4.
 IT 59231-02-6P
 RL: PREP (Preparation)
 (by cycloaddn. of diphenylketene with acetylazobenzene)
 RN 59231-02-6 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-methyl-4,6,6-triphenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 52 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1976:494321 CAPLUS
 DN 85:94321
 TI Synthesis and structure of 1,2,4-triazin-6-ones
 AU Camparini, A.; Ponticelli, F.; Tedeschi, P.; Celli, A.
 CS Ist. Chim. Org., Univ. Siena, Siena, Italy
 SO Chim. Ind. (Milan) (1976), 58(3), 221-2
 CODEN: CINMAB
 DT Journal
 LA Italian
 GI




AB Condensation of EtoOCR:NCHR₁CO₂Et (R, R₁ = Me, Ph) with R₂NHNHMe (R₂ = H, Me) gave triazinones I and II. II were dehydrogenated by HClO.
 IT 60206-70-4P 60206-72-6P 60206-74-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 60206-70-4 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1-methyl-3,5-diphenyl- (9CI) (CA INDEX NAME)




RN 60206-72-6 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1,5-dimethyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 60206-74-8 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1,3-dimethyl-5-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 53 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1975:578784 CAPLUS
 DN 83:178784
 TI Pyrimidine derivatives and related compounds. LXXXVIII. Reactions of 1,3,4-oxadiazolium salts with dialkyl acylphosphonates. Novel synthesis of 1,3,4-oxadiazin-5-one derivatives
 AU Takamizawa, Akira; Sato, Hisao
 CS Shionogi Res. Lab., Shionogi and Co., Ltd., Osaka, Japan
 SO Chem. Pharm. Bull. (1975), 23(5), 948-54
 CODEN: CPBTAL
 DT Journal
 LA English
 GI For diagram(s), see printed CA Issue.
 AB Reaction of 3-ethyl-5-aryl-1,3,4-oxadiazolium salts I (R = H, o-MeO, p-Cl) with R₂O₂P(O)COR₁ (R₁ = Ph, PhCH₂, p-ClC₆H₄, p-MeC₆H₄, p-PrC₆H₄ p-MeOC₆H₄;
 R₂ = Me, Et) in the presence of Et₃NH gave 2-aryl-4-ethyl-6-alkyl (or aryl)-5,6-dihydro-4H-1,3,4-oxadiazin-5-one derivs. II via an acyclic intermediate RC₆H₄CONHNETCOR₁OP(O)(OR₂)₂.
 IT 57180-12-8P 57180-13-9P 57180-14-0P
 57180-15-1P 57180-16-2P 57180-17-3P
 57180-18-4P 57180-19-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 57180-12-8 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-ethyl-2,6-diphenyl- (9CI) (CA INDEX NAME)




RN 57180-13-9 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-ethyl-6-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 57180-14-0 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 6-(4-chlorophenyl)-4-ethyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 57180-15-1 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-ethyl-6-(4-methylphenyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 57180-16-2 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 6-(4-bromophenyl)-4-ethyl-2-phenyl- (9CI)
(CA INDEX NAME)




RN 57180-17-3 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-ethyl-6-(4-methoxyphenyl)-2-phenyl-
(9CI) (CA INDEX NAME)




RN 57180-18-4 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-ethyl-2-(2-methoxyphenyl)-6-phenyl-
(9CI) (CA INDEX NAME)




RN 57180-19-5 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-chlorophenyl)-4-ethyl-6-phenyl- (9CI)
(CA INDEX NAME)




L4 ANSWER 54 OF 61 CAPLUS COPYRIGHT 2002 ACS
AN 1975:458765 CAPLUS
DN 83:58765
TI New syntheses of thiadiazinones, thiazolidinedione hydrazones, and hydroxythiazoles from phenyl (trichloromethyl) carbinols
AU Reeve, Wilkins; Barron, Eugene R.
CS Chem. Dep., Univ. Maryland, College Park, Md., USA
SO J. Org. Chem. (1975), 40(13), 1917-20
CODEN: JOCEAH
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB PhCH(OH)CCl₃ reacts with H₂NCSNH₂ under basic reaction conditions to form 18% dihydro-2-imino-6-phenyl-2H-1,3,4-thiadiazin-5(6H)-one (I) and 10% 5-phenyl-2,4-thiazolidinedione-2-hydrazone (II), with acetone or benzaldehyde thiosemicarbazones to form derivs. of I (65%), and with thioacetamide to form 18% 4-hydroxy-2-methyl-5-phenylthiazole.
IT 55073-92-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 55073-92-2 CAPLUS
CN 4H-1,3,4-Thiadiazin-5(6H)-one, 2-amino-4-methyl-6-phenyl- (9CI) (CA
INDEX
NAME)




L4 ANSWER 55 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1974:552058 CAPLUS
 DN 81:152058
 TI New compounds. 4-Substituted 5,6-dihydro-2-o-hydroxyphenyl-4H-1,3,4-oxadiazine-5-ones, potential psychopharmacological drugs
 AU Sicardi, Susana M.; Lamdan, Samuel; Gaozza, Carlos H.
 CS Fac. Farm. Bioquim., Univ. Buenos Aires, Buenos Aires, Argent.
 SO J. Pharm. Sci. (1974), 63(8), 1336-7
 CODEN: JPMSAE
 DT Journal
 LA English
 GI For diagram(s), see printed CA Issue.
 AB 1,3,4-Oxadiazines I ($n = 2, 3$, R = H, Cl, pyrrolidino, piperidino, morpholino; $n = 2$, R = NMe₂, NEt₂, OPh, OC₆-H₄Cl-p, OC₆H₄Me-p; $n = 1$, R = Ph) were prepd. by 4-alkylation and reaction with a secondary amine.
 IT **53995-34-9P 53995-35-0P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and reaction of, with amines)
 RN 53995-34-9 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-chloroethyl)-2-(2-hydroxyphenyl)-(9CI) (CA INDEX NAME)




RN 53995-35-0 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-chloropropyl)-2-(2-hydroxyphenyl)-(9CI) (CA INDEX NAME)




IT **53995-32-7P 53995-33-8P 53995-36-1P**
53995-37-2P 53995-38-3P 53995-39-4P
53995-40-7P 53995-41-8P 53995-42-9P
53995-43-0P 53995-44-1P 53995-45-2P
53995-46-3P 53995-47-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 53995-32-7 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-ethyl-2-(2-hydroxyphenyl)-(9CI) (CA INDEX NAME)




RN 53995-33-8 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)




RN 53995-36-1 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 53995-37-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)




RN 53995-38-3 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[2-(4-chlorophenoxy)ethyl]-2-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 53995-39-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[2-(4-methylphenoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 53995-40-7 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[2-(dimethylamino)ethyl]-2-(2-hydroxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 53995-41-8 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[2-(diethylamino)ethyl]-2-(2-hydroxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 53995-42-9 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 53995-43-0 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[2-(1-piperidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 53995-44-1 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[2-(4-morpholinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 53995-45-2 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[3-(1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 53995-46-3 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[3-(1-piperidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 53995-47-4 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-[3-(4-morpholinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


L4 ANSWER 56 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1971:529771 CAPLUS
 DN 75:129771
 TI Heterocyclic chemistry. IX. Reaction of 2-(carbonyl)-2H-azirines with hydrazine. Synthesis of 1,2,4-triazin-6-ones
 AU Nishiwaki, Tarozaemon; Saito, Toshinori
 CS Fac. Sci., Yamaguchi Univ., Yamaguchi, Japan
 SO J. Chem. Soc. C (1971), (15), 2648-52
 CODEN: JSOOAX
 DT Journal
 LA English
 GI For diagram(s), see printed CA Issue.
 AB Reaction of 3-aryl-2-phenyl-2H-azirine-2-carboxamides (I, R = H, Cl, Me) with N₂H₄ gave 36-40% 3-aryl-4,5-dihydro-5-phenyl-as-triazin-6(1H)-ones (II, R = H, Cl, Me) and 8-9% 3-aryl-3-hydrazino-2-phenyl-2-aziridinecarboxamides. Reaction of I (R = H) with PhNHNH₂ gave 4,5-dihydro-1,3,5-triphenyl-as-triazin-6(1H)-one. Me 3-(p-chlorophenyl)- and 3-phenyl-2H-azirine-2-carboxylate reacted with N₂H₄ to give 3-aryl-5-oxo-2-pyrazolin-4-ylidenenitrilo-3-aryl-2-pyrazolin-5-ones (III,
 R = H or Cl).
 IT **33859-50-6P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 33859-50-6 CAPLUS
 CN as-Triazin-6(1H)-one, 4,5-dihydro-1,3,5-triphenyl- (8CI) (CA INDEX NAME)




L4 ANSWER 57 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1970:477209 CAPLUS
 DN 73:77209
 TI Intramolecular cyclization of N'-chloroacetylsalicylhydrazide
 AU Gaozza, Carlos H.; Lamdan, Samuel
 CS Fac. Farm. Bioquim., Univ. Buenos Aires, Buenos Aires, Argent.
 SO J. Heterocycl. Chem. (1970), 7(4), 927-30 CODEN: JHTCAD
 DT Journal
 LA English
 AB Treatment of N'-chloroacetylsalicylhydrazide with NaOH in DMF gives an intramol. cyclization to give 5,6-dihydro-2-(.omicron.-hydroxyphenyl)-4H-1,3,4-oxadiazin-5-one. No 1,4,5-benzoxadiazocin-3,6-dione is detected.
 IT 28669-15-0P 28669-16-1P 28669-23-0P 28669-25-2P
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)
 RN 28669-15-0 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 28669-16-1 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(hydroxymethyl)-2-(o-hydroxyphenyl)- (8CI) (CA INDEX NAME)




RN 28669-23-0 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(o-hydroxyphenyl)-4-methyl-, acetate (ester) (8CI) (CA INDEX NAME)




RN 28669-25-2 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(o-hydroxyphenyl)-4-methyl- (8CI) (CA INDEX NAME)




L4 ANSWER 58 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1970:445478 CAPLUS
 DN 73:45478
 TI Pyrimidine derivatives and related compounds. LXVI. Reactions of dialkyl
 acylphosphonates with 1,3,4-thiadiazolium derivatives
 AU Takamizawa, Akira; Sato, Hisao
 CS Shionogi Res. Lab., Shionogi and Co., Ltd., Osaka, Japan
 SO Chem. Pharm. Bull. (1970), 18(6), 1201-10
 CODEN: CPBTAL
 DT Journal
 LA English
 AB The novel reaction of 1,3,4-thiadiazolium halides with dialkyl acylphosphonates in the presence of Et₃N to give 1,3,4-thiadiazine derivs., accompanied by ring expansion, was described. In some of the reactions, 10a-(1-dialkylphosphoroyl)benzyl (or -ethyl)-10,10a-dihydro-5H-pyrimido[4,5-d]-1,3,4-thiadiazolo[3,2-a]pyrimidines were isolated as the intermediates. Neutral and alk. hydrolysis of these are described.
 IT 25626-39-5P 25626-41-9P 26734-74-7P
 26734-75-8P 26734-76-9P 26734-77-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 25626-39-5 CAPLUS
 CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-2,6-diphenyl- (8CI) (CA INDEX NAME)



RN 25626-41-9 CAPLUS
 CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-6-methyl-2-phenyl- (8CI) (CA INDEX NAME)




RN 26734-74-7 CAPLUS
 CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-methyl-2,6-diphenyl- (8CI, 9CI) (CA INDEX NAME)




RN 26734-75-8 CAPLUS

CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4,6-dimethyl-2-phenyl- (8CI) (CA INDEX NAME)




RN 26734-76-9 CAPLUS

CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-benzyl-2,6-diphenyl- (8CI) (CA INDEX NAME)




RN 26734-77-0 CAPLUS

CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-benzyl-6-methyl-2-phenyl- (8CI) (CA INDEX NAME)



L4 ANSWER 59 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1970:425504 CAPLUS
 DN 73:25504
 TI Antipyretic, analgesic, and antiinflammatory 2-methyl-5,10-dihdropyrazolo[1,5-a]pyrimido[4,5-d]pyrimidines
 IN Takamizawa, Akira; Sato, Hisao
 PA Shionogi and Co., Ltd.
 SO Ger. Offen., 20 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1954275	A	19700527	DE 1969-1954275	19691028
	FR 2021718	A5	19700723	FR 1969-36780	19691027
	FR 2021718	B1	19730713		
	GB 1229524	A	19710421	GB 1969-1229524	19691028
	US 3787408	A	19740122	US 1971-199367	19711116
PRAI	JP 1968-78432		19681028		
	JP 1968-78433		19681028		
	JP 1968-78435		19681028		
	US 1969-869379		19691024		
GI	For diagram(s), see printed CA Issue.				
AB	The title compds. (I) were prep'd. either from II and POCl_3 (method A), from III and BzPO(OR)OR_1 in the presence of a base, e.g. pyridine (method B), from IV by thermolysis (method C), or from V by condensation (method D). Thus, II ($R = R_1 = \text{Ph}$) and POCl_3 was heated 8 hr at 110.degree. to give 61.8% I ($R = R_1 = \text{Ph}$) (Ia). III ($R = \text{Ph}$) (544 mg), 486 mg BzPO(OEt)_2 , and 1.6 g pyridine in 16 ml DMF was heated 18 hr at 105.degree. to give 122 mg Ia. Heating 400 mg IV ($R = R_1 = \text{Ph}$) 15 min at 140-50.degree. gave 320 mg Ia. V ($R = R_1 = \text{Ph}$) was refluxed 2 hr with 20% HCl to give 20% Ia. Similarly prep'd. were 65% I ($R = \text{H}, R_1 = \text{Ph}$) (Ib) by methods A, C, and D; 14% I ($R = \text{Me}, R_1 = \text{H}$) by method D; and 61.4% I ($R = \text{Ph}, R_1 = \text{H}$) by method D. Ib had LD ₅₀ >800 mg/kg on subcutaneous application to mice.				
IT	25626-39-5P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (prep'n. of)				
RN	25626-39-5 CAPLUS				
CN	4H-1,3,4-Thiadiazin-5(6H)-one, 4-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-2,6-diphenyl- (8CI) (CA INDEX NAME)				



L4 ANSWER 60 OF 61 CAPLUS COPYRIGHT 2002 ACS

AN 1970:79112 CAPLUS

DN 72:79112

TI 1,3,4-Thiadiazines

IN Takamizawa, Akira; Sato, Hisao

PA Shionogi and Co., Ltd.

SO Jpn. Tokkyo Koho, 4 pp.

CODEN: JAXXAD

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 44028102	B4	19691120	JP	19670926

GI For diagram(s), see printed CA Issue.

AB Manuf. of I, useful as antiinflammatory and antiedema drugs, is described.

In an example, 3.25 g pyridine is dropped into a cold (1-2.degree.) mixt.

of 5 g 3-(2-methyl-4-aminopyrimidin-5-ylmethyl)-1,3,4-thiadiazolium 3-bromide hydrobromide, 3.3 g diethyl benzoylphosphonate, and 35 ml HCONMe₂ with stirring and introduction of N gas, the mixt. stirred at 1-2.degree. 20 min, at room temp. 3 hr, kept overnight, stirred at room

temp. 32 hr, kept 5 days, and stirred 24 hr to give 1.56 g I (R₁ = H, R₂ =

= Ph), m. 147-9.degree. (EtOH-Et₂O). Similarly prepd. are the following I (R₁, R₂, and m.p. given): Ph, Ph, 205-8.degree.; H, Me, 128-30.degree.; Ph, Me, 145-8.degree..


IT 25626-39-5P 25626-41-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 25626-39-5 CAPLUS


CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-

2,6-diphenyl- (8CI) (CA INDEX NAME)



RN 25626-41-9 CAPLUS

CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-6-methyl-2-phenyl- (8CI) (CA INDEX NAME)




L4 ANSWER 61 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1970:55523 CAPLUS
 DN 72:55523
 TI 1,3,4-Thiadiazines
 IN Takamizawa, Akira; Sato, Hisao
 PA Shionogi and Co., Ltd.
 SO Jpn. Tokkyo Koho, 3 pp.
 CODEN: JAXXAD
 DT Patent
 LA Japanese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 44027896	B4	19691118	JP	19670517

GI For diagram(s), see printed CA Issue.
 AB The prepn. of I, an analgesic, sedative, and antiinflammatory drug, is described. Thus, 3.1 g Et₃N is added dropwise to an ice-cooled mixt. of 4.6 g 2-phenyl-4-methyl-1,3,4-thiadiazolium iodide, 3.7 g di-Et benzoylphosphonate, and 15 ml HCONMe₂, the mixt. stirred 2 hr at <2.degree. with bubbling of N gas, and kept 2 nights at room temp. to give 2.7 g I (R₁ = Me, R₂ = Ph), m. 137-8.degree. (dil. EtOH). Similarly prepd. are I (R₁, R₂, and m.p. given): Me, Me, - (oil); PhCH₂, Ph, 115-20.degree.; PhCH₂, Me, - (oil).
 IT 26734-74-7P 26734-75-8P 26734-76-9P 26734-77-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)


RN 26734-74-7 CAPLUS
 CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-methyl-2,6-diphenyl- (8CI, 9CI) (CA INDEX NAME)




RN 26734-75-8 CAPLUS
 CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4,6-dimethyl-2-phenyl- (8CI) (CA INDEX NAME)



RN 26734-76-9 CAPLUS
 CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-benzyl-2,6-diphenyl- (8CI) (CA INDEX NAME)



RN 26734-77-0 CAPLUS
 CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-benzyl-6-methyl-2-phenyl- (8CI) (CA INDEX NAME)



L11 ANSWER 1 OF 14 MARPAT COPYRIGHT 2002 ACS

AN 134:193453 MARPAT

TI Preparation of pesticidal trifluoromethylpyridine(m)idines

IN Farooq, Saleem; Maienfisch, Peter

PA Syngenta Participations A.-G., Switz.

SO PCT Int. Appl., 32 pp.

50 FOR THE APPENDIX

CODEN: DT Patent

Patient
English

LA Eng 1
EAN CNT 1


FAN.CNT 1

PATENT NO.


PI	WO 2001014373	A1	20010301	WO 2000-EP8082	20000818
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI CH 1999-1523 19990820

GI




I



II

AB The title compds. [I; Z = (un)substituted (non)arom. 6-7 membered, heterocyclyl; X = CH, N; Y = halo; n = 1-3; m = 0-1], useful for controlling pests, were claimed (general prepn. was given). E.g., the title compd. II showed efficacy of over 80% against *Diabrotica balteata* and *Myzus persicae*.

MSTR 1




G1 = CH

$$G_4 = N$$

G9 = cycloalkyl<(3-8)>

G22 = 425-4 426-143




MPL: claim 1

NTE: and/or tautomers

L11 ANSWER 2 OF 14 MARPAT COPYRIGHT 2002 ACS
 AN 132:151680 MARPAT
 TI Preparation of carbazoles, isoquinolines, indoles, and related compounds
 as follicle stimulating hormone mimetics for the treatment of
 infertility.
 IN El Tayer, Nabil; Reddy, Adulla; Buckler, David; Magar, Sharad
 PA Applied Research Systems Ars Holding N. V., Neth. Antilles
 SO PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000008015	A2	20000217	WO 1999-US17755	19990805
	WO 2000008015	A3	20000511		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9953931	A1	20000228	AU 1999-53931	19990805
	US 6235755	B1	20010522	US 1999-369222	19990805
	EP 1102763	A2	20010530	EP 1999-939686	19990805
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
PRAI	US 1998-95712		19980807		
	WO 1999-US17755		19990805		
AB	R5ZYR4XR3WNR1R2 [R1, R3, R4, R5 = H, (substituted) alkyl, alkenyl, alkynyl, alkoxy, alkoxy carbonyl, thioalkyl, acyl, acyloxy, aryl, cycloalkyl, heterocyclyl; R2 = H, (substituted) cycloalkyl, heterocyclyl, aryl, heteroaryl; NR1R2 = (substituted) heterocyclyl, heteroaryl; W = CO, NHCO, NHCOCH ₂ , C:NH, CS, SO ₂ , (substituted) CH ₂ ; X, Y = CH, N; Z = CO, NH, C:N, SO ₂ , CONH], were prep'd. Thus, 1-[(2-oxo-6-pentyl-2H-pyran)-3-carbonyl]pyrrolidine-2-carboxylic acid 3-(9-ethylcarbazolyl)amide (prep'd. from BOC-Pro-OH, 3-amino-9-ethylcarbazole, and 2-oxo-6-pentyl-2H-pyran-3-carboxylic acid) stimulated estradiol prodn. in the rat granulosa cell assay with EC ₅₀ = 1.4 .mu.M.				

MSTR 1E



G7 = 21

${}_2\text{C}=\text{G}8$

$\text{G}8 = \text{NH}$
 $\text{G}9 = \text{N}$
 $\text{G}10 = \text{Cb}<\text{EC } (3-10) \text{ C, BD } (0-) \text{ D } (0) \text{ T}> (\text{SO})$
 $\text{G}11 = (0-2) \text{ CH}_2$
 $\text{G}12 = 47$

${}_4\text{G}=\text{G}13$

$\text{G}13 = \text{O}$
 $\text{G}14 = 55$

${}_5\text{N}=\text{G}10$

DER: and pharmaceutically acceptable addition salts
 MPL: claim 1
 NTE: additional ring formation also claimed

L11 ANSWER 3 OF 14 MARPAT COPYRIGHT 2002 ACS
 AN 130:311789 MARPAT
 TI Preparation of pesticidal 3-substituted arylpyrazoles
 IN Wu, Tai-Teh
 PA Rhone-Poulenc Agro, Fr.
 SO Eur. Pat. Appl., 40 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 911329	A1	19990428	EP 1998-118417	19980929
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 5981565	A	19991109	US 1997-946132	19971007
	US 6008353	A	19991228	US 1997-946054	19971007
	US 6107314	A	20000822	US 1997-946648	19971007
	JP 11263777	A2	19990928	JP 1998-283056	19981005
	US 6277848	B1	20010821	US 1999-440850	19991116
PRAI	US 1997-946054		19971007		
	US 1997-946132		19971007		
	US 1997-946648		19971007		

GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = II-IV (R1a = H, alkyl, a lone pair of electrons; R1b = alkyl, aryl; X = O, NH, N(alkyl); Q = CR8R9, C(:Y), etc.;
 R8, R9 = H, alkyl, aryl, etc.; Y = O, S; Z = alkyl, aryl; W = H, alkyl, alkenyl, etc.; V = H, alkyl, CN, etc.); R2 = alkyl, haloalkyl, SOnR2a (R2a = alkyl, alkenyl, alkynyl, etc.); R3 = H, halo, alkyl, etc.; R4, R5, R7 = H, halo, alkyl; R6 = halo, haloalkyl, haloalkoxy, etc.; M = C(halo), C(Me), N, etc.], having pesticidal activity, were prep'd. Thus, reaction of 5-amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-methylsulfinyl-3-[3- (1-amidoxime)]pyrazole (prepn. given) with trifluoroacetic anhydride in dioxane afforded the title compd. V which showed insecticidal activity in one or more of the evaluation methods (described in patent), with particularly good activity in the systemic tests.

MSTR 1



G1 = 24



G23 = 87



G24 = alkyl<(1-6)> (SO)
G25 = 93-21 94-23



G32 = OH

G33 = OH

G30+G31= O

DER: or pesticidally acceptable salts

MPL: claim 1

NTE: additional ring formation also claimed


NTE: substitution is restricted

NTE: also incorporates claim 21, structures II, III, and V

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 14 MARPAT COPYRIGHT 2002 ACS
 AN 130:77484 MARPAT
 TI Pyridazinones as marine antifouling agents
 IN Willingham, Gary Lewis; Sherba, Samuel Eugene; Lange, Barry Clifford;
 Michelotti, Enrique Luis
 PA Rohm and Haas Company, USA
 SO U.S., 7 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5855654 CN 1189293	A	19990105 19980805	US 1997-987081 CN 1998-103686	19971209 19980123
PRAI	US 1997-987081		19971209		
GI					




AB Disclosed is a method of inhibiting the growth of marine organisms on a marine structure, by applying pyridazinone derivs. I [A = (CHR₂)_nCHR₃Z, (CHR₂)_nOZ, (CHR₂)_nSZ, OCHR₃Z, etc.; D = CR₂ or N; Z = CO or CS; Q = (un)substituted Ph, naphthyl, PhCH:CH, etc.; R₁ = alkyl, hydroxyalkyl, cyanoalkyl, etc.; R₂ = H, alkyl or halo; R₃ = R₂, Ph, alkynylalkenyl, etc.; n = 0, 1 or 2]. I may be directly incorporated into the marine structure during manuf., directly applied to the structure, or applied to the structure by means of a coating.

MSTR 2

G26—G23

G1 = 86-2 88-4




G2 = O

G4 = Ph

G13 = Cb<EC (5) C, BD (2) D, RC (1), RS (1) E5>
(SR (1-2) G33)

G23 = alkynyl<(3-10)>

G26 = 4



G32 = N

MPL: disclosure


NTE: additional ring formation also disclosed

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD


L11 ANSWER 5 OF 14 MARPAT COPYRIGHT 2002 ACS
 AN 129:132551 MARPAT
 TI Pyridazinones as marine antifouling agents
 IN Willingham, Gary Lewis; Sherba, Samuel Eugene; Lange, Barry Clifford;
 Michelotti, Enrique Luis
 PA Rohm and Haas Co., USA
 SO Eur. Pat. Appl., 10 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 856255	A2	19980805	EP 1998-300059	19980106
	EP 856255	A3	19981230		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CA 2227511	AA	19980730	CA 1998-2227511	19980120
	JP 10212208	A2	19980811	JP 1998-32403	19980130
PRAI	US 1997-36527		19970130		
AB	Disclosed is a method of inhibiting the growth of marine organisms on a marine structure, by applying dihydropyridazinone and pyridazinone compds.				
	(Markush given). These compds. may be directly incorporated into the marine structure during manuf., directly applied to the structure, or applied to the structure by coating. Suitable agents are 6-(4-chlorophenyl)-2-(2-pentynyl)pyridazin-3-one, 6-(4-chlorophenyl)-2-(2'-pentynyl)-4,5-dihydropyridazin-3-one, etc.				

MSTR 2



G1 = 14-1 16-3




G3 = O
 G4 = N
 G5 = Ph
 G8 = cycloalkyl (SO OH)
 G11 = Ph (SO (-4) G16)
 MPL: disclosure
 NTE: substitution is restricted
 NTE: additional ring formation also disclosed

L11 ANSWER 6 OF 14 MARPAT COPYRIGHT 2002 ACS
 AN 127:274170 MARPAT
 TI Synergistic herbicidal compositions
 IN Hudetz, Manfred; Nelgen, Robert
 PA Novartis A.-G., Switz.; Hudetz, Manfred; Nelgen, Robert
 SO PCT Int. Appl., 67 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9734484	A1	19970925	WO 1997-EP1106	19970305
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2244141	AA	19970925	CA 1997-2244141	19970305
	AU 9720241	A1	19971010	AU 1997-20241	19970305
	EP 888055	A1	19990107	EP 1997-908179	19970305
	EP 888055	B1	20000830		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, PT				
	CN 1213271	A	19990407	CN 1997-192920	19970305
	BR 9708192	A	19990727	BR 1997-8192	19970305
	JP 2000508626	T2	20000711	JP 1997-533083	19970305
	AT 195846	E	20000915	AT 1997-908179	19970305
	ES 2150226	T3	20001116	ES 1997-908179	19970305
	CN 1194096	A	19980930	CN 1998-106340	19980126
	US 6159899	A	20001212	US 1998-160201	19980914
PRAI	CH 1996-691		19960315		
	WO 1997-EP1106		19970305		


GI




I

AB Synergistic herbicidal compns. comprise the phenylpyrimidinone deriv. phenylpyrimidinone deriv.(I) and any of 6 classes of known herbicides (Markush given), such as glyphosate, atrazine, etc.

MSTR 2



G1 = 10-5 11-3



G2 = cyclohexyl
G4 = 28-4 29-2




G5 = Cl
G8 = Ph
MPL: claim 1

L11 ANSWER 7 OF 14 MARPAT COPYRIGHT 2002 ACS
 AN 126:317387 MARPAT
 TI Preparation of 2-(1,3-benzodioxol-5-yl)-2,3-dihydropyridazin-3-on-2-ylacetates and related compounds as endothelin receptor antagonist.
 IN Dorsch, Dieter; Oswald, Mathias; Mederski, Werner; Wilm, Claudia;
 Schmitges, Claus; Christadler, Mara
 PA Merck Patent GmbH, Germany
 SO Ger. Offen., 28 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19537548	A1	19970410	DE 1995-19537548	19951009
	CA 2207243	AA	19970417	CA 1996-2207243	19960919
	WO 9713758	A1	19970417	WO 1996-EP4111	19960919
	W: AU, BR, CA, CN, CZ, HU, JP, KR, MX, NO, PL, RU, SK, UA, US RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	AU 9672119	A1	19970430	AU 1996-72119	19960919
	EP 796250	A1	19970924	EP 1996-933341	19960919
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT,				
SE	BR 9606668	A	19970930	BR 1996-6668	19960919
	CN 1168137	A	19971217	CN 1996-191388	19960919
	JP 10511118	T2	19981027	JP 1996-514665	19960919
	ZA 9608483	A	19970520	ZA 1996-8483	19961008
	NO 9702612	A	19970808	NO 1997-2612	19970606
	US 5883090	A	19990316	US 1997-849344	19970606
PRAI	DE 1995-19537548	19951009			
	WO 1996-EP4111	19960919			

GI




AB Title compds. [I; Y = CR4R41CR4R41, CR4:CR41, CR4R41S; R1 = (substituted)
 Ph, naphthyl, heterocyclyl, R3, R4; R2 = (substituted) (anellated) aryl;
 R3 = cyano, CO2H, (modified) alkylcarbonyl, sulfonylaminocarbonyl,
 tetrazol-5-yl; R4, R41 = H, (modified) alkyl; R5 = (modified) alkyl,
 (substituted) aryl], were prepd. for treatment of hypertension, heart
 failure, kidney failure, brain infarct, coronary heart disease, renal,
 cerebral, and myocardial ischemia, subarachnoid hemorrhage,
 inflammation,
 asthma, and endotoxic shock (no data). Thus, 2,3-dihydro-4,6-
 dimethylpyridazin-3-one, 2-(1,3-benzodioxol-5-yl)-2-bromo-N-(4-
 isopropylphenylsulfonyl)acetamide, and Cs2CO3 were stirred 2 h in DMF to
 give 2-(1,3-benzodioxol-5-yl)-2-(2,3-dihydro-4,6-dimethylpyridazin-3-on-
 2-yl)-N-(4-isopropylphenylsulfonyl)acetamide.

MSTR 1



G1 = 37-2 38-4



G10 = Hy<EC (1-4) Q (0-) N (0-) O (0-) S (0) OTHERQ,
RC (1-2)> (SO (1-3) G11)
G24 = CN
DER: and salts
MPL: claim 1


L11 ANSWER 8 OF 14 MARPAT COPYRIGHT 2002 ACS
 AN 125:320561 MARPAT
 TI Synergistic herbicidal compositions of metolachlor
 IN Hudetz, Manfred; Kidder, Dan Worden; Milliken, Robert Franklin; Nelgen, Norbert
 PA CIBA Ltd., Switz.
 SO PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9632013	A1	19961017	WO 1996-EP1431	19960401
	W: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2213498	AA	19961017	CA 1996-2213498	19960401
	AU 9652763	A1	19961030	AU 1996-52763	19960401
	AU 697026	B2	19980924		
	EP 820227	A1	19980128	EP 1996-909161	19960401
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
	CN 1180993	A	19980506	CN 1996-193193	19960401
	BR 9604943	A	19980609	BR 1996-4943	19960401
	JP 11503438	T2	19990326	JP 1996-530685	19960401
	ZA 9602877	A	19961014	ZA 1996-2877	19960411
	US 5981432	A	19991109	US 1998-930901	19980202
	AU 9898218	A1	19990304	AU 1998-98218	19981224
	AU 723452	B2	20000824		
	CN 1311990	A	20010912	CN 2001-101289	20010117
	CN 1326677	A	20011219	CN 2001-121937	20010622
	CN 1327727	A	20011226	CN 2001-121938	20010622
	CN 1327728	A	20011226	CN 2001-121939	20010622
	CN 1327729	A	20011226	CN 2001-121940	20010622
	CN 1327730	A	20011226	CN 2001-121941	20010622
PRAI	CH 1995-1072		19950412		
	AU 1996-52763		19960401		
	WO 1996-EP1431		19960401		


AB Herbicidal compns. comprise the most active optical isomer of metolachlor

and a synergistic other known herbicide, i.e. a sulfonylurea, sulfonanilide, triazines, triazinones, pyridazinone, organophosphate, aryloxylakanoic acid, aryloxyphenoxypropanoic acid, pyridinecarboxylic acid, benzoic acid, di-Ph ether, imidazolinone, dinitroaniline, benzonitrile, chloroacetanilide, benzothiadiazinone, thio- or biscarbamate, urea, cyclohexanedione oxime and/or bipyridylum deriv.


MSTR 2



G1 = 19-2 20-4




G2 = Ph
G4 = 22-3 23-1




G5 = Cl
G7 = Ph
MPL: claim 1

L11 ANSWER 9 OF 14 MARPAT COPYRIGHT 2002 ACS
 AN 123:55870 MARPAT
 TI Preparation of indazole derivatives as antipsychotics
 IN Sasaki, Toshiro; Nakatani, Juko; Hiranuma, Toyoichi; Kashima, Hiroko;
 Fukuda, Yoshimasa
 PA Meiji Seika Co, Japan
 SO Jpn. Kokai Tokkyo Koho, 23 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07033744	A2	19950203	JP 1993-204612	19930727
GI					




I




II

AB The title compds. I [$n = 2 - 6$; $V = H$, halo; $R1 = H$, alkyl, etc.; $W =$ heterocycle (further details on said heterocycle are given)] are prepd. Indazole deriv. II (prepn. given) showed ED₅₀ of 0.50 mg/Kg i.p. against methamphetamine-induced activities in mice, vs. ED₅₀ of 0.16 mg/Kg i.p. shown by haloperidol. In a test for catalepsy-causing activity in mice, II showed ED₅₀ of 18 mg/Kg i.p., vs. ED₅₀ of 1.3 mg/Kg i.p. shown by haloperidol.

MSTR 1



G1 = (2-6) CH₂
 G4 = 40



G5 = CH
G6 = alkyl<(1-6)> (SO) / OH
G7 = S
G8 = N / 45



MPL: claim 1
NTE: additional ring formation allowed

L11 ANSWER 10 OF 14 MARPAT COPYRIGHT 2002 ACS
AN 123:33104 MARPAT
TI Preparation of substituted caprolactams and derivatives useful for treatment of HIV disease
IN Hodge, Carl Nicholas; Fernandez, Christina Howard; Jadhav, Prabhakar Kondaji; Lam, Patrick Yuk-Sun
PA Du Pont Merck Pharmaceutical Co., USA
SO PCT Int. Appl., 403 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9422840	A1	19941013	WO 1994-US3224	19940328
	W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5663333	A	19970902	US 1993-40324	19930330
	AU 9464159	A1	19941024	AU 1994-64159	19940328
	EP 691961	A1	19960117	EP 1994-911704	19940328
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE					
PRAI	US 1993-40324		19930330		
	US 1992-965061		19921022		
	WO 1994-US3224		19940328		

GI



AB Title compds. I (X = S, O, substituted N; X1 = (R4a)(R4)C, R4N wherein R4 = C1-8 alkyl, C2-8 alkenyl, alkynyl, or cycloalkyl, C6-10 bicycloalkyl, aryl, C6-14 carbocyclyl, 5-10-membered heterocyclyl all substituted, R4a = H, substituted C1-4 alkyl, substituted PhCh2, etc.; R5, R5a = H halo, substituted C1-6 alkyl, (substitute) amino, etc.; R5R5a = O, S, ketal ring; W = substituted NHCO, substituted OCO2, etc.; n = 0-2; R33, R33a = H, substituted C1-3 alkyl, R33R33a = O, fused 5-6-membered ring) or a salt or prodrug thereof, are prep'd. The silyl ether II (prepn. given) in Bu4N+F- was stirred under N to give the deprotected compd. which in a test for IHV inhibitory activity had IC 90 = <10 .mu.g/mL.

MSTR 1A




G1 = 6




G2 = cycloalkyl<(3-8)> (SO) /
Cb<EC (6-10) C, AR (1-), BD (ALL) N, RC (1-2),
RS (1-2) E6 (0) OTHER> (SO)


G3 = 10



G7 = O
G14 = 24-2 26-4



G16 = 29



G18 = 170




G19 = O
DER: or pharmaceutically acceptable salts or prodrug forms
MPL: claim 1
NTE: additional ketal and ring formation allowed

L11 ANSWER 11 OF 14 MARPAT COPYRIGHT 2002 ACS
 AN 121:255795 MARPAT
 TI Preparation of benzimidazole derivatives as angiotensin II antagonists
 IN Dorsch, Dieter; Mederski, Werner; Osswald, Mathias; Schelling, Pierre;
 Beier, Norbert; Lues, Ingeborg; Minck, Klaus Otto
 PA Merck Patent GmbH, Germany
 SO Eur. Pat. Appl., 20 pp.
 CODEN: EPXXDW
 DT Patent
 LA German
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 574787	A2	19931222	EP 1993-109121	19930607
	EP 574787	A3	19940622		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE DE 4237656 JP 06065234 CA 2098243 NO 9302146 AU 9341237 ZA 9304160 US 5401738 HU 69712 CN 1082542	A1	19931216	DE 1992-4237656	19921107
		A2	19940308	JP 1993-137689	19930608
		AA	19931214	CA 1993-2098243	19930611
		A	19931214	NO 1993-2146	19930611
		A1	19931223	AU 1993-41237	19930611
		A	19940113	ZA 1993-4160	19930611
		A	19950328	US 1993-75247	19930611
		A2	19950928	HU 1993-1714	19930611
		A	19940223	CN 1993-107011	19930612
PRAI	DE 1992-4219409	19920613			
	DE 1992-4237656	19921107			

GI




AB Title compds. [I; R1 = H, alkyl, alkoxy, alkylthio, (substituted) aryl,
 heterocycl; R2, R3 = Q1, Q2, Q3, etc.; R4 = CO₂R, cyano, tetrazolyl;
 R5 = CO₂R, cyano, nitro, amino, NHCOCF₃, tetrazolyl; T = null, NRCO, CH:CH;
 U = CH:C(CO₂R), CH:C(CN), etc.; Y = CR₂CR₂, CR:CR, CR₂S; R = H, alkyl],
 were
 prep'd. as angiotensin II antagonists (no data). Thus,
 2-butyl-5-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)benzimidazole
 in THF was treated with KOCMe₃ and then with Me 4'-bromomethylbiphenyl-
 2-
 carboxylate to give a mixt. of 2 isomers which were alkylated with Me
 bromoacetate followed by sapon. with aq. NaOH to give 2-butyl-1-(2'-
 carboxybiphenyl-4-methyl)-5-(1-carboxymethyl-1,4,5,6-tetrahydro-4-
 methyl-
 6-oxo-3-pyridazinyl)benzimidazole and 2-butyl-1-(2'-carboxybiphenyl-4-
 methyl)-6-(1-carboxymethyl-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-
 pyridazinyl)benzimidazole. Generic I formulations are given.

MSTR 1




G1 = 15-17 16-192 10-2



G8 = Cb<EC (10) C, AR (1-), BD (ALL) N, FA (2) C,
RC (2), RS (2) E6 (0) OTHER> (SO (1-2) G5)

G22 = 287-2 286-4




DER: or salts

MPL: claim 1


NTE: substitution is restricted

NTE: also incorporates claim 3

MSTR 3




G1 = 16-17 10-2 16-192



G8 = Cb<EC (10) C, AR (1-), BD (ALL) N, FA (2) C,
RC (2), RS (2) E6 (0) OTHER> (SO (1-2) G5)

G22 = 287-2 286-4




MPL: claim 3

NTE: substitution is restricted

L11 ANSWER 12 OF 14 MARPAT COPYRIGHT 2002 ACS
 AN 120:191707 MARPAT
 TI 2-Substituted saccharin derivative proteolytic enzyme inhibitors
 IN Hlasta, Dennis John; Desai, Ranjit Chimanlal; Subramanyam, Chakrapani;
 Lodge, Eric Piatt; Dunlap, Richard Paul; Boaz, Neil Warren; Mura, Albert
 Joseph; Latimer, Lee Hamilton
 PA Sterling Winthrop Inc., USA
 SO Eur. Pat. Appl., 77 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 542372	A1	19930519	EP 1992-203469	19921112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 5236917	A	19930817	US 1991-793033	19911115
	AU 9225340	A1	19930520	AU 1992-25340	19920925
	AU 654581	B2	19941110		
	CA 2079822	AA	19930516	CA 1992-2079822	19921005
	NO 9204401	A	19930518	NO 1992-4401	19921113
	HU 66873	A2	19950130	HU 1992-3566	19921113
	IL 103748	A1	19970218	IL 1992-103748	19921113
	RU 2101281	C1	19980110	RU 1992-4381	19921113
	JP 05194444	A2	19930803	JP 1992-305295	19921116
	US 5371074	A	19941206	US 1993-67637	19930524
	US 5650422	A	19970722	US 1994-270964	19940705
	US 5596012	A	19970121	US 1995-449152	19950524
	US 5874432	A	19990223	US 1997-803297	19970220
PRAI	US 1991-793033	19911115			
	US 1989-347125	19890504			
	US 1989-347126	19890504			
	US 1990-514920	19900426			
	US 1993-67637	19930524			
	US 1994-270964	19940705			


GI




AB The title compds. I [L = O, S, SO, SO₂; R1 = (un)substituted Ph,
 (un)substituted heterocyclyl, etc.; R2 = H, lower alkoxy carbonyl, Ph,
 PhS;
 R3 = H, halogen, (un)substituted alkyl, Ph, lower alkoxy, lower
 alkoxy carbonyl, CN, etc.; R4 = H or 1-3 substituents selected from
 halogen, CN, NO₂, NH₂, etc.; m, n = 0, 1; when m = 0 then R1 can only be
 heterocyclyl and CHR2 can only be bonded to a ring N of R1; when m = 0,
 n = 1 and L is O, S, or SO, then R2-R4 = H; when m = 0, n = 1, L is S, R2,

R₄ = H and R₃ = halogen; when m = 0, n = 1, and L is SO or SO₂ then R₂ is lower alkoxy carbonyl and R₃ = R₄ = H while R₁ .noteq. substituted Ph], useful for the treatment of degenerative diseases (no data), are prep'd. Thus, 2-hydroxymethyl-4-chlorosaccharin was reacted with thionyl chloride, producing 2-chloromethyl-4-chlorosaccharin (II). II demonstrated inhibition const. for human leukocyte elastase (rate of reactivation of enzyme to rate of inactivation of enzyme) of 0.5 nM and 26 nM for .alpha.-chymotrypsin.

MSTR 1G



G3 = 302




G12 = furyl / Ph (SO)

MPL: claim 1

NTE: substitution is restricted


L11 ANSWER 13 OF 14 MARPAT COPYRIGHT 2002 ACS
 AN 118:59590 MARPAT
 TI Heterocyclic amidine derivatives [(heteroaryl methyl)nitroguanidine derivatives] and their use as pesticides (insecticides and acaricides)
 IN Kristiansen, Odd; Gsell, Laurenz; Maienfisch, Peter
 PA Ciba-Geigy A.-G., Switz.
 SO Eur. Pat. Appl., 63 pp.
 CODEN: EPXXDW
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 507736 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT US 5223520 CA 2064920 JP 05117237 AU 9214036 CN 1065456 HU 60721 BR 9201197 ZA 9202450	A1 A AA A2 A1 A A2 A A	19921007 19930629 19921005 19930514 19921008 19921021 19921028 19921201 19930405	EP 1992-810225 US 1992-858910 CA 1992-2064920 JP 1992-109199 AU 1992-14036 CN 1992-102347 HU 1992-1140 BR 1992-1197 ZA 1992-2450	19920326 19920327 19920402 19920402 19920403 19920403 19920403 19920403 19920403
PRAI	CH 1991-1004		19910404		
OS	CASREACT 118:59590				
GI					




AB Some heterocyclic amidine derivs. and a process for their prepn. are claimed. The use of these compds. as pesticides (insecticides and acaricides) is claimed. Condensation of 1-amino-2-[(2-chloro-5-pyridyl)methylamino]-2-nitroethene with DMF di-Et acetal gave the acyclic amidine I. I had activity against Nilaparvata lugens, Nephrotettix cincticeps, Bemisia tabaci and Ctenocephalides felis (flea; systemic).


MSTR 1A



G12 = 340




G18 = alkyl<(1-4)>
G19 = O
G20 = 326




DER: or acid addition salts
MPL: claim 1


MSTR 2A



G12 = 340



G18 = alkyl<(1-4)>
G19 = O
G20 = 326




MPL: claim 21

App's

L4 ANSWER 5 OF 61 CAPLUS COPYRIGHT 2002 ACS
AN 2000:573782 CAPLUS
DN 133:164066
TI Preparation of heterodiazinone derivatives as AMPA receptor antagonists
IN Ito, Koichi; Kitazawa, Noritaka; Nagato, Satoshi; Kajiwara, Akiharu;
Fukushima, Tatsuto; Hatakeyama, Shinji; Hanada, Takahisa; Ueno,
Masataka; Ueno, Kohshi; Kawano, Koki
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047567	A1	20000817	WO 2000-JP799	20000215
	W: AU, BR, CA, CN, HU, KR, MX, NO, NZ, RU, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 2000302770	A2	20001031	JP 2000-34407	20000214
	EP 1153922	A1	20011114	EP 2000-902953	20000215
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	JP 1999-36233	A	19990215		
	WO 2000-JP799	W	20000215		
OS	MARPAT	133:164066			
GI					



AB Heterodiazinone derivs. represented by general formula (I), pharmacol. acceptable salts of the same, or hydrates of both, [wherein A is O, S or NR3 (wherein R3 is hydrogen or lower alkyl); R1 and R2 are each independently optionally substituted (hetero)aryl, aralkyl, heteroarylalkyl, arylalkenyl, or heteroarylalkenyl, piperidyl, piperazinyl, morpholinyl, (un)substituted lower cycloalkyl, tetrahydrofuranlyl, tetrahydropyranyl, adamantlyl, (un)substituted NH2, (un)substituted amido; and R4 and R5 are each independently hydrogen, hydroxyl, halogeno, cyano, nitro, lower alkyl, or (hetero)aryl], exhibiting 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonism, are prep'd. These compds. are useful for the treatment, prevention, or improvement of diseases where AMPA receptor antagonism is effective, such as neurodegenerative diseases, more specifically acute neurodegeneration suffered after brain ischemia, head injury, and spinal cord injury, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington chorea, epilepsy, pain, multiple sclerosis, cerebral meningitis, Guillain-Barre syndrome, HIV- or HTLV-related myelitis, or white encephalitis. Thus, picolinic acid was condensed with phneylhydrazine using 1,1'-carbonyldimidazole

in DMF/THF to give 86% picolinic acid phenylhydrazide which was cyclocondensed with chloroacetyl chloride in Me Et ketone under reflux for 1 h to give 2-(2-pyridyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one (II). II.HCl and 2-phenyl-4-(2-chlorophenyl)-4H-1,3,4-oxadiazin-5(6H)-one showed IC₅₀ of 11.8 and 0.8 μM, resp., for inhibiting AMPA-induced influx of calcium into rat cerebral nerve cells.


IT 28669-15-0P 135585-97-6P 287953-92-8P
287953-95-1P 287953-97-3P 287953-99-5P
287954-02-3P 287954-04-5P 287954-06-7P
287954-08-9P 287954-10-3P 287954-12-5P
287954-14-7P 287954-16-9P 287954-18-1P
287954-20-5P 287954-22-7P 287954-23-8P
287954-25-0P 287954-27-2P 287954-29-4P
287954-31-8P 287954-33-0P 287954-35-2P
287954-37-4P 287954-39-6P 287954-41-0P
287954-43-2P 287954-45-4P 287954-47-6P
287954-49-8P 287954-51-2P 287954-53-4P
287954-54-5P 287954-55-6P 287954-56-7P
287954-57-8P 287954-58-9P 287954-59-0P
287954-60-3P 287954-62-5P 287954-65-8P
287954-66-9P 287954-68-1P 287954-70-5P
287954-72-7P 287954-74-9P 287954-75-0P
287954-77-2P 287954-79-4P 287954-81-8P
287954-83-0P 287954-85-2P 287954-88-5P
287954-90-9P 287954-92-1P 287954-94-3P
287954-96-5P 287954-98-7P 287955-01-5P
287955-02-6P 287955-03-7P 287955-04-8P
287955-05-9P 287955-06-0P 287955-07-1P
287955-08-2P 287955-09-3P 287955-10-6P
287955-11-7P 287955-12-8P 287955-13-9P
287955-14-0P 287955-15-1P 287955-16-2P
287955-17-3P 287955-18-4P 287955-19-5P
287955-20-8P 287955-21-9P 287955-22-0P
287955-23-1P 287955-24-2P 287955-25-3P
287955-26-4P 287955-27-5P 287955-28-6P
287955-29-7P 287955-30-0P 287955-31-1P
287955-32-2P 287955-33-3P 287955-34-4P
287955-35-5P 287955-36-6P 287955-37-7P
287955-38-8P 287955-39-9P 287955-40-2P
287955-42-4P 287955-43-5P 287955-44-6P
287955-45-7P 287955-46-8P 287955-47-9P
287955-48-0P 287955-49-1P 287955-50-4P
287955-51-5P 287955-52-6P 287955-53-7P
287955-54-8P 287955-55-9P 287955-56-0P
287955-57-1P 287955-58-2P 287955-59-3P
287955-60-6P 287955-61-7P 287955-62-8P
287955-63-9P 287955-65-1P 287955-66-2P
287955-67-3P 287955-68-4P 287955-69-5P
287955-70-8P 287955-71-9P 287955-72-0P
287955-73-1P 287955-74-2P 287955-75-3P
287955-76-4P 287955-77-5P 287955-78-6P
287955-79-7P 287955-81-1P 287955-82-2P
287955-83-3P 287955-84-4P 287955-85-5P
287955-86-6P 287955-87-7P 287955-88-8P
287955-89-9P 287955-90-2P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); USES (Uses) (prepn. of heterodiazinone derivs. as AMPA receptor antagonists and therapeutics)


RN 28669-15-0 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-hydroxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 135585-97-6 CAPLUS

CN 4H-1,3,4-Thiadiazin-5(6H)-one, 2,4-diphenyl- (9CI) (CA INDEX NAME)



RN 287953-92-8 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-(2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 287953-95-1 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 287953-97-3 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-pyrazinyl- (9CI) (CA INDEX NAME)




RN 287953-99-5 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(1-methyl-1H-pyrrol-2-yl)-4-phenyl- (9CI)
(CA INDEX NAME)




RN 287954-02-3 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2,3-dimethoxyphenyl)-4-phenyl- (9CI)
(CA INDEX NAME)



RN 287954-04-5 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)




RN 287954-06-7 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-(2-quinolinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 287954-08-9 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(6-methyl-2-pyridinyl)-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 287954-10-3 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(6-methyl-2-pyridinyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 287954-12-5 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[2-[(benzoyloxy)methyl]phenyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 287954-14-7 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2,4-difluorophenyl)-2-(2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 287954-16-9 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2,4-difluorophenyl)-2-(2-pyridinyl)-, (9CI) (CA INDEX NAME)



RN 287954-18-1 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-cyclohexyl-2-(2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 287954-20-5 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-cyclohexyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 287954-22-7 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-chloro-4-pyridinyl)-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 287954-23-8 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3-methoxy-2-pyridinyl)-4-phenyl- (9CI)
(CA INDEX NAME)




RN 287954-25-0 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3-hydroxy-2-pyridinyl)-4-phenyl- (9CI)
(CA INDEX NAME)




RN 287954-27-2 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-(2-phenylethenyl)- (9CI) (CA INDEX NAME)




RN 287954-29-4 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[2-(3-pyridinyl)ethenyl]- (9CI)
(CA INDEX NAME)




RN 287954-31-8 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-bromophenyl)-2-(2-methoxyphenyl)-(9CI)
(CA INDEX NAME)




RN 287954-33-0 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-nitrophenyl)-4-phenyl- (9CI) (CA INDEX
NAME)




RN 287954-35-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3-nitrophenyl)-4-phenyl- (9CI) (CA INDEX
NAME)




RN 287954-37-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-nitrophenyl)-4-phenyl- (9CI) (CA INDEX
NAME)




RN 287954-39-6 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-morpholinyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 287954-41-0 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-cyclohexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 287954-43-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(dimethylamino)-4-phenyl- (9CI) (CA INDEX NAME)



RN 287954-45-4 CAPLUS
CN 4H-1,3,4-Thiadiazin-5(6H)-one, 2-(dimethylamino)-4-phenyl- (9CI) (CA INDEX NAME)




RN 287954-47-6 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2,6-dimethoxyphenyl)-4-phenyl- (9CI)


(CA

INDEX NAME)




RN 287954-49-8 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-fluorophenyl)-2-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 287954-51-2 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-cyclohexyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 287954-53-4 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-cyclohexyl-2-(2-methoxyphenyl)- (9CI) (CA

INDEX NAME)




RN 287954-54-5 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-(3-pyridinyl)-,
 monohydrochloride
 (9CI) (CA INDEX NAME)




● HCl

RN 287954-55-6 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-bromophenyl)-2-phenyl- (9CI) (CA
 INDEX
 NAME)




RN 287954-56-7 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-(2-thienyl)- (9CI) (CA INDEX
 NAME)




RN 287954-57-8 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-(phenylmethyl)- (9CI) (CA
 INDEX)

NAME)




RN 287954-58-9 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-bromophenyl)-2-(2-pyridinyl)- (9CI)
(CA INDEX NAME)




RN 287954-59-0 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-fluorophenyl)-2-(2-pyridinyl)- (9CI)
(CA INDEX NAME)




RN 287954-60-3 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-methoxyphenyl)-2-(2-pyridinyl)- (9CI)
(CA INDEX NAME)



RN 287954-62-5 CAPLUS

CN Benzonitrile, 2-(5,6-dihydro-5-oxo-2-phenyl-4H-1,3,4-oxadiazin-4-yl)- (9CI) (CA INDEX NAME)




RN 287954-65-8 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-nitrophenyl)-2-phenyl- (9CI) (CA

INDEX


NAME)



RN 287954-66-9 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-phenyl-4-(2-pyridinyl)-, monohydrochloride

(9CI) (CA INDEX NAME)




● HCl

RN 287954-68-1 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-phenyl-4-(3-pyridinyl)-, monohydrochloride


(9CI) (CA INDEX NAME)



● HCl

RN 287954-70-5 CAPLUS


CN 3-Pyridinecarbonitrile, 2-(5,6-dihydro-5-oxo-2-phenyl-4H-1,3,4-oxadiazin-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 287954-72-7 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[2-(hydroxymethyl)phenyl]-2-phenyl-
(9CI) (CA INDEX NAME)



RN 287954-74-9 CAPLUS


CN 2-Pyridinecarbonitrile, 3-(5,6-dihydro-5-oxo-2-phenyl-4H-1,3,4-oxadiazin-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 287954-75-0 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-phenyl-4-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 287954-77-2 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-phenyl-4-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 287954-79-4 CAPLUS

CN Benzonitrile, 4-(5,6-dihydro-5-oxo-2-phenyl-4H-1,3,4-oxadiazin-4-yl)- (9CI) (CA INDEX NAME)




RN 287954-81-8 CAPLUS

CN Benzonitrile, 3-(5,6-dihydro-5-oxo-2-phenyl-4H-1,3,4-oxadiazin-4-yl)- (9CI) (CA INDEX NAME)




RN 287954-83-0 CAPLUS

CN 2-Thiophenecarbonitrile, 3-(5,6-dihydro-5-oxo-2-phenyl-4H-1,3,4-oxadiazin-4-yl)- (9CI) (CA INDEX NAME)




RN 287954-85-2 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-bromophenyl)-2-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 287954-88-5 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-hydroxyphenyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 287954-90-9 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-fluorophenyl)-2-(2-hydroxyphenyl)-
(9CI) (CA INDEX NAME)




RN 287954-92-1 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-fluorophenyl)-2-(2-hydroxyphenyl)-
(9CI) (CA INDEX NAME)




RN 287954-94-3 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2,4-difluorophenyl)-2-(2-hydroxyphenyl)-
(9CI) (CA INDEX NAME)




RN 287954-96-5 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-bromophenyl)-2-[2-[2-(dimethylamino)ethoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 287954-98-7 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-bromophenyl)-2-[2-[2-(dimethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 287955-01-5 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[2-(4-pyridinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 287955-02-6 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[2-[2-(4-morpholinyl)ethoxy]phenyl]-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 287955-03-7 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[2-[2-(4-morpholinyl)ethoxy]phenyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 287955-04-8 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[2-(2-pyridinylmethoxy)phenyl]-
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 287955-05-9 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[2-(2-pyridinylmethoxy)phenyl]-
(9CI) (CA INDEX NAME)



RN 287955-06-0 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[2-(3-pyridinylmethoxy)phenyl]-
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 287955-07-1 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[2-(3-pyridinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 287955-08-2 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[2-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 287955-09-3 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[2-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 287955-10-6 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[2-[2-(dimethylamino)ethoxy]phenyl]-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 287955-11-7 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[2-[2-(dimethylamino)ethoxy]phenyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 287955-12-8 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[2-[3-(dimethylamino)propoxy]phenyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 287955-13-9 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[2-[3-(dimethylamino)propoxy]phenyl]-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 287955-14-0 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[2-[3-(1-piperidinyl)propoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 287955-15-1 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[2-[3-(1-piperidinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 287955-16-2 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[2-[2-(4-morpholinyl)ethoxy]phenyl]-2-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 287955-17-3 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[2-[2-(4-morpholinyl)ethoxy]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 287955-18-4 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[2-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 287955-19-5 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[2-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 287955-20-8 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[2-[2-(dimethylamino)ethoxy]phenyl]-4-

(2-
fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 287955-21-9 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[2-[2-(dimethylamino)ethoxy]phenyl]-4-
(2-
fluorophenyl)- (9CI) (CA INDEX NAME)




RN 287955-22-0 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-fluorophenyl)-2-[2-[2-(4-
morpholinyl)ethoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 287955-23-1 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-fluorophenyl)-2-[2-[2-(4-
morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 287955-24-2 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-bromophenyl)-2-[2-[2-(4-morpholinyl)ethoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 287955-25-3 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-bromophenyl)-2-[2-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 287955-26-4 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-cyclohexyl-2-[2-[2-(4-morpholinyl)ethoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 287955-27-5 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-cyclohexyl-2-[2-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 287955-28-6 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-fluorophenyl)-2-[2-[2-(4-morpholinyl)ethoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HC1


RN 287955-29-7 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-fluorophenyl)-2-[2-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 287955-30-0 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2,4-difluorophenyl)-2-[2-[2-(4-morpholinyl)ethoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 287955-31-1 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2,4-difluorophenyl)-2-[2-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 287955-32-2 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[3-(2-hydroxyethoxy)-2-pyridinyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 287955-33-3 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[3-[2-(4-morpholinyl)ethoxy]-2-pyridinyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 287955-34-4 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[3-[2-(1-piperidinyl)ethoxy]-2-pyridinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 287955-35-5 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[3-[2-(1-pyrrolidinyl)ethoxy]-2-pyridinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 287955-36-6 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[3-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-2-pyridinyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 287955-37-7 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[3-[2-(dimethylamino)ethoxy]-2-pyridinyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 287955-38-8 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(3-aminophenyl)-4-phenyl- (9CI) (CA
INDEX
NAME)




RN 287955-39-9 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-aminophenyl)-4-phenyl- (9CI) (CA
INDEX
NAME)



RN 287955-40-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-phenyl-4-(tetrahydro-2H-pyran-4-yl)-
(9CI)
(CA INDEX NAME)




RN 287955-42-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(1-methyl-4-piperidinyl)-2-phenyl-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 287955-43-5 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(1-methyl-4-piperidinyl)-2-phenyl- (9CI)

(CA INDEX NAME)




RN 287955-44-6 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(1-azabicyclo[2.2.2]oct-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 287955-45-7 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[1-(phenylmethyl)-4-piperidinyl]-2-(2-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 287955-46-8 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[1-(phenylmethyl)-4-piperidinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 287955-47-9 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-phenyl-4-(tetrahydro-3-furanyl)- (9CI) (CA INDEX NAME)



RN 287955-48-0 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-cyclopentyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 287955-49-1 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-phenyl-4-[1-(phenylmethyl)-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 287955-50-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-phenyl-4-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 287955-51-5 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-phenyl-4-[1-(2-pyridinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 287955-52-6 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-phenyl-4-[1-(2-pyridinyl)ethyl]- (9CI)
(CA INDEX NAME)



RN 287955-53-7 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-phenyl-4-[1-(3-pyridinyl)ethyl]- (9CI)
(CA INDEX NAME)




RN 287955-54-8 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-phenyl-4-[1-(3-pyridinyl)ethyl]-,
ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 287955-53-7

CMF C16 H15 N3 O2




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 287955-55-9 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-phenyl-4-[1-(4-pyridinyl)ethyl]- (9CI)
(CA INDEX NAME)



RN 287955-56-0 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-phenyl-4-[1-(4-pyridinyl)ethyl]-,
ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 287955-55-9
CMF C16 H15 N3 O2




CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 287955-57-1 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[3-(dimethylamino)phenyl]-4-phenyl- (9CI)


(CA INDEX NAME)



RN 287955-58-2 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[2-(dimethylamino)phenyl]-4-phenyl- (9CI)

(CA INDEX NAME)




RN 287955-59-3 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[2-[(4-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 287955-60-6 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[2-[(3-pyridinylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 287955-61-7 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-(4-pyridinyl)-,
monohydrochloride
(9CI) (CA INDEX NAME)




● HCl

RN 287955-62-8 CAPLUS
CN 4H-1,3,4-Oxadiazine-2-carboxamide, 5,6-dihydro-5-oxo-4-phenyl-N-2-
pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 287955-63-9 CAPLUS
CN 4H-1,3,4-Oxadiazine-2-carboxamide, 5,6-dihydro-5-oxo-4-phenyl-N-2-
pyridinyl- (9CI) (CA INDEX NAME)




RN 287955-65-1 CAPLUS
CN 4H-1,3,4-Oxadiazine-2-carboxamide, 5,6-dihydro-5-oxo-4-phenyl-N-3-
pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 287955-66-2 CAPLUS

CN 4H-1,3,4-Oxadiazine-2-carboxamide, 5,6-dihydro-5-oxo-4-phenyl-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 287955-67-3 CAPLUS


CN 4H-1,3,4-Oxadiazine-2-carboxamide, 5,6-dihydro-5-oxo-4-phenyl-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 287955-68-4 CAPLUS


CN 4H-1,3,4-Oxadiazine-2-carboxamide, 5,6-dihydro-5-oxo-4-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 287955-69-5 CAPLUS


CN 1,2,4-Triazin-6(1H)-one, 4,5-dihydro-4-methyl-1,3-diphenyl- (9CI) (CA INDEX NAME)

INDEX NAME)




RN 287955-70-8 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 4,5-dihydro-4-methyl-1-phenyl-3-(2-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 287955-71-9 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-chlorophenyl)-2-phenyl- (9CI) (CA
INDEX NAME)




RN 287955-72-0 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2,6-dichlorophenyl)-2-phenyl- (9CI)
(CA
INDEX NAME)




RN 287955-73-1 CAPLUS

CN 4H-1,3,4-Thiadiazin-5(6H)-one, 6-hydroxy-2,4-diphenyl- (9CI) (CA INDEX
NAME)




RN 287955-74-2 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-bromophenyl)-2-[2-[2-[(methyl(phenylmethyl)amino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 287955-75-3 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-bromophenyl)-2-[2-[2-[(methylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 287955-76-4 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-iodophenyl)-2-(2-pyridinyl)- (9CI)
(CA INDEX NAME)



RN 287955-77-5 CAPLUS

CN Benzonitrile, 2-[5,6-dihydro-5-oxo-2-(2-pyridinyl)-4H-1,3,4-oxadiazin-4-yl]- (9CI) (CA INDEX NAME)




RN 287955-78-6 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 6,6-dimethyl-2,4-diphenyl- (9CI) (CA


INDEX

NAME)



RN 287955-79-7 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2,4,6-triphenyl- (9CI) (CA INDEX NAME)




RN 287955-81-1 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-(2-quinolinyl)- (9CI) (CA


INDEX

NAME)




RN 287955-82-2 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(2-chloro-4-pyridinyl)-4-phenyl- (9CI)
(CA INDEX NAME)




RN 287955-83-3 CAPLUS

CN 3-Pyridinecarbonitrile, 2-(5,6-dihydro-5-oxo-2-phenyl-4H-1,3,4-oxadiazin-4-yl)- (9CI) (CA INDEX NAME)




RN 287955-84-4 CAPLUS

CN 2-Pyridinecarbonitrile, 3-(5,6-dihydro-5-oxo-2-phenyl-4H-1,3,4-oxadiazin-4-yl)- (9CI) (CA INDEX NAME)




RN 287955-85-5 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[6-[2-(4-morpholinyl)ethoxy]-2-pyridinyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 287955-86-6 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[6-[2-(1-piperidinyl)ethoxy]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 287955-87-7 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-[6-[2-(1-pyrrolidinyl)ethoxy]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 287955-88-8 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[6-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-2-pyridinyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 287955-89-9 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[6-[2-(dimethylamino)ethoxy]-2-pyridinyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 287955-90-2 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-phenyl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




IT **287955-64-0P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of heterodiazinone derivs. as AMPA receptor antagonists and therapeutics)

RN 287955-64-0 CAPLUS

CN 4H-1,3,4-Oxadiazine-2-carboxylic acid, 5,6-dihydro-5-oxo-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 61 CAPLUS COPYRIGHT 2002 ACS
AN 2001:615166 CAPLUS
DN 136:37580
TI Solid-phase synthesis of 1-substituted 4,5-dihydro-1,2,4-triazin-6-ones
AU Martinez-Teipel, B.; Michelotti, E.; Kelly, M. J.; Weaver, D. G.;
Acholla, F.; Beshah, K.; Teixido, J.
CS Exploratory Agricultural Products Research, Rohm and Haas Company,
Spring House, PA, 19477, USA
SO Tetrahedron Letters (2001), 42(37), 6455-6457
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
AB The solid-phase synthesis of 1-substituted 4,5-dihydro-1,2,4-triazin-6-
ones from imidate esters and substituted hydrazines is reported. The
synthesis starts with the reaction of imidic esters with polymer-bound
glycine to form the imidate esters. A rehearsal library of 59 compds.
was synthesized.
IT **380887-15-0P**
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP
(Preparation)
 (solid-phase synthesis of 1-substituted 2,5-dihydro-1,2,4-triazin-6-
 ones)
RN 380887-15-0 CAPLUS
CN 1,2,4-Triazin-6(1H)-one, 1-butyl-2,5-dihydro-3-(4-phenoxyphenyl)- (9CI)
(CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 2 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 2001:282783 CAPLUS
 DN 135:122725
 TI Novel approaches to optically active substituted 4,5-dihydro-1,2,4-triazin-6(1H)-ones as conformationally constrained peptidomimetics
 AU Saniere, Laurent; Schmitt, Martine; Pellegrini, Nadia; Bourguignon, Jean-Jacques
 CS Laboratoire de Pharmacochimie de la Communication Cellulaire - UMR 7081
 du CNRS, Faculte de Pharmacie, Illkirch, 67400, Fr.
 SO Heterocycles (2001), 55(4), 671-688
 CODEN: HTCYAM; ISSN: 0385-5414
 PB Japan Institute of Heterocyclic Chemistry
 DT Journal
 LA English
 AB The synthesis of 4,5-dihydro-1,2,4-triazin-6-ones bearing different chiral .alpha.-amino acid residues at the C(3) and N(1) positions is reported. Cyclocondensation of N-thioacylphthalimides with .alpha.-amino hydrazides afforded C(3)-functionalized dihydrotriazinones in good yields without detectable epimerization. Moreover, N(1)-alkylation of the dihydrotriazinone ring with several .alpha.-bromo esters was performed with satisfactory yields. This alkylation reaction was found to be regioselective with respect to N(4) and NHBoc. This class of compds. represents a new series of small conformationally constrained peptide derivs.
 IT 350984-56-4P 350984-57-5P 350984-58-6P
 350984-59-7P 350984-60-0P 350984-61-1P
 350984-62-2P 350984-63-3DP, rotation can be - or +
 350984-64-4DP, rotation can be - or + 350984-65-5P
 350984-66-6P 350984-67-7P 350984-68-8P
 350984-69-9P 350984-70-2P 350984-71-3P
 350984-72-4P 350984-73-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of dihydrotriazinones as peptidomimetics)
 RN 350984-56-4 CAPLUS
 CN 1,2,4-Triazine-1(2H)-acetic acid, 5,6-dihydro-5-methyl-6-oxo-3-phenyl-, ethyl ester, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 350984-57-5 CAPLUS
 CN 1,2,4-Triazine-1(2H)-acetic acid, 5,6-dihydro-6-oxo-3-phenyl-5-(phenylmethyl)-, ethyl ester, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 350984-58-6 CAPLUS

CN 1,2,4-Triazine-1(2H)-acetic acid, 5,6-dihydro-6-oxo-3-phenyl-5-(phenylmethyl)-, phenylmethyl ester, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 350984-59-7 CAPLUS

CN 1,2,4-Triazine-1(2H)-acetic acid, 5,6-dihydro-.alpha.-methyl-6-oxo-3-phenyl-5-(phenylmethyl)-, ethyl ester, (.alpha.R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 350984-60-0 CAPLUS

CN 1,2,4-Triazine-1(2H)-acetic acid, 5,6-dihydro-.alpha.-methyl-6-oxo-3-phenyl-5-(phenylmethyl)-, ethyl ester, (.alpha.S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 350984-61-1 CAPLUS

CN 1,2,4-Triazine-1(2H)-acetic acid, 5,6-dihydro-5-(2-methylpropyl)-6-oxo-

3-

phenyl-, phenylmethyl ester, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 350984-62-2 CAPLUS

CN 1,2,4-Triazine-1(2H)-acetic acid, 5,6-dihydro-5-(2-methylpropyl)-6-oxo-3-

phenyl-.alpha.- (phenylmethyl)-, ethyl ester, (.alpha.S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 350984-63-3 CAPLUS

CN 1,2,4-Triazine-1(2H)-acetic acid, 5,6-dihydro-5-(2-methylpropyl)-6-oxo-3-

phenyl-.alpha.- (phenylmethyl)-, ethyl ester, (.alpha.R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 350984-64-4 CAPLUS

CN 1,2,4-Triazine-1(2H)-acetic acid, 5,6-dihydro-.alpha.-methyl-5-(2-methylpropyl)-6-oxo-3-phenyl-, ethyl ester, (.alpha.R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 350984-65-5 CAPLUS

CN 1,2,4-Triazine-1(2H)-acetic acid, 5,6-dihydro-.alpha.-methyl-5-(2-methylpropyl)-6-oxo-3-phenyl-, ethyl ester, (.alpha.S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 350984-66-6 CAPLUS

CN 1,2,4-Triazine-1,4-diacetic acid, 5,6-dihydro-5-methyl-6-oxo-3-phenyl-, diethyl ester, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 350984-67-7 CAPLUS

CN 1,2,4-Triazine-1,4-diacetic acid, 5,6-dihydro-6-oxo-3-phenyl-5-(phenylmethyl)-, diethyl ester, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 350984-68-8 CAPLUS


CN 1,2,4-Triazine-1,4-diacetic acid, 5,6-dihydro-5-(2-methylpropyl)-6-oxo-3-phenyl-, bis(phenylmethyl) ester, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 350984-69-9 CAPLUS
CN 1,2,4-Triazine-1,4-diacetic acid, 5,6-dihydro-.alpha.,.alpha.'-dimethyl-6-oxo-3-phenyl-5-(phenylmethyl)-, diethyl ester, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 350984-70-2 CAPLUS
CN 1,2,4-Triazine-1,4-diacetic acid, 5,6-dihydro-5-(2-methylpropyl)-6-oxo-3-phenyl-.alpha.,.alpha.'-bis(phenylmethyl)-, diethyl ester, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 350984-71-3 CAPLUS
CN 1,2,4-Triazine-1,4-diacetic acid, 5,6-dihydro-.alpha.,.alpha.'-dimethyl-5-(2-methylpropyl)-6-oxo-3-phenyl-, diethyl ester, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 350984-72-4 CAPLUS

CN Carbamic acid, [(1S)-2-phenyl-1-[(5S)-1,2,5,6-tetrahydro-1-methyl-6-oxo-5-(phenylmethyl)-1,2,4-triazin-3-yl]ethyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 350984-73-5 CAPLUS

CN 1,2,4-Triazine-1(2H)-acetic acid, 3-[(1S)-1-[(1,1-dimethylethoxy)carbonyl]amino]-2-phenylethyl]-5,6-dihydro-6-oxo-5-(phenylmethyl)-, ethyl ester, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RE.CNT 24


THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 2001:12432 CAPLUS
 DN 134:86283
 TI Preparation of N-[4-(6-oxotetrahydrotriazinyl)phenyl]amides for treatment of anemia.
 IN Stoltzfuss, Jürgen; Braunlich, Gabriele; Logers, Michael; Schmeck, Carsten; Fugmann, Burkhard; Nielsch, Ulrich; Bechem, Martin; Gerdes, Christian; Sperzel, Michael; Lustig, Clemens; Sturmer, Werner
 PA Bayer Aktiengesellschaft, Germany; et al.
 SO PCT Int. Appl., 71 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001000598	A1	20010104	WO 2000-EP5572	20000616
			W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
			RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
DE 19929781	A1	20010104	DE 1999-19929781	19990629
PRAI DE 1999-19929781	A	19990629		
OS MARPAT 134:86283				
GI				




AB Title compds. [I; A, D, E = H, halo, CF₃, OH, alkyl, alkoxy; R₁-R₄ = H, alkyl; R₅ = (substituted) cycloalkyl, aryl, heteroaryl, amino], were prepd. as stimulators of erythropoiesis (no data). Thus, 6-(4-nitrophenyl)-2H-1,2,5-triazin-3-one (prepn. given) was hydrogenated in dioxane over Pd/C to give 95.92% 6-(4-aminophenyl)-2H-1,2,5-triazin-3-one. The latter in DMF contg. Et₃N at 0.degree. was treated with furan-2-carbonyl chloride to give 59.87% furan-2-carboxylic acid [4-(6-oxo-1,4,5,6-tetrahydro-1,2,4-triazin-3-yl)phenyl]amide.
 IT 316812-55-2P 316812-58-5P 316812-60-9P
316812-62-1P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of N-[4-(6-oxotetrahydrotriazinyl)phenyl]amides for treatment of anemia)
 RN 316812-55-2 CAPLUS
 CN 2-Furancarboxamide, N-[4-(1,2,5,6-tetrahydro-1-methyl-6-oxo-1,2,4-triazin-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 316812-58-5 CAPLUS

CN Cyclohexanecarboxamide, N-[4-(1,2,5,6-tetrahydro-1-methyl-6-oxo-1,2,4-triazin-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 316812-60-9 CAPLUS

CN Benzamide, N-[4-(1,2,5,6-tetrahydro-1-methyl-6-oxo-1,2,4-triazin-3-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 316812-62-1 CAPLUS

CN 2-Pyridinecarboxamide, N-[4-(1,2,5,6-tetrahydro-1-methyl-6-oxo-1,2,4-triazin-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 4 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 2001:6481 CAPLUS
 DN 134:202083
 TI Transition metal complexes of derivatized chiral dihydro-1,2,4-triazin-
 6-ones. part III. X-ray crystal structure analysis of N,N'-bis[(1-phenyl-
 5- isopropyl-4,5-dihydro-6-oxo-1,2,4-triazin-3-yl)ethylidene]propane-1,3-
 diamine nickel(II)
 AU Abushamleh, Ahmad S.; El-Abadelah, Mustafa M.; Voelter, Wolfgang
 CS Chem. Dep., Fac. Arts and Sci., The Hashemite Univ., Zarqa, Jordan
 SO Z. Naturforsch., B: Chem. Sci. (2000), 55(11), 1074-1078
 CODEN: ZNBSEN; ISSN: 0932-0776
 PB Verlag der Zeitschrift fuer Naturforschung
 DT Journal
 LA English
 AB Template reaction of (S)-3-acetyl-1-phenyl-5-isopropyl-4,5-dihydro-
 1,2,4- triazin-6-one with 1,3-diaminopropane and nickel acetate gave the
 corresponding chiral nickel complex in high yield. X-ray structure
 detn.
 showed that the nickel complex is square planar, and the ligand
 N,N'-bis[(1-phenyl-5-isopropyl-4,5-dihydro-6-oxo-1,2,4-triazin-3-
 yl)ethylidene]propane-1,3-diamine is of the tetraaza type where the
 imine
 nitrogens and the ring HN(4) nitrogens are the coordinating sites. MS-
 FAB
 and NMR spectral data are in agreement with the x-ray structure.
 IT 327065-05-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and template condensation reaction with propanediamine and
 nickel acetate)
 RN 327065-05-4 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-2,5-dihydro-5-(1-methylethyl)-1-
 phenyl-,
 (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 2000:565918 CAPLUS
 DN 133:350195
 TI Action of perfluoroalkylated hydrazines on iminoesters. Synthesis of perfluoroalkyl-3-aminothienopyrimidinones and perfluoroalkyl-1,2,4-triazin-6-ones
 AU Kammoun, M.; Khemakhem, A. M.; Hajjem, B.
 CS Laboratoire de Chimie Organique, Institut National Agronomique de Tunisie, Tunis-Mahrajene, 1082, Tunisia
 SO J. Fluorine Chem. (2000), 105(1), 83-86
 CODEN: JFLCAR; ISSN: 0022-1139
 PB Elsevier Science S.A.
 DT Journal
 LA French
 OS CASREACT 133:350195
 AB Treatment of N-(2-methoxycarbonylthienyl), N-(3-ethoxycarbonyl)-4,5,6,7-tetrahydrobenzothienyl, and N-ethoxycarbonylmethyl imides with perfluoroalkylated hydrazines yields perfluoroalkyl-3-amino[3,2-d]4(3H)thienopyrimidinones, perfluoroalkyl-3-amino-2-methyl-5,6,7,8-tetrahydrobenzo[2,3-d]4(3H)thienopyrimidinones, and perfluoro-alkyl-1,2,4-triazin-6-ones. The products obtained gave information on the mechanism of cyclization.
 IT 305838-71-5P 305838-72-6P 305838-73-7P
 305838-74-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (reaction of perfluoroalkylated hydrazines with iminoesters)
 RN 305838-71-5 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1-(pentafluorophenyl)-3-phenyl-
 (9CI)
 (CA INDEX NAME)




RN 305838-72-6 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-3-phenyl-1-(2,2,2-trifluoroethyl)-
 (9CI) (CA INDEX NAME)




RN 305838-73-7 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-5-methyl-1-(pentafluorophenyl)-3-

phenyl- (9CI) (CA INDEX NAME)



RN 305838-74-8 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-5-methyl-3-phenyl-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 61 CAPLUS COPYRIGHT 2002 ACS
AN 2000:557902 CAPLUS
DN 133:260733
TI Synthesis and structural characterization of palladium(II) complex with (L)-3-acetyl-5-benzyl-1-phenyl-4,5-dihydro-1,2,4-triazin-6-one oxime.

Part

II

AU Abushamleh, Ahmad S.; El-Abadelah, Mustafa M.; Mossmer, Cacilia M.
CS Chemistry Department, Faculty of Arts and Sciences, The Hashemite University, Zarka, Jordan
SO Heterocycles (2000), 53(8), 1737-1744
CODEN: HTCYAM; ISSN: 0385-5414
PB Japan Institute of Heterocyclic Chemistry
DT Journal
LA English
AB The synthesis and structural properties of the four-coordinate Pd(L)2 (4), where L is chiral 3-acetyl-5-benzyl-1-phenyl-4,5-dihydro-1,2,4-triazin-6-one oxime (2), are described. Deep-red needles of 4 crystallize in the hexagonal space group P61. The crystallog. data reveal that the two oxime ligands are not sym. coordinated to Pd(II) ion, and the 4N-donor set comprises both oxime nitrogens, an amidrazone N and a hydrazone N. 1H-, 13C-NMR and FD-MS spectral data of 4 are consistent with its x-ray mol. structure.

IT **294842-56-1P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and complexation with palladium(II))

RN 294842-56-1 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-3-[1-(hydroxyimino)ethyl]-1-phenyl-5-(phenylmethyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




IT **294842-57-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction with hydroxylamine hydrochloride)

RN 294842-57-2 CAPLUS


CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-2,5-dihydro-1-phenyl-5-(phenylmethyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 2000:411851 CAPLUS
 DN 133:193125
 TI Dihydro-1,2,4-triazin-6(1H)-ones. IV Chemical modification of
 3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-ones
 AU Collins, David J.; Hughes, Timothy C.; Johnson, Wynona M.
 CS Department of Chemistry, Monash University, Clayton, 3168, Australia
 SO Aust. J. Chem. (2000), 53(2), 137-141
 CODEN: AJCHAS; ISSN: 0004-9425
 PB CSIRO Publishing
 DT Journal
 LA English
 AB Reaction of 3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-one (1) and its
 5,5-di-Me deriv. with phosphorus pentasulfide gave the corresponding
 6-thiones (2) and (5); methylation of 2 gave 6-methylsulfanyl-3-phenyl-
 4,5-dihydro-1,2,4-triazine, also obtained by reaction of 6-chloro-3-phenyl-
 4,5-dihydro-1,2,4-triazine (8) with sodium thiomethoxide. Reaction of 8
 with morpholine afforded the 6-(morpholin-4'-yl) deriv. Reaction of 1 with
 iso-Pr isocyanate gave N-isopropyl-6-oxo-3-phenyl-1,4,5,6-tetrahydro-
 1,2,4-triazine-1-carboxamide, and a Mannich reaction of 1 with morpholine and
 formaldehyde gave the 1-morpholinomethylene deriv.
 IT 289622-92-0P 289622-93-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (reactions of phenyldihydro-1,2,4-triazin-6(1H)-ones)
 RN 289622-92-0 CAPLUS
 CN 1,2,4-Triazine-1(2H)-carboxamide, 5,6-dihydro-N-(1-methylethyl)-6-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 289622-93-1 CAPLUS
 CN 1,2,4-Triazine-1(2H)-one, 2,5-dihydro-1-(4-morpholinylmethyl)-3-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 9 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 2000:297013 CAPLUS
 DN 133:37285
 TI Transition metal complexes of derivatized chiral dihydro-1,2,4-triazin-6-ones. Part I. Nickel(II) complex of (D)-3-acetyl-5-benzyl-1-phenyl-4,5-dihydro-1,2,4-triazin-6-one oxime. An instance of a carbon-carbon coupling reaction
 AU Abushamleh, Ahmad S.; El-Abadelah, Mustafa M.; Mossmer, Cacilia M.
 CS Chemistry Department, Faculty of Arts and Sciences, The Hashemite University, Zarka, Jordan
 SO Heterocycles (2000), 53(5), 1155-1165
 CODEN: HTCYAM; ISSN: 0385-5414
 PB Japan Institute of Heterocyclic Chemistry
 DT Journal
 LA English
 AB The reaction of (D)-3-acetyl-5-benzyl-1-phenyl-4,5-dihydro-1,2,4-triazin-6-one oxime (2) with nickel acetate in refluxing ethanol afforded the resp. square planar Ni(II) complex (3). This is evidenced from an x-ray study which reveals that the Ni(II) ion is coordinated to the ring N(4) and oxime nitrogen atoms. The crystallog. data of 3 also unraveled that the nickel-complexation gave one .pi.-bond across the N(14)-C(15) bond and one .sigma.-bond between a benzylic carbon atom of one ligand and the chiral (C5) carbon atom of the other ligand in the bis-ligand complex 3. Evidently, the complexed Ni(II) ion plays a template effect role in initiating such a cascade of .pi.- and .sigma.- bond forming reactions. 1H-, 13C-NMR and FD-MS spectral data of 3 are in full agreement with its mol. structure.
 IT 273756-54-0P, (D)-3-Acetyl-5-benzyl-1-phenyl-4,5-dihydro-1,2,4-triazin-6-one 273756-55-1P, (D)-3-Acetyl-5-benzyl-1-phenyl-4,5-dihydro-1,2,4-triazin-6-one oxime
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (for prepn. of nickel(II) complex from templated carbon-carbon coupling reaction of nickel acetate with (D)-3-acetyl-5-benzyl-1-phenyl-4,5-dihydro-1,2,4-triazin-6-one oxime)
 RN 273756-54-0 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-2,5-dihydro-1-phenyl-5-(phenylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 273756-55-1 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-3-[(1E)-1-(hydroxyimino)ethyl]-1-phenyl-5-(phenylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RE.CNT 16 . THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 10 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 2000:100200 CAPLUS
 DN 132:251127
 TI Regioselective alkylations of optically active 4,5-dihydro-1,2,4-triazin-6(1H)-ones
 AU Saniere, Laurent; Schmitt, Martine; Bourguignon, Jean-Jacques
 CS Laboratoire de Pharmacochimie de la Communication Cellulaire, UMR 7081
 du CNRS, Faculte de Pharmacie, Illkirch, 67400, Fr.
 SO Tetrahedron Lett. (2000), 41(5), 671-674
 CODEN: TELEAY; ISSN: 0040-4039
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 OS CASREACT 132:251127
 AB Regiocontrolled alkylations of chiral 4,5-dihydrotriazin-6-ones using sodium hydride in DMF are reported. By this approach different N1-alkyl-, N1,N4-dialkyl-, and N4-alkyldihydrotriazinones could be obtained in good yields with conservation of their optical activity.
 IT 262861-96-1P 262861-97-2P 262861-99-4P
 262862-01-1P 262862-03-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (regioselective alkylations of optically active dihydrotriazinones)
 RN 262861-96-1 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1-methyl-3-phenyl-5-(phenylmethyl)-
 (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 262861-97-2 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-5-methyl-3-phenyl-1-(phenylmethyl)-
 (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 262861-99-4 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-5-methyl-3-phenyl-1-[(phenylmethoxy)methyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 262862-01-1 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 4,5-dihydro-4,5-dimethyl-3-phenyl-1-[(phenylmethoxy)methyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 262862-03-3 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 4,5-dihydro-4,5-dimethyl-3-phenyl-1-[(phenylmethoxy)methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 262861-95-0P 262861-98-3P 262862-00-0P


262862-02-2P 262862-05-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(regioselective alkylations of optically active dihydrotriazinones)

RN 262861-95-0 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1,5-dimethyl-3-phenyl-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 262861-98-3 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 1-butyl-2,5-dihydro-5-methyl-3-phenyl-, (5S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 262862-00-0 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 4,5-dihydro-1-methyl-3-phenyl-4,5-bis(phenylmethyl)-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 262862-02-2 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 4,5-dihydro-5-methyl-3-phenyl-1,4-bis(phenylmethyl)-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 262862-05-5 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 4,5-dihydro-1,4,5-trimethyl-3-phenyl-, (5S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RE.CNT 8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 2000:61869 CAPLUS
 DN 132:207829
 TI Dihydro-1,2,4-triazin-6(1H)-ones. III. Oxidation products of
 1-methyl-3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-one
 AU Collins, David J.; Hughes, Timothy C.; Johnson, Wynona M.
 CS Department of Chemistry, Monash University, Clayton, 3168, Australia
 SO Aust. J. Chem. (1999), 52(10), 971-975
 CODEN: AJCHAS; ISSN: 0004-9425
 PB CSIRO Publishing
 DT Journal
 LA English
 OS CASREACT 132:207829
 GI




AB 1-Methyl-3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-one (I) undergoes
 aerial
 oxidn. to give a mixt. of 1-methyl-3-phenyl-1,2,4-triazin-6(1H)-one (II)
 and 1-methyl-3-phenyl-1,4-dihydro-1,2,4-triazine-5,6-dione (III). II
 was
 cleanly prep'd. by oxidn. of I with 2,3-dichloro-5,6-dicyano-1,4-
 benzoquinone (DDQ). II underwent a surprising rearrangement to the
 triazole IV upon oxidn. with Oxone. Several attempts at unambiguous
 synthesis of III were unsuccessful; it was obtained, together with the
 1,4-di-Me deriv. by methylation of 3-phenyl-1,4-dihydro-1,2,4-triazine-
 5,6-
 dione with sodium hydride and Me iodide.
 IT 180901-61-5
 RL: RCT (Reactant)
 (oxidn. of)
 RN 180901-61-5 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1-methyl-3-phenyl- (9CI) (CA INDEX
 NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1999:601669 CAPLUS
 DN 131:322605
 TI Dihydro-1,2,4-triazin-6(1H)-ones. II. Synthesis of several methylated
 3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-ones
 AU Collins, David J.; Hughes, Timothy C.; Johnson, Wynona M.
 CS Department of Chemistry, Monash University, Clayton, 3168, Australia
 SO Aust. J. Chem. (1999), 52(5), 379-385
 CODEN: AJCHAS; ISSN: 0004-9425
 PB CSIRO Publishing
 DT Journal
 LA English
 OS CASREACT 131:322605
 GI




AB Novel syntheses of 4,5-dihydro-1,2,4-triazin-6(1H)-ones were developed by use of imidoyl chlorides. The overall yield of 4,5-dihydro-1,2,4-triazin-6(1H)-ones prepd. from amino acid imidates and hydrazines was improved by development of a much more efficient synthesis of the imidates. The new 1,2-, 1,4-, and 5,5-dimethylidihydro-1,2,4-triazin-6(1H)-ones have been synthesized by cyclocondensation/cycloaddn. pathways. Base-catalyzed methylation of 3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-one (I, R = H) gave I (R = Me); under similar conditions 2-methyl-3-phenyl-2,5-dihydro-1,2,4-triazin-6(1H)-one (II, R1 = H) afforded II (R1 = Me).

IT 180901-61-5P 248937-01-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of methylated 3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-ones)


RN 180901-61-5 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1-methyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 248937-01-1 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 4,5-dihydro-1,4-dimethyl-3-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 61 CAPLUS COPYRIGHT 2002 ACS
AN 1999:535323 CAPLUS
DN 131:228705
TI Utility of 2-hydrazino-4,6-dimethylpyrimidine in heterocyclic synthesis
AU Al-Ashmawy, M. I.; El-Samii, Z. K. Abd; El Feky, S. A.; Osman, N. A.
CS Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Zagazig
University, Zagazig, Egypt
SO Boll. Chim. Farm. (1998), 137(4), 110-114
CODEN: BCFAAI; ISSN: 0006-6648
PB Società Editoriale Farmaceutica
DT Journal
LA English
OS CASREACT 131:228705
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB 2-Hydrazino-4,6-dimethylpyrimidine (I) readily underwent ring closure with benzoyl chloride to give 5,7-dimethyl-3 phenyl-1,2,4-triazolo[4,3-a]pyrimidine (II). Reaction of compd. I with acetylacetone gave the pyrazole deriv. III rather than 1,2,4-triazepine deriv. The pyrrole IV was the sole product from cyclization of I with 2,5-hexanedione.

Reaction


of compd. I with carbon disulfide or Et chloroformate gave 1,2,4-triazolo[4,3-a]pyrimidines V (X = S, O). The reaction of thiosemicarbazides VI (R = Ph, Me, allyl) with Et bromoacetate and dicyclohexylcarbodiimide was investigated.

IT 211574-53-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of pyrimidine derivs. from hydrazinodimethylpyrimidine)


RN 211574-53-7 CAPLUS

CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-(4,6-dimethyl-2-pyrimidinyl)-2-(phenylamino)- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 61 CAPLUS COPYRIGHT 2002 ACS
AN 1999:177027 CAPLUS
DN 130:311739
TI Synthesis and Reactivity of 3-Alkylthio-5-cyanomethyl-4-phenyl-1,2,4-triazoles
AU Mekheimer, Ramadan A.; Shaker, Rafat M.
CS Faculty of Science, Chemistry Department, El-Minia University, El-Minia, 61519, Egypt
SO J. Chem. Res., Synop. (1999), (2), 76-77, 449-459
CODEN: JRPSDC; ISSN: 0308-2342
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 130:311739
AB Ph isothiocyanate reacts with 2-cyanoacetohydrazide to yield the corresponding 1-cyanoacetyl-4-Ph thiosemicarbazide, via acid hydrolysis of an intermediate, whereas cyclization of 1-cyanoacetyl-4-Ph thiosemicarbazide gave 1,2,4-triazoles, 1,3,4-thiadiazole and 1,3,4-thiadiazine-5-one. The products obtained from a reaction of 5-(ethylthio)-4-phenyl-4H-1,2,4-triazole-2-acetonitrile with Ph isothiocyanate, dicyandiamide, mercaptoacetic acid and benzaldehyde were described.
IT 223589-39-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 223589-39-7 CAPLUS
CN 4H-1,3,4-Thiadiazine, 4-(cyanoacetyl)-5,6-dihydro-5-oxo-2-(phenylamino)-(9CI) (CA INDEX NAME)




RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1999:130935 CAPLUS
 DN 130:219496
 TI Nitrogen heterocyclic compounds and insecticidal and acaricidal compositions containing them
 IN Kato, Yasuhito; Sugisaki, Hiroyasu; Kodama, Seiichiro; Wada, Hisao
 PA Nippon Kayaku Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 21 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11049755	A2	19990223	JP 1997-218367	19970730

OS MARPAT 130:219496
 GI



AB N-contg. heterocyclic compds. AQ [A = (substituted) aryl; Q = Q1-Q4; Y = OCH₂, CH₂CH₂, CH:CH; Z = CH₂, CO, CS; when Y = OCH₂, then Z .noteq. CH₂; R = C₁₋₄ haloalkyl, (CH₂)_mG; G = H, substituent; m = 0-3; when m = 0 or 1, then G .noteq. H] or their salts are useful for insecticidal and acaricidal compns. Refluxing 4-(4-bromophenyl)-4-oxobutyric acid with hydrazine in EtOH and reaction of the resulting 3-(4-bromophenyl)-1H,4H,5H-1,2-diazin-6-one with 1-bromo-2-fluoroethane in DMF in the presence of NaH gave 2-(2-fluoroethyl)-6-(4-bromophenyl)-4H,5H-1,2-diazin-3-one, which (at 200 ppm) showed .gtoreq. 80% control of *Aphis gossypii* on cucumber leaf disks. Formulation examples are given.

IT 221187-77-5P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of N heterocycles for insecticides and acaricides)

RN 221187-77-5 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-fluoroethyl)-2-phenyl- (9CI) (CA

INDEX

NAME)




L4 ANSWER 16 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1998:401624 CAPLUS
 DN 129:175611
 TI Utility of 2-hydrazino-4,6-dimethylpyrimidine in heterocyclic synthesis
 AU Al-Ashmawy, Mohamed I.; Abd El-Samii, Zakaria K.; El-Feky, Said A.;
 Osman,
 Nermin A.
 CS Department of Organic Pharmaceutical Chemistry, Faculty of Pharmacy,
 Zagazig University, Zagazig, Egypt
 SO Zagazig J. Pharm. Sci. (1997), 6(1), 1-6
 CODEN: ZJPSEV; ISSN: 1110-5089
 PB University of Zagazig, Faculty of Pharmacy
 DT Journal
 LA English
 AB 2-Hydrazino-4,6-dimethylpyrimidine readily underwent ring closure with
 benzoyl chloride to give 5,7-dimethyl-3-phenyl-1,2,4-triazolo[4,3-
 a]pyrimidine. Reaction of 2-hydrazino-4,6-dimethylpyrimidine with
 acetylacetone gave a pyrazole deriv. rather than 1,2,4-triazepine
 deriv..
 A pyrrole deriv. was the sole product from cyclization of
 2-hydrazino-4,6-dimethylpyrimidine with 2,5-hexanedione. Reaction of
 2-hydrazino-4,6-dimethylpyrimidine with carbon disulfide or Et
 chloroformate gave 1,2,4-triazolo[4,3-a]pyrimidines. The reaction of
 thiosemicarbazides with Et bromoacetate and DCCD was investigated.
 IT 211574-53-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of heterocyclic compds. from (hydrazino)dimethylpyrimidine)
 RN 211574-53-7 CAPLUS
 CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-(4,6-dimethyl-2-pyrimidinyl)-2-
 (phenylamino)- (9CI) (CA INDEX NAME)




L4 ANSWER 17 OF 61 CAPLUS COPYRIGHT 2002 ACS
AN 1998:351114 CAPLUS
DN 129:122647
TI Reactions of zwitterionic thioxamic acid derivatives with alkyl bromoacetates
AU Drexler, Kerstin; Dehne, Heinz; Reinke, Helmut; Michalik, Manfred
CS Universitat Rostock, Fachbereich Chemie, Rostock, D-18051, Germany
SO Sulfur Lett. (1998), 21(4), 163-177
CODEN: SULED2; ISSN: 0278-6117
PB Harwood Academic Publishers
DT Journal
LA English
AB Reactions of alkyl bromoacetates with zwitterionic thioxamic acid derivs. lead to new salts or to non-salt-like products, dependent on the base used. In the case of the formation of cyclic derivs. alkyl bromoacetates act as C2-building blocks to give the corresponding 1,3,4-thiadiazine and 1,2,4-triazine derivs., resp.

IT **210234-72-3P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 210234-72-3 CAPLUS
CN 4H-1,3,4-Thiadiazine-2-carboximidic acid, 5,6-dihydro-4-methyl-5-oxo-,
2-methylhydrazide (9CI) (CA INDEX NAME)




IT **210234-71-2P 210234-73-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 210234-71-2 CAPLUS
CN 4H-1,3,4-Thiadiazine-2-carboximidic acid, 5,6-dihydro-4-methyl-5-oxo-,
2-methylhydrazide, monohydrobromide (9CI) (CA INDEX NAME)




● HBr
RN 210234-73-4 CAPLUS
CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-methyl-2-(1,2,5,6-tetrahydro-1-methyl-5-oxo-1,2,4-triazin-3-yl)- (9CI) (CA INDEX NAME)




L4 ANSWER 18 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1998:126019 CAPLUS
 DN 128:267203
 TI Studies on structure-activity relationship of 2-(4-methylphenyl)-4-(substituted)phenyl-1,3,4-oxadiazin-5-one derivatives by T. Kohonen self-organization model
 AU Lu, Wencong; Chen, Wei; Fang, Jianhui; Ding, Yiming; Yan, Licheng; Chen, Nianyi
 CS School of Chemistry and Chemical Engineering, Shanghai University, Shanghai, 201800, Peop. Rep. China
 SO Shanghai Daxue Xuebao, Ziran Kexueban (1997), 3(3), 319-325
 CODEN: SDXKFV; ISSN: 1007-2861
 PB Shanghai Daxue
 DT Journal
 LA Chinese
 AB A nonlinear relationship between the characteristic parameters and biol. activities of a series of 2-(4-methylphenyl)-4-(substituted)phenyl-1,3,4-oxadiazin-5-one derivs. was calcd. by T. kohonen self-organization model. The results showed that the performance of the neural network was good and the successful classification rate was high. The model can be used as an effective auxiliary technique for the investigation of structure-activity relationship of insecticides.
 IT 109462-78-4 109462-78-4D, derivs. 109463-19-6
 109463-23-2 109463-24-3 109491-76-1
 109491-77-2 109491-78-3 109491-79-4
 109491-80-7 109491-81-8 109491-86-3
 109491-87-4 109491-88-5 109491-89-6
 109491-99-8 109492-00-4 109525-24-8
 109551-08-8 129786-74-9 129786-75-0
 129786-76-1 129786-77-2 129786-78-3
 129786-79-4 129786-80-7 129786-82-9
 129786-83-0 129786-84-1 129786-86-3
 129786-87-4 129786-88-5 129786-89-6
 129786-95-4 205578-71-8 205578-73-0
 RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)
 (structure-activity relationship of 2-(4-methylphenyl)-4-(substituted)phenyl-1,3,4-oxadiazin-5-one derivs. by T. Kohonen self-organization model)
 RN 109462-78-4 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109462-78-4 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 109463-19-6 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2,4-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 109463-23-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-methylphenyl)-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 109463-24-3 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-[2-(phenylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 109491-76-1 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-methoxyphenyl)-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 109491-77-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-methoxyphenyl)-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 109491-78-3 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-bromophenyl)-2-(4-methylphenyl)-
(9CI)


(CA INDEX NAME)



RN 109491-79-4 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-fluorophenyl)-2-(4-methylphenyl)-
(9CI)


(CA INDEX NAME)



RN 109491-80-7 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-fluorophenyl)-2-(4-methylphenyl)-
(9CI)


(CA INDEX NAME)




RN 109491-81-8 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-bromophenyl)-2-(4-methylphenyl)-
(9CI)


(CA INDEX NAME)




RN 109491-86-3 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-[2-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 109491-87-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[1,1'-biphenyl]-2-yl-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 109491-88-5 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 109491-89-6 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-ethylphenyl)-2-(4-methylphenyl)- (9CI)
(CA INDEX NAME)




RN 109491-99-8 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-aminophenyl)-2-(4-methylphenyl)- (9CI)
(CA INDEX NAME)




RN 109492-00-4 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-aminophenyl)-2-(4-methylphenyl)-
(9CI)
(CA INDEX NAME)




RN 109525-24-8 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-fluorophenyl)-2-(4-methylphenyl)-
(9CI)
(CA INDEX NAME)




RN 109551-08-8 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-[3-(phenylmethoxy)phenyl]-
(9CI)
(CA INDEX NAME)



RN 129786-74-9 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-methylphenyl)-2-(4-methylphenyl)-
(9CI)
(CA INDEX NAME)



RN 129786-75-0 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-cyclohexylphenyl)-2-(4-methylphenyl)-


(9CI) (CA INDEX NAME)



RN 129786-76-1 CAPLUS

CN Benzenaminium, 3-[5,6-dihydro-2-(4-methylphenyl)-5-oxo-4H-1,3,4-oxadiazin-4-yl]-N,N,N-trimethyl-


(9CI) (CA INDEX NAME)



RN 129786-77-2 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-(2-nitrophenyl)-


(9CI) (CA INDEX NAME)



RN 129786-78-3 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-aminophenyl)-2-(4-methylphenyl)-


(9CI) (CA INDEX NAME)




RN 129786-79-4 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-hydroxyphenyl)-2-(4-methylphenyl)-


(9CI) (CA INDEX NAME)




RN 129786-80-7 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-chlorophenyl)-2-(4-methylphenyl)-
(9CI)
(CA INDEX NAME)




RN 129786-82-9 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-ethylphenyl)-2-(4-methylphenyl)-
(9CI)
(CA INDEX NAME)




RN 129786-83-0 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-[3-
(methylthio)phenyl]-
(9CI) (CA INDEX NAME)




RN 129786-84-1 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[1,1'-biphenyl]-4-yl-2-(4-methylphenyl)-
(9CI) (CA INDEX NAME)




RN 129786-86-3 CAPLUS
CN Benzoic acid, 4-[5,6-dihydro-2-(4-methylphenyl)-5-oxo-4H-1,3,4-
oxadiazin-4-yl]- (9CI) (CA INDEX NAME)




RN 129786-87-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-[3-
(phenylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 129786-88-5 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[1,1'-biphenyl]-3-yl-2-(4-methylphenyl)-
 (9CI) (CA INDEX NAME)




RN 129786-89-6 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[4-[(methylamino)carbonyloxy]phenyl]-
 2-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 129786-95-4 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-(3-nitrophenyl)-
 (9CI) (CA INDEX NAME)




RN 205578-71-8 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-ethylphenyl)-2-(4-methylphenyl)-
 (9CI) (CA INDEX NAME)




RN 205578-73-0 CAPLUS
 CN Benzoic acid, 4-[5,6-dihydro-2-(4-methylphenyl)-5-oxo-4H-1,3,4-oxadiazin-4-yl]-, ethenyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 61 CAPLUS COPYRIGHT 2002 ACS
AN 1997:644178 CAPLUS
DN 127:316156
TI Reversible inhibition of type B monoamine oxidase. Theoretical study of model diazo heterocyclic compounds
AU Wouters, J.; Ooms, F.; Jegham, S.; Koenig, J. J.; George, P.; Durant, F.
CS Laboratoire de Chimie Moleculaire Structurale, Facultes N-D de-la-Paix, Namur, B-5000, Belg.
SO Eur. J. Med. Chem. (1997), 32(9), 721-730
CODEN: EJMCA5; ISSN: 0223-5234
PB Elsevier
DT Journal
LA English
AB Different families of heterocycles contg. 2 to 4 nitrogen atoms (oxadiazolones, tetrazoles and oxadiazinone derivs., so-called diazoheterocyclics) are currently used as lead compds. for the design of reversible and selective monoamine oxidase B (MAO-B) inhibitors. To clarify the mechanism of interaction of these mols. with the enzyme, we adopted a theor. approach (ab initio calcns.) and studied several structural and electronic properties of prototype mols. of the aryl diazo heterocyclic chem. series. This work provides a theor. basis for structure-inhibition relationships in chem. series with potential IMAO-B properties.
IT 197662-35-4
RL: BAC (Biological activity or effector, except adverse); PEP (Physical, engineering or chemical process); BIOL (Biological study); PROC (Process)
(reversible inhibition of type B monoamine oxidase, theor. study of model diazo heterocyclic compds.)
RN 197662-35-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methoxyphenyl)-4-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 20 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1997:84656 CAPLUS
 DN 126:131444
 TI Synthesis of methyl 4-amino-1-aryl-1,4,5,6-tetrahydro-6-oxo-1,2,4-triazine-3-carboxylates
 AU El-Abadelah, Mustafa M.; Nazer, Musa Z.; El-Abadlah, Naser S.; Meier, Herbert
 CS Chemistry Department, University Jordan, Amman, Jordan
 SO J. Prakt. Chem./Chem.- Ztg. (1997), 339(1), 90-91
 CODEN: JPCCEM; ISSN: 0941-1216
 PB Barth
 DT Journal
 LA English
 OS CASREACT 126:131444
 GI



AB The reaction of EtO₂CCH₂NHNH₂ with nitrile imines MeO₂C.tplbond.N+N-C₆H₄-4-
 R (R = H, F, Cl, Br), generated in situ from appropriate hydrazoneoyl chlorides in the presence of Et₃N, yields the corresponding 1,2,4-triazines I in 65-76% yield by cyclocondensation.
 IT 186404-53-5P 186404-59-1P 186404-63-7P
186404-69-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prep. of aminotetrahydrooxotriazinecarboxylates)
 RN 186404-53-5 CAPLUS
 CN 1,2,4-Triazine-3-carboxylic acid, 4-amino-1,4,5,6-tetrahydro-6-oxo-1-phenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 186404-59-1 CAPLUS
 CN 1,2,4-Triazine-3-carboxylic acid, 4-amino-1-(4-fluorophenyl)-1,4,5,6-tetrahydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 186404-63-7 CAPLUS

CN 1,2,4-Triazine-3-carboxylic acid, 4-amino-1-(4-chlorophenyl)-1,4,5,6-tetrahydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 186404-69-3 CAPLUS

CN 1,2,4-Triazine-3-carboxylic acid, 4-amino-1-(4-bromophenyl)-1,4,5,6-tetrahydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 21 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1996:696055 CAPLUS
 DN 126:19285
 TI 1,2,4-triazin-6-ones as peptidomimetic templates for cholecystokinin-A agonists
 AU Schmittner, H. F.; Doring, K. G.; Downs, E. S.; Simmons, R. D.;
 Zongrone, J. A.; Julien, R. P.; Kaiser, F. C.; Goodman, T. D.; Rosamond,
 J. D.
 CS Department Chemistry and Biology, Astra Research Corporation, Rochester,
 NY, 14602, USA
 SO Pept.: Chem., Struct. Biol., Proc. Am. Pept. Symp., 14th (1996),
 Meeting
 Date 1995, 687-688. Editor(s): Kaumaya, Pravin T. P.; Hodges, Robert S.
 Publisher: Mayflower Scientific, Kingswinford, UK.
 CODEN: 63NTAF
 DT Conference
 LA English
 GI



AB A report from a symposium on the prepn. of triazinone analogs I (R1 = Me3C, Me2CH, R2 = OH, OSO3H) as cholecystokinin-A receptor agonists.
 IT 165450-93-1P 165450-94-2P 165876-83-5P
165876-86-8P
 RL: BAC (Biological activity or effector, except adverse); SPN
 (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. of triazinone peptidomimetics as cholecystokinin A receptor
 agonists)
 RN 165450-93-1 CAPLUS
 CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-
 1,2,5,6-tetrahydro-3-[5-[[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]amino]-1-
 [[3-(1H-indol-3-yl)-2-[(1-methylethoxy)carbonyl]amino]-1-
 oxopropyl]amino]pentyl]-6-oxo-, [5S-[1(R*)],3[1S*(R*),5(E)],5R*]]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 165450-94-2 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-3-[1-[3-(1H-indol-3-yl)-2-[[1-methylethoxy]carbonyl]amino]-1-oxopropyl]amino]-5-[[1-oxo-3-[4-sulfooxy]phenyl]-2-propenyl]amino]pentyl]-6-oxo-, [5S-[1(R*),3[1S*(R*),5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 165876-83-5 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*),5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 165876-86-8 CAPLUS


CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-

[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[1-oxo-3-[4-(sulfoxy)phenyl]-2-propenyl]amino]pentyl]-


1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*),5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Double bond geometry as shown.



L4 ANSWER 22 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1996:399514 CAPLUS
 DN 125:195591
 TI Regiospecific syntheses of the monomethylated 3-phenyldihydro-1,2,4-triazin-6(1H)-ones
 AU Collins, David J.; Hughes, Timothy C.; Johnson, Wynona M.
 CS Dep. Chem., Monash Univ., Clayton, 3168, Australia
 SO Aust. J. Chem. (1996), 49(4), 463-468
 CODEN: AJCHAS; ISSN: 0004-9425
 DT Journal
 LA English
 AB Unambiguous syntheses of four unreported monomethylated derivs. of 3-phenyldihydro-1,2,4-triazin-6(1H)-ones, namely, the 1-Me (2), 2-Me (3), 4-Me (4) and the imidic O-Me deriv. (5), are described.
 Regioselectivity
 was achieved for the synthesis of 2 by addn. of Et glycinate to the 1,3-dipolar nitrile imine derived from N-methylbenzohydrazonoyl bromide hydrobromide. The key step for the synthesis of 3 was addn. of benzyl 3-methylcarbazate to Et N-[chloro(phenyl)methylene]glycinate. The 4-Me compd. (4) was prep'd. by cycloaddn. of Et N-(thiobenzoyl)sarcosinate with hydrazine hydrate, and the O-Me compd. (5) was prep'd. by reaction of sodium methoxide with 6-chloro-3-phenyl-4,5-dihydro-1,2,4-triazine.
 IT 180901-61-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 180901-61-5 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1-methyl-3-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 61 · CAPLUS COPYRIGHT 2002 ACS
 AN 1995:874345 CAPLUS
 DN 124:56682
 TI Synthesis and evaluation of diacylhydrazines as inhibitors of the interleukin-1. β . converting enzyme (ICE)
 AU Graybill, Todd L.; Dolle, Roland E.; Helaszek, Carla T.; Ator, Mark A.; Strasters, Joost
 CS Department Medicinal Chemistry, Biochemistry, Analytical Chemistry, Sterling Winthrop Pharmaceuticals Research Division, Collegeville, PA, 19426, USA
 SO Bioorg. Med. Chem. Lett. (1995), 5(11), 1197-202
 CODEN: BMCLE8; ISSN: 0960-894X
 DT Journal
 LA English
 GI



AB Diacylhydrazines [azaaspartic acid derivs. I; X = N, R = Cl, Br, O₂C₆H₃Cl₂-2,6, OP(O)Ph₂, Q, Q¹] were prep'd. and shown to inactivate interleukin-1. β . converting enzyme (ICE) in a time-dependent manner. Inactivation rates for most of these diacylhydrazines were 10-fold slower than their .alpha.-substituted methylketone congeners I (X = CH). Rates for I [X = N, R = Cl, OP(O)Ph₂] (ca. 18,000 M⁻¹s⁻¹) compared favorably to those reported for Ac-Tyr-Val-Ala-Asp-CHN₂ and azapeptide inhibitors for other cysteine proteases.


IT 171978-49-7P

RL: BYP (Byproduct); PREP (Preparation)
 (prepn., hydrolytic stability, and interleukin-1. β . converting enzyme inhibitory activity of peptidyl diacylhydrazine inhibitors)


RN 171978-49-7 CAPLUS

CN 4H-1,3,4-Oxadiazine-4-acetic acid, 5,6-dihydro-2-[1-[[3-methyl-1-oxo-2-[(phenylmethoxy)carbonyl]amino]butyl]amino]ethyl]-5-oxo-, 1,1-dimethylethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 24 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1995:782508 CAPLUS
 DN 124:55907
 TI A one step synthesis of 4,5-dihydro-1,2,4-triazin-6-ones
 AU Algharib, Mohammed S.
 CS Faculty of Engineering, Suez Canal University, Port Said, Egypt
 SO Zagazig J. Pharm. Sci. (1994), Volume Date 1994, 3(3B), 156-61
 CODEN: ZJPSEV
 DT Journal
 LA English
 GI




AB The reaction of nitrilimines $\text{RCOC.tplbond.N+N-Ar}$ ($\text{R} = \text{PhNH, 2-naphthyl, OEt, Me, Ph, 2-thienyl; Ar} = \text{Ph, MeC}_6\text{H}_4, 4-\text{ClC}_6\text{H}_4$) with α -amino esters $\text{H}_2\text{NCHYCOOEt}$ ($\text{Y} = \text{H, CH}_2\text{Ph}$) afforded 4,5-dihydro-1,2,4-triazin-6-one derivs. I. The structure assignments of I were confirmed by elemental anal. and spectral data.
 IT 139455-95-1P 139455-97-3P 173560-05-9P
 173560-06-0P 173560-07-1P 173560-08-2P
 173560-09-3P 173560-10-6P 173560-11-7P
 173560-12-8P 173560-13-9P 173560-14-0P
 173560-15-1P 173560-16-2P 173560-17-3P
 173560-18-4P 173560-19-5P 173560-20-8P
 173560-21-9P 173560-22-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of triazinones)
 RN 139455-95-1 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 3-benzoyl-2,5-dihydro-1-phenyl-5-(phenylmethyl)-,
 (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 139455-97-3 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-chlorophenyl)-2,5-dihydro-5-(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173560-05-9 CAPLUS

CN 1,2,4-Triazine-3-carboxamide, 1,2,5,6-tetrahydro-6-oxo-N,1-diphenyl-
(9CI) (CA INDEX NAME)




RN 173560-06-0 CAPLUS

CN 1,2,4-Triazine-3-carboxamide, 1,2,5,6-tetrahydro-1-(2-methylphenyl)-6-
oxo-
N-phenyl- (9CI) (CA INDEX NAME)




RN 173560-07-1 CAPLUS

CN 1,2,4-Triazine-3-carboxamide, 1,2,5,6-tetrahydro-1-(3-methylphenyl)-6-
oxo-
N-phenyl- (9CI) (CA INDEX NAME)




RN 173560-08-2 CAPLUS

CN 1,2,4-Triazine-3-carboxamide, 1,2,5,6-tetrahydro-1-(4-methylphenyl)-6-
oxo-
N-phenyl- (9CI) (CA INDEX NAME)



RN 173560-09-3 CAPLUS


CN 1,2,4-Triazine-3-carboxamide, 1-(4-chlorophenyl)-1,2,5,6-tetrahydro-6-oxo-
N-phenyl- (9CI) (CA INDEX NAME)



RN 173560-10-6 CAPLUS


CN 1,2,4-Triazine-3-carboxamide, 1,2,5,6-tetrahydro-6-oxo-N,1-diphenyl-5-(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173560-11-7 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-3-(2-naphthalenylcarbonyl)-1-phenyl-
(9CI) (CA INDEX NAME)



RN 173560-12-8 CAPLUS


CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1-(4-methylphenyl)-3-(2-naphthalenylcarbonyl)- (9CI) (CA INDEX NAME)



RN 173560-13-9 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-3-(2-naphthalenylcarbonyl)-1-phenyl-5-(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173560-14-0 CAPLUS


CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1-(4-methylphenyl)-3-(2-naphthalenylcarbonyl)-5-(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173560-15-1 CAPLUS

CN 1,2,4-Triazine-3-carboxylic acid, 1-(4-chlorophenyl)-1,2,5,6-tetrahydro-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 173560-16-2 CAPLUS


CN 1,2,4-Triazin-6(1H)-one, 3-benzoyl-2,5-dihydro-1-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 173560-17-3 CAPLUS


CN 1,2,4-Triazin-6(1H)-one, 3-benzoyl-2,5-dihydro-1-(4-methylphenyl)-5-(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173560-18-4 CAPLUS


CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-2,5-dihydro-1-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 173560-19-5 CAPLUS


CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-2,5-dihydro-1-(4-methylphenyl)-5-(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173560-20-8 CAPLUS


CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1-phenyl-3-(2-thienylcarbonyl)- (9CI) (CA INDEX NAME)



RN 173560-21-9 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1-phenyl-5-(phenylmethyl)-3-(2-thienylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173560-22-0 CAPLUS



CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1-(4-methylphenyl)-5-(phenylmethyl)-3-(2-thienylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 25 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1995:701732 CAPLUS
 DN 123:112726
 TI Preparation of peptide 1,2,4-triazinone derivatives as cholecystokinin receptor ligands.
 IN Schmitthenner, Hans Frederick; Rosamond, James Donald
 PA Fisons PLC, UK; Fisons Corp.
 SO PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9418229	A1	19940818	WO 1994-GB200	19940202
	W: AU, CA, FI, JP, NO, US			RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE	
	AU 9459750	A1	19940829	AU 1994-59750	19940202
PRAI	US 1993-12587		19930203		
	WO 1994-GB200		19940202		
OS	MARPAT 123:112726				
GI					



AB Title compds. [I; R1 = H, NH₂, C₁₋₆ alkyl optionally substituted by Ph, naphthyl, R₆CONH, R₇OCONH, R₈NHCONH; R2 = H, C₁₋₆ alkyl optionally substituted by phenyl; R3 = H, Ph, C₁₋₆ alkyl optionally substituted by Ph, naphthyl, C₃₋₈ cycloalkyl; R4 = H, CONR₉R₁₀; R5 = NH₂, NHCOR₁₁, NHCONR₁₂R_{12a}, NHCOOR₁₃ or NHSO₂R₁₄; R6, R7, R8 = H, Ph, C₁₋₆ alkyl optionally substituted by Ph, naphthyl, 1- or 2-adamantyl, 3-quinuclidinyl; R9, R10 = H, C₁₋₆ alkyl; R11 = C₁₋₆ alkyl, C₂₋₆ alkenyl, Ph, naphthyl, which groups are optionally substituted by Ph, naphthyl; R12 = H, Ph, naphthyl or C₁₋₆ alkyl optionally substituted by Ph, naphthyl;

R12a = H, Ph; R13 = Ph, C1-6 alkyl optionally substituted by Ph, naphthyl;
R14 = Ph, naphthyl, C1-6 alkyl optionally substituted by Ph, naphthyl;
the
Ph and naphthyl groups above being optionally substituted; R15 = H, C1-6
alkyl; m, n = 1-4; p = 3-7], were prep'd. BOC-Trp-D-
Lys(4HcISE).PSI.[2(H)Taz(Asp)]Phe-NH₂ [4HcISE = sulfated
trans-4-hydroxycinnamoyl, Lys.PSI.[2(H)Taz(Asp)]Phe-NH₂ = Q1], prep'd. by
soln. phase methods, showed EC₅₀ = 130 nM in the guinea pig gallbladder
contraction assay and inhibited feeding in rats with RD₅₀ = 1.1 .mu.g/kg
in the 3 h test.

IT 165450-69-1P 165450-70-4P 165450-71-5P
165450-72-6P 165450-73-7P 165450-74-8P
165450-75-9P 165450-76-0P 165450-77-1P
165450-78-2P 165450-79-3P 165450-80-6P
165450-81-7P 165450-82-8P 165450-83-9P
165450-84-0P 165450-85-1P 165450-86-2P
165450-87-3P 165450-88-4P 165450-89-5P
165450-90-8P 165450-91-9P 165450-92-0P
165450-93-1P 165450-94-2P 165450-95-3P
165450-96-4P 165450-97-5P 165450-98-6P
165450-99-7P 165451-00-3P 165451-01-4P
165451-02-5P 165451-03-6P 165451-04-7P
165451-05-8P 165451-06-9P 165451-07-0P
165451-08-1P 165451-09-2P 165451-10-5P
165451-11-6P 165451-12-7P 165451-13-8P
165451-14-9P 165451-15-0P 165451-16-1P
165451-17-2P 165451-18-3P 165451-19-4P
165451-20-7P 165451-21-8P 165876-65-3P
165876-66-4P 165876-67-5P 165876-68-6P
165876-69-7P 165876-70-0P 165876-71-1P
165876-72-2P 165876-73-3P 165876-74-4P
165876-75-5P 165876-76-6P 165876-77-7P
165876-78-8P 165876-79-9P 165876-80-2P
165876-81-3P 165876-82-4P 165876-83-5P
165876-84-6P 165876-85-7P 165876-86-8P
165876-87-9P 165876-88-0P 165876-89-1P
165876-90-4P 165876-91-5P 165876-92-6P
165876-93-7P 165876-94-8P 165876-95-9P
165876-96-0P 165876-97-1P 165876-98-2P
165876-99-3P 166019-33-6P 166019-34-7P

RL: BAC (Biological activity or effector, except adverse); SPN

(Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)

(prepn. of peptide 1,2,4-triazinone derivs. as cholecystokinin
receptor

ligands)


RN 165450-69-1 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-[(1,1-
dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-
[[[(phenylmethoxy)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-
phenylethyl)-, phenylmethyl ester, [5S-[3[R*(R*)],5R*]]- (9CI) (CA

INDEX

NAME)


Absolute stereochemistry.



RN 165450-70-4 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[(phenylmethoxy)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5S-[3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165450-71-5 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[5-amino-1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5S-[3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165450-72-6 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[[(2-methylphenyl)amino]carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5S-[3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165450-73-7 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5S-[3[1R*(R*),5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 165450-74-8 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[3-(4-hydroxyphenyl)-1-oxopropyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5S-[3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165450-75-9 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[(2-[(1,1-dimethylethoxy)carbonyl]amino)-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[(phenylamino)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5S-[3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165450-76-0 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[(2-[(1,1-dimethylethoxy)carbonyl]amino)-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[(2-naphthalenylamino)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5S-[3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165450-77-1 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[5-[(2-chlorophenyl)amino]carbonyl]amino]-1-[(2-[(1,1-dimethylethoxy)carbonyl]amino)-3-(1H-indol-3-yl)-1-

oxopropyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-,
[5S-[3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165450-78-2 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[4-methylphenyl]sulfonyl]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5S-[3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165450-79-3 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[(phenylmethoxy)carbonyl]pentyl]-1,2,5,6-tetrahydro-6-oxo-, phenylmethyl ester, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165450-80-6 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[(phenylmethoxy)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165450-81-7 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[5-amino-1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]pentyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165450-82-8 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-


[1-
 [[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-
 oxopropyl]amino]-5-[[[(2-methylphenyl)amino]carbonyl]amino]pentyl]-
 1,2,5,6-
 tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165450-83-9 CAPLUS
 CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
 [[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-
 oxopropyl]amino]-5-[[phenylamino]carbonyl]amino]pentyl]-1,2,5,6-
 tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 165450-84-0 CAPLUS
 CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
 [[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-
 oxopropyl]amino]-5-[[[(phenylmethyl)amino]carbonyl]amino]pentyl]-
 1,2,5,6-
 tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165450-85-1 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[1R*(R*),5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 165450-86-2 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165450-87-3 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-amino-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[[(2-methylphenyl)amino]carbonyl]amino]pentyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165450-88-4 CAPLUS


CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-amino-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[[(phenylamino)carbonyl]amino]pentyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165450-89-5 CAPLUS
 CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
 [[2-(benzoylamino)-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[[(2-
 methylphenyl)amino]carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-,
 [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165450-90-8 CAPLUS
 CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
 [[2-(benzoylamino)-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-
 [[(phenylamino)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-,
 [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 165450-91-9 CAPLUS
 CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-(benzoylamino)-3-(1H-indol-3-yl)-
 1-oxopropyl]amino]-5-[[[(2-methylphenyl)amino]carbonyl]amino]pentyl]-
 1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 165450-92-0 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-
oxopropyl]amino]-5-[[1-oxo-3-[4-(sulfoxy)phenyl]-2-
propenyl]amino]pentyl]-
1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[1R*(R*),5(E)],5R*]]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 165450-93-1 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-
1,2,5,6-tetrahydro-3-[5-[[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]amino]-1-
[[3-(1H-indol-3-yl)-2-[[1-methylethoxy)carbonyl]amino]-1-
oxopropyl]amino]pentyl]-6-oxo-, [5S-[1(R*),3[1S*(R*),5(E)],5R*]]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 165450-94-2 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-3-[1-[(3-(1H-indol-3-yl)-2-[[1-methylethoxy]carbonyl]amino]-1-oxopropyl]amino]-5-[[1-oxo-3-[4-(sulfoxy)phenyl]-2-propenyl]amino]pentyl]-6-oxo-, [5S-[1(R*),3[1S*(R*),5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 165450-95-3 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[[3-[(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]amino]-1-[[2-[[1,1-dimethylethoxy]carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[1R*(R*),5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 165450-96-4 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-
oxopropyl]amino]-5-[(1-oxo-3-phenyl-2-propenyl)amino]pentyl]-1,2,5,6-
tetrahydro-6-oxo-, [5S-[1(R*),3[1S*(R*),5(E)],5R*]]- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 165450-97-5 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-
oxopropyl]amino]-5-[(2-naphthalenylcarbonyl)amino]pentyl]-1,2,5,6-
tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165450-98-6 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-
oxopropyl]amino]-5-[[1-oxo-3-[4-(sulfoxy)phenyl]propyl]amino]pentyl]-
1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 165450-99-7 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-
oxopropyl]amino]-5-[[3-(4-nitrophenyl)-1-oxo-2-propenyl]amino]pentyl]-
1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 165451-00-3 CAPLUS


CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[5-

[(3-(4-aminophenyl)-1-oxo-2-propenyl]amino]-1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]pentyl]-

1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[1S*(R*),5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 165451-01-4 CAPLUS


CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-

[(2-[(1,1-dimethylethoxy)carbonyl]amino)-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[(1-oxo-3-[4-(sulfoamino)phenyl]-2-propenyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[1S*(R*),5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


—SO₃H

RN 165451-02-5 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-
oxopropyl]amino]-5-[[3-(3-hydroxyphenyl)-1-oxo-2-propenyl]amino]pentyl]-
1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[1S*(R*),5(E)],5R*]]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 165451-03-6 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-


oxopropyl]amino]-5-[[1-oxo-3-[3-(sulfoxy)phenyl]-2-propenyl]amino]pentyl]-
 1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[1S*(R*),5(E)],5R*]]- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 165451-04-7 CAPLUS
 CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-3-[1-[[3-(1H-indol-3-yl)-2-[[[(1-methylethoxy)carbonyl]amino]-1-oxopropyl]amino]-5-[(1-oxo-3-phenyl-2-propenyl)amino]pentyl]-6-oxo-, [5S-[1(R*),3[1S*(R*),5(E)],5R*]]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 165451-05-8 CAPLUS
 CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-3-[5-[[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]amino]-1-[[3-(1H-indol-2-yl)-1-oxopropyl]amino]pentyl]-6-oxo-, [5S-[1(R*),3[R*(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 165451-06-9 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[[(2-[(ethoxycarbonyl)amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[(3-hydroxyphenyl)-1-oxo-2-propenyl]amino]pentyl-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[1S*(R*),5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 165451-07-0 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-3-[5-[(3-4-hydroxyphenyl)-1-oxo-2-propenyl]amino]-1-[(3-(1H-indol-3-yl)-2-[(methoxycarbonyl)amino]-1-oxopropyl]amino]pentyl-1-oxo-, [5S-[1(R*),3[1S*(R*),5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 165451-08-1 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-3-[1-[(3-(1H-indol-3-yl)-2-[(methoxycarbonyl)amino]-1-oxopropyl]amino]-5-[[1-oxo-3-[4-(sulfoxy)phenyl]-2-propenyl]amino]pentyl]-6-oxo-, [5S-[1(R*),3[1S*(R*),5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 165451-09-2 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-3-[5-[[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]amino]-1-[[3-(1H-indol-3-yl)-2-[(2-methyl-1-oxopropyl)amino]-1-oxopropyl]amino]pentyl]-6-oxo-, [5S-[1(R*),3[1S*(R*),5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 165451-10-5 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-3-[1-[[3-(1H-indol-3-yl)-2-[(2-methyl-1-oxopropyl)amino]-1-oxopropyl]amino]-5-[[1-oxo-3-[4-(sulfooxy)phenyl]-2-propenyl]amino]pentyl]-6-oxo-, [5S-[1(R*),3[1S*(R*),5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 165451-11-6 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[4'-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165451-12-7 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[[4'-(sulfoxy)[1,1'-biphenyl]-4-yl]carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—OSO₃H

RN 165451-13-8 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-

[[2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[(6-hydroxy-2-naphthalenyl)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-14-9 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[[6-(sulfooxy)-2-naphthalenyl]carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-15-0 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[(diphenylamino)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-16-1 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-[[(2-[(1,1-dimethylethoxy)carbonyl]amino)-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[[(2-phenylethyl)amino]carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-17-2 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-[[(2-[(1,1-dimethylethoxy)carbonyl]amino)-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[[(2-phenylmethyl)phenyl]amino]carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165451-18-3 CAPLUS

CN 1,2,4-Triazine-5-propanoic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[[(2-methylphenyl)amino]carbonyl]amino]pentyl]-1,2,5,6-

tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165451-19-4 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[1-(aminocarbonyl)-3-phenylpropyl]-3-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[[(2-methylphenyl)amino]carbonyl]amino]pentyl]-1,2,5,6-

tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-20-7 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-1-(cyclohexylmethyl)-2-oxoethyl]-
3-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[[(2-methylphenyl)amino]carbonyl]amino]pentyl]-
1,2,5,6-
tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-21-8 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-
[1-
[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-4-[[[(2-methylphenyl)amino]carbonyl]amino]butyl]-
1,2,5,6-
tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165876-65-3 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[(phenylmethoxy)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, phenylmethyl ester, [5S-[3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165876-66-4 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[(phenylmethoxy)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5S-[3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165876-67-5 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[5-amino-1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]pentyl]-

1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5S-[3[S*(R*)],5R*]]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 165876-68-6 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[[(2-methylphenyl)amino]carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5S-[3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165876-69-7 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5S-[3[1S*(R*),5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 165876-70-0 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[(phenylamino)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5S-[3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165876-71-1 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[(phenylmethoxy)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, phenylmethyl ester, [5R-[3[S*(S*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165876-72-2 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[(phenylmethoxy)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5R-[3[S*(S*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165876-73-3 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[5-amino-1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5R-[3[S*(S*)],5R*]]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 165876-74-4 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[[(2-methylphenyl)amino]carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5R-[3[S*(S*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165876-75-5 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[3-[(4-hydroxyphenyl)-1-oxo-2-propenyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5R-[3[1S*(S*),5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 165876-76-6 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[[(phenylamino)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5R-[3[S*(S*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165876-77-7 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[[(4-methylphenyl)sulfonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5R-[3[S*(S*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165876-78-8 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-
oxopropyl]amino]-5-[[phenylmethoxy]carbonyl]amino]pentyl]-1,2,5,6-
tetrahydro-6-oxo-, phenylmethyl ester, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 165876-79-9 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-
oxopropyl]amino]-5-[[phenylmethoxy]carbonyl]amino]pentyl]-1,2,5,6-
tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165876-80-2 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[5-amino-1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]pentyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*), 3[S*(R*)], 5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165876-81-3 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[[(2-methylphenyl)amino]carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*), 3[S*(R*)], 5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165876-82-4 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[(phenylamino)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*), 3[S*(R*)], 5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165876-83-5 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*), 3[S*(R*)], 5(E)], 5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 165876-84-6 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-amino-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[[(2-methylphenyl)amino]carbonyl]amino]pentyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*), 3[S*(R*)], 5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165876-85-7 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-amino-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[(phenylamino)carbonyl]amino]pentyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165876-86-8 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[1-oxo-3-[4-(sulfooxy)phenyl]-2-propenyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*),5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 165876-87-9 CAPLUS


CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[5-

[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]amino]-1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]pentyl]-

1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*)],5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 165876-88-0 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-

[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[3-(4-hydroxyphenyl)-1-oxopropyl]amino]pentyl]-

1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165876-89-1 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-3-[5-[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]amino]-1-[[3-(1H-indol-2-yl)-1-oxopropyl]amino]pentyl]-6-oxo-, [5S-[1(R*),3[S*(R*)],5(E)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 165876-90-4 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[4'-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165876-91-5 CAPLUS
 CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
 [[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-
 oxopropyl]amino]-5-[[[4'-(sulfoxy)[1,1'-biphenyl]-4-
 yl]carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-
 [1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

$\text{--OSO}_3\text{H}$

RN 165876-92-6 CAPLUS
 CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
 [[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-
 oxopropyl]amino]-5-[(2-naphthalenylcarbonyl)amino]pentyl]-1,2,5,6-
 tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165876-93-7 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-
oxopropyl]amino]-5-[[[6-hydroxy-2-naphthalenyl]carbonyl]amino]pentyl]-
1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 165876-94-8 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-
oxopropyl]amino]-5-[[[6-(sulfoxy)-2-
naphthalenyl]carbonyl]amino]pentyl]-
1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 165876-95-9 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-
oxopropyl]amino]-5-[(1-oxo-3-phenyl-2-propenyl)amino]pentyl]-1,2,5,6-
tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*),5(E)],5R*]]- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 165876-96-0 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-
oxopropyl]amino]-5-[[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]amino]pentyl]-
1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[R*(S*),5(E)],5R*]]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 165876-97-1 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[(phenylamino)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5R-[1(S*),3[S*(S*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165876-98-2 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*),5(E)],5S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 165876-99-3 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-
[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-
oxopropyl]amino]-4-[[[(2-methylphenyl)amino]carbonyl]amino]butyl]-
1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 166019-33-6 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-amino-3-(1H-indol-3-yl)-1-
oxopropyl]amino]-5-[[[(2-methylphenyl)amino]carbonyl]amino]pentyl]-1-[2-
amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-,
monohydrochloride, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 166019-34-7 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-amino-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[(phenylamino)carbonyl]amino]pentyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, monohydrochloride, [5S-[1(R*),3[S*(R*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 165451-24-1P 165451-25-2P 165451-28-5P
 165451-29-6P 165451-33-2P 165451-34-3P
 165451-37-6P 165451-38-7P 165451-39-8P
 165451-40-1P 165451-41-2P 165451-42-3P
 165451-43-4P 165451-44-5P 165451-45-6P
 165451-46-7P 165451-47-8P 165451-48-9P
 165451-49-0P 165451-50-3P 165451-54-7P
 165451-55-8P 165451-56-9P 165451-57-0P
 165877-00-9P 165877-01-0P 165877-02-1P
 165877-03-2P 165877-04-3P 165877-05-4P
 165877-06-5P 165877-07-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of peptide 1,2,4-triazinone derivs. as cholecystokinin

receptor
 ligands)

RN 165451-24-1 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[(1,1-dimethylethoxy)carbonyl]amino]-5-[(phenylmethoxy)carbonyl]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, phenylmethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-25-2 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-amino-5-[(phenylmethoxy)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, phenylmethyl ester, monohydrochloride, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 165451-28-5 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[(1,1-dimethylethoxy)carbonyl]amino]-5-[(phenylmethoxy)carbonyl]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, phenylmethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-29-6 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-amino-5-
[(phenylmethoxy)carbonyl]amino]
pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, phenylmethyl
ester,
monohydrochloride, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 165451-33-2 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[(1,1-dimethylethoxy)carbonyl]amino]-5-
[(phenylmethoxy)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, phenylmethyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165451-34-3 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-amino-5-
[(phenylmethoxy)carbonyl]amino]
pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, phenylmethyl

ester,

monohydrochloride, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 165451-37-6 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[(1,1-dimethylethoxy)carbonyl]amino]-5-[(phenylmethoxy)carbonyl]pentyl-1,2,5,6-tetrahydro-6-oxo-phenylmethyl ester, [5S-[1(R*),3(R*),5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-38-7 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[1-[(2-amino-3-(1H-indol-3-yl)-1-oxopropyl)amino]-5-[(phenylmethoxy)carbonyl]amino]pentyl-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-phenylmethyl ester, monohydrochloride, [5S-[1(R*),3(S*(R*)),5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 165451-39-8 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-3-[1-[[3-(1H-indol-3-yl)-2-[[[(1-methylethoxy)carbonyl]amino]-1-oxopropyl]amino]-5-[[[(phenylmethoxy)carbonyl]amino]pentyl]-6-oxo-, phenylmethyl ester, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-40-1 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[5-amino-1-[[3-(1H-indol-3-yl)-2-[[[(1-methylethoxy)carbonyl]amino]-1-oxopropyl]amino]pentyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-41-2 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-3-[1-[[3-(1H-indol-2-yl)-1-oxopropyl]amino]-5-[(phenylmethoxy)carbonyl]amino]pentyl]-6-oxo-, phenylmethyl ester, [5S-[1(R*),3(R*),5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-42-3 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[5-amino-1-[[3-(1H-indol-2-yl)-1-oxopropyl]amino]pentyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3(R*),5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165451-43-4 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[[2-[(ethoxycarbonyl)amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[(phenylmethoxy)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-,

phenylmethyl ester, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-44-5 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[5-amino-1-[[2-[(ethoxycarbonyl)amino]-1-(1H-indol-3-yl)-1-oxopropyl]amino]pentyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-45-6 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-3-[1-[[3-(1H-indol-3-yl)-2-[(methoxycarbonyl)amino]-oxopropyl]amino]-5-[(phenylmethoxy)carbonyl]amino]pentyl]-6-oxo-, phenylmethyl ester, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-46-7 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[5-amino-1-[[3-(1H-indol-3-yl)-2-[(methoxycarbonyl)amino]-1-oxopropyl]amino]pentyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-47-8 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-3-[1-[[3-(1H-indol-3-yl)-2-[(2-methyl-1-oxopropyl)amino]-1-oxopropyl]amino]-5-[[phenylmethoxy]carbonyl]amino]pentyl]-6-oxo-, phenylmethyl ester, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-48-9 CAPLUS


CN 1,2,4-Triazine-5-acetic acid, 3-[5-amino-1-[[3-(1H-indol-3-yl)-2-[(2-methyl-1-oxopropyl)amino]-1-oxopropyl]amino]pentyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*)],5R*]]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 165451-49-0 CAPLUS
 CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-amino-5-[(phenylmethoxy)carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, phenylmethyl ester, monohydrochloride, [5S-[1(R*),3(R*),5R*]]- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 165451-50-3 CAPLUS
 CN 1,2,4-Triazine-5-acetic acid, 3-[1-[[2-amino-3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-[[[(2-methylphenyl)amino]carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-1-(2-phenylethyl)-, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-54-7 CAPLUS

CN 1,2,4-Triazine-5-propanoic acid, 3-[5-amino-1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]pentyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-55-8 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[1-(aminocarbonyl)-3-phenylpropyl]-3-[5-amino-1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165451-56-9 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-1-(cyclohexylmethyl)-2-oxoethyl]-

3-[5-amino-1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165451-57-0 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[4-amino-1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]butyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165877-00-9 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-5-[[phenylmethoxy]carbonyl]amino]pentyl]-1,2,5,6-tetrahydro-6-oxo-, phenylmethyl ester, [5S-[1(R*),3(S*),5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165877-01-0 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-3-[1-[[3-(1H-indol-2-yl)-1-oxopropyl]amino]-5-[(phenylmethoxy)carbonyl]amino]pentyl-6-oxo-, phenylmethyl ester, [5S-[1(R*),3(S*),5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165877-02-1 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[5-amino-1-[[3-(1H-indol-2-yl)-1-oxopropyl]amino]pentyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3(S*),5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165877-03-2 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-3-[1-amino-5-[(phenylmethoxy)carbonyl]amino]pentyl-1,2,5,6-tetrahydro-6-

oxo-,
 phenylmethyl ester, monohydrochloride, [5S-[1(R*),3(S*),5R*]]- (9CI)
 (CA
 INDEX NAME)


Absolute stereochemistry.



● HCl


RN 165877-04-3 CAPLUS
 CN 1,2,4-Triazine-5-acetic acid, 3-[5-amino-1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]pentyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[R*(S*)],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 165877-05-4 CAPLUS
 CN 1,2,4-Triazine-5-acetic acid, 3-[5-amino-1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]pentyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, [5R-[1(S*),3[S*(S*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165877-06-5 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[5-amino-1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]pentyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(S*),3[R*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 165877-07-6 CAPLUS

CN 1,2,4-Triazine-5-acetic acid, 3-[4-amino-1-[[2-[(1,1-dimethylethoxy)carbonyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]butyl]-1-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-1,2,5,6-tetrahydro-6-oxo-, [5S-[1(R*),3[S*(R*)],5R*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L4 ANSWER 26 OF 61 CAPLUS COPYRIGHT 2002 ACS
AN 1995:201294 CAPLUS
DN 122:133128
TI Heterocycles from nitrile imines. Part V. 6-Imino-4,5-dihydro-1,2,4-triazines
AU Hussein, A. Q.; El-Abadelah, M.; Ferwanah, A. S.
CS Faculty Science, University Jordan, Jordan
SO Dirasat - Univ. Jordan, Ser. B (1994), 21B(4), 71-8
CODEN: DJSSE8
DT Journal
LA English
AB The title compds. were obtained in good yields from the reaction of nitrile imines and .alpha.-amino nitriles. Glycinonitrile gave only acyclic addn. products RNHN:C(COMe)NHCH₂CN [R = (un)substituted Ph].
The 6-iminotriazines undergo facile hydrolysis to 4,5-dihydro-1,2,4-triazin-6-ones.
IT 160974-02-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reactions of iminotriazines)
RN 160974-02-7 CAPLUS
CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-2,5-dihydro-1,5-diphenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 27 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1994:666290 CAPLUS
 DN 121:266290
 TI Electrochemical oxidation of 4,5-dihydro-1,2,4-triazin-6-one derivatives at carbon electrode in acetonitrile
 AU Chirchi, L.; Boujlel, K.; Hajjem, B.; Baccar, B.
 CS Dep. Chimie, Fac. Sci., Tunis, Tunisia
 SO J. Electrochem. Soc. (1994), 141(9), 2283-52
 CODEN: JESOAN; ISSN: 0013-4651
 DT Journal
 LA English
 AB Stationary carbon electrode voltammetry was used for studying the electrochem. oxidn. processes of 4,5-dihydro-1,2,4-triazin-6-one in acetonitrile. The electron process of dihydrotriazine electrochem. oxidn. is shown to correspond to the multistage oxidn. of both nonprotonated and protonated forms. Surface protonation is due to the rapid addn. of protons formed during the electrooxidn. process of initial dihydrotriazine mols. It gives extra mols. in the protonated form which oxidize to the end product. The protonation of the final products is also shown. The electrochem. oxidn. mechanism of dihydrotriazine was verified by IR and NMR anal. of products obtained during macroscale electrolysis at controlled potential.
 IT 82059-55-0 158817-59-5 158817-60-8
 RL: PRP (Properties); RCT (Reactant)
 (electrochem. oxidn. in acetonitrileo)
 RN 82059-55-0 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1,3-diphenyl- (9CI) (CA INDEX NAME)



RN 158817-59-5 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-5-methyl-1,3-diphenyl- (9CI) (CA INDEX NAME)



RN 158817-60-8 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 3-cyclohexyl-2,5-dihydro-1-phenyl- (9CI) (CA INDEX NAME)




IT 158817-61-9
 RL: FMU (Formation, unclassified); PRP (Properties); FORM (Formation, nonpreparative)

(formation in electrooxidn. of dihydrotriazinone derivs. and NMR of)
RN 158817-61-9 CAPLUS
CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-5-methyl-1,3-diphenyl-,
monoperchlorate (9CI) (CA INDEX NAME)


CM 1

CRN 158817-59-5
CMF C16 H15 N3 O




CM 2

CRN 7601-90-3
CMF Cl H O4



L4 ANSWER 28 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1994:579621 CAPLUS
 DN 121:179621
 TI Antiasthmatic triazine-based heterocyclic compounds
 IN Kutscher, Bernhard; Engel, Juergen; Metzenauer, Peter;
 Achterrath-Tuckermann, Ute; Szelenyi, Istvan
 PA Asta Medica AG, Germany
 SO Ger. Offen., 14 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4239540	A1	19940526	DE 1992-4239540	19921125
	EP 599152	A1	19940601	EP 1993-118319	19931112
SE	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
	CA 2109900	AA	19940526	CA 1993-2109900	19931124
	FI 9305218	A	19940526	FI 1993-5218	19931124
	NO 9304249	A	19940526	NO 1993-4249	19931124
	AU 9351901	A1	19940609	AU 1993-51901	19931124
	BR 9304818	A	19940621	BR 1993-4818	19931124
	ZA 9308799	A	19940630	ZA 1993-8799	19931124
	JP 06239868	A2	19940830	JP 1993-293134	19931124
	CN 1094050	A	19941026	CN 1993-121108	19931124
	HU 70491	A2	19951030	HU 1993-3344	19931124
PRAI	DE 1992-4239540		19921125		
OS	MARPAT	121:179621			
GI					



AB The title compds. [I; A-B = N:CR₄, CH:CR₄, R₄CH:N; R₄ = (un)branched C₁₋₄ alkyl, (un)substituted Ph; A = (un)branched C₁₋₆ alkyl, (un)substituted PhCH₂; B = H, etc.; R₁, R₂ = H, (un)substituted C₁₋₄ alkyl, PhCH₂; X = aryl, heteroaryl; Y = halogen, HO, alkoxy, NO₂, (un)substituted NH₂, etc.], which have antiasthmatic (no data), antiallergic (no data), blood pressure-lowering properties (no data), etc., are prep'd. Thus, 4-phenylphthalazinone was reacted with Et bromoacetate, followed by the Lawesson reagent, and the intermediate refluxed with hydrazene hydrate, producing 7-phenyl-2H-triazino[3,4-a]phthalazin-3-(4H)-one.

IT 157568-56-4P


RL: BAC (Biological activity or effector, except adverse); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(prepn. of, as pharmaceutical)


RN 157568-56-4 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 4,5-dihydro-4-methoxy-1-methyl-3-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 29 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1993:671203 CAPLUS
 DN 119:271203
 TI Heterocyclic compounds and cardiotonics, containing the same as active ingredients
 IN Kobayashi, Hideshi; Yoshioka, Kimitomo; Yamazaki, Hiroaki
 PA Zenyaku Kogyo K. K., Japan
 SO PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9311123	A1	19930610	WO 1992-JP1548	19921127
	W: AU, CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9229562	A1	19930628	AU 1992-29562	19921127
	AU 665590	B2	19960111		
	EP 618204	A1	19941005	EP 1992-924016	19921127
	EP 618204	B1	19980610		
	R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	ES 2117057	T3	19980801	ES 1992-924016	19921127
	JP 3114996	B2	20001204	JP 1993-509999	19921127
	US 5446042	A	19950829	US 1994-244195	19940527
	US 5574033	A	19961112	US 1995-505112	19950721
PRAI	JP 1991-340273	A	19911129		
	WO 1992-JP1548	A	19921127		
	US 1994-244195	A1	19940527		
OS	MARPAT	119:271203			
GI					




AB Title compds. I (R, R1 = H, alkyl; R2,R3 = H, alkyl, alkoxy, CF3, halo, nitro, amino, cyano, OH; R2R3 = methylenedioxy, R2R3 together with benzene ring may form naphthyl; A-E = SCR4R5, CH2S, NHCH2, CH2CH2; R4,R5 = H, alkyl) and their pharmacol. acceptable salts, useful as cardiotonics, were prepd. Thus, redn. of 1-(4-methoxyphenylcarbonylmethyl)-4-(4H,6H-1,3,4-thiadiazin-5-on-2-yl)pyridinium bromide with NaBH4 in MeOH-H2O gave 70%

I (R, R1, R3 = H, R3 = 4-MeO) (II). II showed cardiotonic activity at 3 times. 10-5M in isolated heart of guinea pig.


IT 151093-31-1

RL: RCT (Reactant)
 (condensation of, with phenacyl bromide)


RN 151093-31-1 CAPLUS
CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-methyl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



IT 151092-97-6P 151092-98-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and redn. of)
RN 151092-97-6 CAPLUS
CN Pyridinium, 4-(5,6-dihydro-4-methyl-5-oxo-4H-1,3,4-thiadiazin-2-yl)-1-[2-hydroxy-2-(4-methoxyphenyl)ethyl]-, bromide (9CI) (CA INDEX NAME)



RN 151092-98-7 CAPLUS
CN Pyridinium, 1-[2-(2-chlorophenyl)-2-hydroxyethyl]-4-(5,6-dihydro-4-methyl-5-oxo-4H-1,3,4-thiadiazin-2-yl)-, bromide (9CI) (CA INDEX NAME)




IT 151092-17-0P 151092-18-1P
RL: BAC (Biological activity or effector, except adverse); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses) (prepn. of, as cardiotonic)


RN 151092-17-0 CAPLUS

CN 4H-1,3,4-Thiadiazin-5(6H)-one, 4-methyl-2-[1,2,3,6-tetrahydro-1-[2-hydroxy-2-(4-methoxyphenyl)ethyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 151092-18-1 CAPLUS

CN 4H-1,3,4-Thiadiazin-5(6H)-one, 2-[1-[2-(2-chlorophenyl)-2-hydroxyethyl]-1,2,3,6-tetrahydro-4-pyridinyl]-4-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 30 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1993:485790 CAPLUS
 DN 119:85790
 TI 5-[4-(Benzyl)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related
 analogs: new reversible, highly potent, and selective monoamine oxidase type B inhibitors
 AU Mazouz, Fathi; Gueddari, Salah; Burstein, Claude; Mansuy, Daniel; Milcent,
 Rene
 CS Fac. Med. Xavier Bichat, Univ. Paris, Paris, F-75018, Fr.
 SO J. Med. Chem. (1993), 36(9), 1157-67
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 GI




AB Thirty-three new 5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivs. including related analogs, designed as inhibitors of monoamine oxidase type B (MAO B), were prep'd. and investigated both in vitro and ex vivo for their abilities to inhibit selectively rat brain MAO B over MAO A. Three inhibitors acted as reversible, highly potent, and selective MAO B inhibitors, I and 2 closely related homologs, the corresponding oxadiazolethione (II) and the alc. (III). Their IC₅₀(MAO B) values were in the low nanomolar range of 1.4-4.6 nM and their selectivities, estd. by the ratio of IC₅₀ values (A/B), are from 3200 to >74 400. I showed the highest activity against MAO B. Its IC₅₀ was evaluated to be 1.4 nM with a quasitotal selectivity (>71 400) toward this enzyme. In ex vivo studies, I showed a reversible and short duration of action. MAO B was markedly inhibited with the oral dose of 1 mg/kg without any alteration of MAO A, and the inhibition almost did not exceed 24 h. Its ED₅₀ (1 h after oral administration) was evaluated to be 0.56 mg (1.7 .mu.mol)/kg. Remarkably, MAO A was not affected at doses as high as 1500 mg/kg, po. In addn., no apparent toxicity or behavioral anomaly was obsd. during the treatment even at the max. administered dose. Structure-activity studies emphasize the existence of 3 binding sites to the enzyme with a special importance of the terminal Ph. Anal. of the inhibition kinetics indicated that I acts in a 2-step mechanism as a competitive, slow, and tight-binding inhibitor of MAO B with a Ki value of 0.22 .mu.M and an


overall K_i^* value at equil. of 0.7 nM.
IT 147807-46-3P 147807-47-4P 147807-48-5P
147807-49-6P 147807-50-9P 147807-51-0P
147807-52-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and monoamine oxidase B inhibition by, structure in relation
to)
RN 147807-46-3 CAPLUS
CN 4H-1,3,4-Oxadiazine-4-propanenitrile, 5,6-dihydro-2-[4-[(3-
methoxyphenyl)methoxy]phenyl]-5-oxo- (9CI) (CA INDEX NAME)




RN 147807-47-4 CAPLUS
CN 4H-1,3,4-Oxadiazine-4-propanenitrile, 5,6-dihydro-2-[4-[(4-
methoxyphenyl)methoxy]phenyl]-5-oxo- (9CI) (CA INDEX NAME)



RN 147807-48-5 CAPLUS
CN 4H-1,3,4-Oxadiazine-4-propanenitrile, 5,6-dihydro-2-[4-[(3-
methylphenyl)methoxy]phenyl]-5-oxo- (9CI) (CA INDEX NAME)




RN 147807-49-6 CAPLUS
CN 4H-1,3,4-Oxadiazine-4-propanenitrile, 5,6-dihydro-2-[4-[(4-
methylphenyl)methoxy]phenyl]-5-oxo- (9CI) (CA INDEX NAME)




RN 147807-50-9 CAPLUS

CN 4H-1,3,4-Oxadiazine-4-propanenitrile, 2-[4-[(3-chlorophenyl)methoxy]phenyl]-5,6-dihydro-5-oxo- (9CI) (CA INDEX NAME)




RN 147807-51-0 CAPLUS

CN 4H-1,3,4-Oxadiazine-4-propanenitrile, 2-[4-[(4-chlorophenyl)methoxy]phenyl]-5,6-dihydro-5-oxo- (9CI) (CA INDEX NAME)



RN 147807-52-1 CAPLUS

CN 4H-1,3,4-Oxadiazine-4-propanenitrile, 5,6-dihydro-2-[4-[(4-nitrophenyl)methoxy]phenyl]-5-oxo- (9CI) (CA INDEX NAME)




IT 147807-45-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 147807-45-2 CAPLUS

CN 4H-1,3,4-Oxadiazine-4-propanenitrile, 5,6-dihydro-5-oxo-2-[(4-phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 31 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1992:531213 CAPLUS
 DN 117:131213
 TI Preparation of dihydropyridazinones and related compounds as fungicides
 IN Egan, Anne Ritchie; Michelotti, Enrique Luis; Ross, Ronald, Jr.; Wilson,
 Willie Joe
 PA Rohm and Haas Co., USA
 SO Eur. Pat. Appl., 85 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 478195	A1	19920401	EP 1991-308404	19910913
	EP 478195	B1	19990526		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 180475	E	19990615	AT 1991-308404	19910913
	ES 2131506	T3	19990801	ES 1991-308404	19910913
	CA 2051471	AA	19920322	CA 1991-2051471	19910916
	AU 9184602	A1	19920326	AU 1991-84602	19910919
	AU 651375	B2	19940721		
	ZA 9107466	A	19920527	ZA 1991-7466	19910919
	HU 59379	A2	19920528	HU 1991-3020	19910920
	BR 9104043	A	19920602	BR 1991-4043	19910920
	JP 05025164	A2	19930202	JP 1991-241806	19910920
	JP 3166782	B2	20010514		
	JP 2001139553	A2	20010522	JP 2000-341752	19910920
	JP 2001172264	A2	20010626	JP 2000-342863	19910920
	JP 2001181261	A2	20010703	JP 2000-342924	19910920
	CN 1069729	A	19930310	CN 1991-110000	19911028
	CN 1038249	B	19980506		
	JP 05286944	A2	19931102	JP 1992-62341	19920318
	US 5552409	A	19960903	US 1994-221229	19940331
	US 5631254	A	19970520	US 1995-467384	19950606
	US 5753642	A	19980519	US 1995-462472	19950606
	US 5726176	A	19980310	US 1996-740546	19961030
	US 5726162	A	19980310	US 1996-741248	19961030
	US 5728698	A	19980317	US 1996-740548	19961030
	US 5728694	A	19980317	US 1996-740549	19961030
	US 5728715	A	19980317	US 1996-741249	19961030
PRAI	US 1990-586633	A	19900921		
	US 1991-749576	A	19910828		
	JP 1991-241806	A3	19910920		
	US 1994-221229	A3	19940331		
	US 1995-467384	A3	19950606		
OS	MARPAT	117:131213			
GI					




AB Title compds. I [A = (CHR₂)_nCHR₇Z, (CHR₂)_nOZ, (CHR₂)_nSZ, OCHR₇Z, etc.; n = 0-2; D = N, CR₂; Q = (substituted) Ph, -naphthyl, -styryl, -pyridyl, -quinolyl, -indolyl, etc.; Z = CO, C:S; R₁ = (substituted) alkyl, -alkynyl, -alkenyl, Ph, etc.; R₂ = H, Cl-3 alkyl, Ph, halo; R₇ = R₂, alkenylalkenyl, alkynyl, dialkynyl, halolkynyl, alkenylalkynyl; or R₂ and R₇ form fused Ph ring, etc., with provisos] were prep'd. as medical and agrochem. fungicides. Thus, 3-(4-chlorobenzoyl)propionic acid (prepn. given) in abs. EtOH was refluxed for 3 h with hydrazine and the dihydropyridazinone formed was N-alkynylated by 1-bromopent-2-yne to give title compd. II. II at 200 ppm gave 99% control of Pyricularia oryzae on rice and at 100 ppm gave 100% control of Candida albicans.
 IT **142028-52-2P**
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. of, as fungicide)
 RN 142028-52-2 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-chlorophenyl)-4-(2-pentynyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 32 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1992:235588 CAPLUS
 DN 116:235588
 TI Synthesis of 1,2,4-triazino[3,4-d][1,3,4]oxadiazine
 AU Nabar, U. V.; Mayadeo, M. S.; Deodhar, K. D.
 CS Org. Chem. Res. Lab., Ramnarayan Ruia Coll., Bombay, 400 019, India
 SO J. Indian Chem. Soc. (1991), 68(10), 574-6
 CODEN: JICSAH; ISSN: 0019-4522
 DT Journal
 LA English
 OS CASREACT 116:235588
 GI




AB Title compds. I (R = H, Ph) were prep'd. by the cyclocondensation of oxadiazinethione deriv. II (X = S) with RNHNH₂. II (X = S) was prep'd. by N-alkylation of oxadiazinone III with BrCH₂CO₂Et, followed by sulfuration with P₂S₅.
 IT 141213-03-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and esterification of)
 RN 141213-03-8 CAPLUS
 CN 4H-1,3,4-Oxadiazine-4-acetic acid, 5,6-dihydro-2-(2-hydroxyphenyl)-5-oxo-
 (9CI) (CA INDEX NAME)



IT 141212-98-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and sulfuration of)
 RN 141212-98-8 CAPLUS
 CN 4H-1,3,4-Oxadiazine-4-acetic acid, 5,6-dihydro-2-(2-hydroxyphenyl)-5-

oxo-,
ethyl ester (9CI) (CA INDEX NAME)




IT 141213-02-7P


RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 141213-02-7 CAPLUS


CN 4H-1,3,4-Oxadiazine-4-acetic acid, 5,6-dihydro-2-(2-hydroxyphenyl)-5-oxo-,
hydrazide (9CI) (CA INDEX NAME)




L4 ANSWER 33 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1992:213796 CAPLUS
 DN 116:213796
 TI Ring contraction of 5-oxo-4-phenyl-5,6-dihydro-4H-1,3,4-thiadiazine with sodium methoxide
 AU Matsubara, Yoshio; Kitano, Kazutada; Yamada, Sigeji; Yoshihara, Masakuni;
 Maeshima, Toshihisa
 CS Fac. Sci. Eng., Kinki Univ., Higashi-Osaka, 577, Japan
 SO Yakugaku Zasshi (1991), 111(11), 672-5
 CODEN: YKKZAJ; ISSN: 0031-6903
 DT Journal
 LA Japanese
 GI



AB The reaction of the title compd. I ($R = H$) with NaOMe in methanol at 35.degree. gave anilino oxothiazoline (II) in a quant. yield via cleavage of the nitrogen-nitrogen bond. The mechanisms of formation of II were discussed by a few kinetic studies using I ($R = \text{Me, Cl}$) and related reactions.
 IT **135585-97-6**
 RL: RCT (Reactant)
 (attempted reaction of, with sodium methoxide)
 RN 135585-97-6 CAPLUS
 CN 4H-1,3,4-Thiadiazin-5(6H)-one, 2,4-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 34 OF 61 CAPLUS COPYRIGHT 2002 ACS
AN 1992:128869 CAPLUS
DN 116:128869
TI Heterocycles from nitrile imines. Part IV. Chiral 4,5-dihydro-1,2,4-triazin-6-ones
AU El-Abadelah, Mustafa M.; Hussein, Ahmad Q.; Thaher, Bassam A.
CS Chem. Dep., Univ. Jordan, Amman, Jordan
SO Heterocycles (1991), 32(10), 1879-95
CODEN: HTCYAM; ISSN: 0385-5414
DT Journal
LA English
OS CASREACT 116:128869
GI




AB The reaction of nitrile imines $\text{RC}(\text{COPh})\text{N}=\text{N}-\text{C}_6\text{H}_4\text{R}1-4$ (I; R = COMe, CO2Me; R1 = H, Me, OMe, F, Cl, Br, iodo, cyano, COMe, NO2, CO2Me) with α -amino esters, e.g., II (R2 = H, Me, CHMe2, Ph, CH2OH, PhCH2, R3 = H) proceeds with no detectable racemization and constitutes a convenient synthetic route to 4,5-dihydro-1,2,4-triazin-6-ones III. Permanganate oxidn. of the heterocycles III affords the corresponding 1,2,4-triazin-6-ones. The reaction of I with β -amino esters gives the resp. acyclic amidrazone adducts $4-\text{R}1\text{C}_6\text{H}_4\text{NHN:CRNH}(\text{CH}_2)_2\text{CO}_2\text{Me}$ (R = COMe, R1 = F, Cl).


IT	139455-67-7P	139455-68-8P	139455-69-9P
	139455-70-2P	139455-71-3P	139455-72-4P
	139455-73-5P	139455-74-6P	139455-75-7P
	139455-76-8P	139455-77-9P	139455-78-0P
	139455-79-1P	139455-80-4P	139455-81-5P
	139455-82-6P	139455-83-7P	139455-84-8P
	139455-85-9P	139455-86-0P	139455-87-1P
	139455-88-2P	139455-89-3P	139455-90-6P
	139455-91-7P	139455-92-8P	139455-93-9P
	139455-94-0P	139455-95-1P	139455-96-2P
	139455-97-3P	139455-98-4P	139455-99-5P
	139456-00-1P	139456-01-2P	139456-02-3P
	139456-03-4P	139456-04-5P	139456-05-6P
	139456-06-7P	139456-19-2P	139456-20-5P
	139456-21-6P	139456-22-7P	139560-65-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 139455-67-7 CAPLUS
CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-chlorophenyl)-2,5-dihydro- (9CI)
(CA INDEX NAME)



RN 139455-68-8 CAPLUS
CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-2,5-dihydro-1-(4-iodophenyl)- (9CI)
(CA INDEX NAME)




RN 139455-69-9 CAPLUS
CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-acetylphenyl)-2,5-dihydro- (9CI)
(CA INDEX NAME)




RN 139455-70-2 CAPLUS
CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-2,5-dihydro-1-(4-methoxyphenyl)-5-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 139455-71-3 CAPLUS
CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-fluorophenyl)-2,5-dihydro-5-methyl-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-72-4 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-chlorophenyl)-2,5-dihydro-5-methyl-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-73-5 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-bromophenyl)-2,5-dihydro-5-methyl-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-74-6 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-fluorophenyl)-2,5-dihydro-5-(1-methylethyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-75-7 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-chlorophenyl)-2,5-dihydro-5-(1-methylethyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-76-8 CAPLUS

CN 1,2,4-Triazine-3-carboxylic acid, 1,2,5,6-tetrahydro-5-(1-methylethyl)-1-(4-nitrophenyl)-6-oxo-, methyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-77-9 CAPLUS


CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-fluorophenyl)-2,5-dihydro-5-(2-methylpropyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 139455-78-0 CAPLUS
CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-chlorophenyl)-2,5-dihydro-5-(2-methylpropyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 139455-79-1 CAPLUS
CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-bromophenyl)-2,5-dihydro-5-(2-methylpropyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 139455-80-4 CAPLUS
CN Benzonitrile, 4-[3-acetyl-5,6-dihydro-5-(2-methylpropyl)-6-oxo-1,2,4-triazin-1(2H)-yl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 139455-81-5 CAPLUS
CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-fluorophenyl)-2,5-dihydro-5-(1-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-82-6 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-chlorophenyl)-2,5-dihydro-5-(1-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-83-7 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-bromophenyl)-2,5-dihydro-5-(1-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-84-8 CAPLUS

CN Benzonitrile, 4-[3-acetyl-5,6-dihydro-5-(1-methylpropyl)-6-oxo-1,2,4-triazin-1(2H)-yl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-85-9 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-fluorophenyl)-2,5-dihydro-5-[2-(methylthio)ethyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-86-0 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-chlorophenyl)-2,5-dihydro-5-[2-(methylthio)ethyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-87-1 CAPLUS


CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-fluorophenyl)-2,5-dihydro-5-(hydroxymethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 139455-88-2 CAPLUS
CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-chlorophenyl)-2,5-dihydro-5-(hydroxymethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 139455-89-3 CAPLUS
CN 1,2,4-Triazine-5-acetic acid, 3-acetyl-1-(4-fluorophenyl)-1,2,5,6-tetrahydro-6-oxo-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 139455-90-6 CAPLUS
CN 1,2,4-Triazine-5-acetic acid, 3-acetyl-1-(4-chlorophenyl)-1,2,5,6-tetrahydro-6-oxo-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 139455-91-7 CAPLUS
CN 1,2,4-Triazine-5-propanoic acid, 3-acetyl-1-(4-fluorophenyl)-1,2,5,6-tetrahydro-6-oxo-, methyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-92-8 CAPLUS

CN 1,2,4-Triazine-5-propanoic acid, 3-acetyl-1-(4-chlorophenyl)-1,2,5,6-tetrahydro-6-oxo-, methyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-93-9 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-2,5-dihydro-1,5-diphenyl-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-94-0 CAPLUS

CN 1,2,4-Triazine-3-carboxylic acid, 1,2,5,6-tetrahydro-1-(4-nitrophenyl)-6-oxo-5-phenyl-, methyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-95-1 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-benzoyl-2,5-dihydro-1-phenyl-5-(phenylmethyl)-,
(S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-96-2 CAPLUS

CN 1,2,4-Triazine-3-carboxylic acid, 1-(4-fluorophenyl)-1,2,5,6-tetrahydro-6-
oxo-5-(phenylmethyl)-, methyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-97-3 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-chlorophenyl)-2,5-dihydro-5-(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-98-4 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-2,5-dihydro-5-[(4-hydroxyphenyl)methyl]-1-(4-methylphenyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139455-99-5 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-chlorophenyl)-2,5-dihydro-5-[(4-hydroxyphenyl)methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139456-00-1 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-bromophenyl)-2,5-dihydro-5-[(4-hydroxyphenyl)methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139456-01-2 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-fluorophenyl)-2,5-dihydro-5-(1H-indol-3-ylmethyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139456-02-3 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-chlorophenyl)-2,5-dihydro-5-(1H-indol-3-ylmethyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139456-03-4 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-chlorophenyl)-2,5-dihydro-5-(1H-imidazol-4-ylmethyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139456-04-5 CAPLUS


CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-2,5-dihydro-5,5-dimethyl-1-phenyl- (9CI)

(CA INDEX NAME)




RN 139456-05-6 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-fluorophenyl)-2,5-dihydro-5,5-dimethyl- (9CI) (CA INDEX NAME)




RN 139456-06-7 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-chlorophenyl)-2,5-dihydro-5,5-dimethyl- (9CI) (CA INDEX NAME)




RN 139456-19-2 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-fluorophenyl)-4,5-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 139456-20-5 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-chlorophenyl)-4,5-dihydro-4-methyl-
(9CI) (CA INDEX NAME)




RN 139456-21-6 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-fluorophenyl)-4,5-dihydro-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 139456-22-7 CAPLUS

CN 1,2,4-Triazin-6(1H)-one, 3-acetyl-1-(4-chlorophenyl)-4,5-dihydro-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 139560-65-9 CAPLUS

L4 ANSWER 35 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1991:536053 CAPLUS
 DN 115:136053
 TI Synthesis of 2,4-diphenyl-5-oxo-4,5-dihydro-1,3,4-thiadiazole and
 2,4-diphenyl-5-oxo-5,6-dihydro-1,3,4-thiadiazine
 AU Matsubara, Yoshio; Kitano, Kazutada; Kashimoto, Tetsuya; Yamada, Sigeji;
 Yoshihara, Masakuni; Maeshima, Toshihisa
 CS Fac. Sci. Eng., Kinki Univ., Higashi-Osaka, 577, Japan
 SO Chem. Express (1991), 6(6), 411-14
 CODEN: CHEXEU; ISSN: 0911-9566
 DT Journal
 LA Japanese
 OS CASREACT 115:136053
 GI




AB The title compds. I and II were prep'd. in 73 and 90% yield resp. by
 reaction of PhNHNHC(S)Ph, prep'd. from thiation of PhNHNHBZ with
 Lawesson's
 reagent, with ClCO₂CH₂Ph or BrCH₂CO₂H.
 IT 135585-97-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 135585-97-6 CAPLUS
 CN 4H-1,3,4-Thiadiazin-5(6H)-one, 2,4-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 36 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1991:514776 CAPLUS
 DN 115:114776
 TI Preparation of oxadiazinyl organophosphorothioates as insecticides
 IN Dekeyser, Mark A.; Moore, Richard C.
 PA Uniroyal Chemical Co., Inc., USA; Uniroyal Chemical Ltd.
 SO U.S., 7 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5010068	A	19910423	US 1989-454668	19891221
	WO 9109863	A1	19910711	WO 1990-US7448	19901214
	W: AU, BR, CA, JP, KR RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	AU 9171766	A1	19910724	AU 1991-71766	19901214
	ZA 9010191	A	19911030	ZA 1990-10191	19901218
PRAI	US 1989-454668		19891221		
	WO 1990-US7448		19901214		
OS	MARPAT 115:114776				
GI					




AB The title compds. [I; R1 = H, C1-12 alkyl, C2-13 alkoxy, C7-9 aralkyl, Ph, NO₂, etc.; R2 = C1-4 alkyl; R3 = C1-4 alkyl, alkoxy, alkylthio; X = O, S], effective insecticides, nematocides, and mitocides, are prepd. ClCH₂COCl was added dropwise to a soln. of ClCH₂CONHNHPh (prepn. given) in MeCOEt with stirring, and the soln. was refluxed to give oxadiazinone deriv. II, which was treated with (EtO)₂P(S)NH₄⁺ in Me₂CO to give I (R1 = H, R2 = Et, R3 = EtO, X = S) (III). III showed 100% control of corn rootworm at 500 ppm. Also prepd. were other I, some of which showed 100% control of mites at 100 ppm and 100% control of nematode at 50 ppm.

IT 135588-23-7P 135588-24-8P 135588-25-9P
 135588-26-0P 135588-27-1P 135588-28-2P
 135588-29-3P 135616-93-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and reaction of, in prepn. of pesticide)


RN 135588-23-7 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(chloromethyl)-4-phenyl- (9CI) (CA
 INDEX

NAME)




RN 135588-24-8 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(chloromethyl)-4-(2-chloro-6-methylphenyl)-
(9CI) (CA INDEX NAME)




RN 135588-25-9 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(chloromethyl)-4-(2-nitrophenyl)- (9CI)
(CA INDEX NAME)




RN 135588-26-0 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(chloromethyl)-4-(2-methylphenyl)- (9CI)
(CA INDEX NAME)




RN 135588-27-1 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(chloromethyl)-4-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)




RN 135588-28-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(chloromethyl)-4-[4-(methoxysulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 135588-29-3 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[1,1'-biphenyl]-2-yl-2-(chloromethyl)- (9CI) (CA INDEX NAME)



RN 135616-93-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(chloromethyl)-4-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 135588-30-6P 135588-31-7P 135588-32-8P
135588-33-9P 135588-34-0P 135588-35-1P
135588-36-2P 135588-37-3P 135588-38-4P
135588-39-5P 135588-40-8P 135588-41-9P
135588-42-0P 135588-43-1P 135588-44-2P
135588-45-3P 135588-46-4P 135588-47-5P
135616-94-3P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as insecticide)


RN 135588-30-6 CAPLUS
CN Phosphorodithioic acid, S-[(5,6-dihydro-5-oxo-4-phenyl-4H-1,3,4-oxadiazin-

2-yl)methyl] O,O-diethyl ester (9CI) (CA INDEX NAME)




RN 135588-31-7 CAPLUS

CN Phosphorodithioic acid, S-[5,6-dihydro-4-(4-methoxyphenyl)-5-oxo-4H-1,3,4-oxadiazin-2-yl]methyl] O,O-diethyl ester (9CI) (CA INDEX NAME)




RN 135588-32-8 CAPLUS

CN Phosphorodithioic acid, S-[5,6-dihydro-4-(4-methylphenyl)-5-oxo-4H-1,3,4-oxadiazin-2-yl]methyl] O,O-diethyl ester (9CI) (CA INDEX NAME)




RN 135588-33-9 CAPLUS

CN Phosphorodithioic acid, S-[5,6-dihydro-4-(2-methylphenyl)-5-oxo-4H-1,3,4-oxadiazin-2-yl]methyl] O,O-diethyl ester (9CI) (CA INDEX NAME)




RN 135588-34-0 CAPLUS

CN Phosphorodithioic acid, S-[5,6-dihydro-4-(2-nitrophenyl)-5-oxo-4H-1,3,4-oxadiazin-2-yl]methyl] O,O-diethyl ester (9CI) (CA INDEX NAME)




RN 135588-35-1 CAPLUS

CN Phosphorodithioic acid, S-[[4-(2-chloro-6-methylphenyl)-5,6-dihydro-5-oxo-4H-1,3,4-oxadiazin-2-yl]methyl] O,O-diethyl ester (9CI) (CA INDEX NAME)




RN 135588-36-2 CAPLUS

CN Phosphorodithioic acid, S-[[5,6-dihydro-4-[4-(methylsulfonyl)phenyl]-5-oxo-4H-1,3,4-oxadiazin-2-yl]methyl] O,O-diethyl ester (9CI) (CA INDEX NAME)




RN 135588-37-3 CAPLUS

CN Phosphorotrithioic acid, S-[[5,6-dihydro-4-(2-methylphenyl)-5-oxo-4H-1,3,4-oxadiazin-2-yl]methyl] O-ethyl S-propyl ester (9CI) (CA INDEX NAME)




RN 135588-38-4 CAPLUS

CN Phosphorotrithioic acid, S-[[5,6-dihydro-4-(4-methylphenyl)-5-oxo-4H-1,3,4-oxadiazin-2-yl]methyl] O-ethyl S-propyl ester (9CI) (CA INDEX NAME)




RN 135588-39-5 CAPLUS

CN Phosphorodithioic acid, S-[5,6-dihydro-4-(4-methylphenyl)-5-oxo-4H-1,3,4-oxadiazin-2-yl]methyl] O-ethyl O-methyl ester (9CI) (CA INDEX NAME)




RN 135588-40-8 CAPLUS

CN Phosphorodithioic acid, S-[5,6-dihydro-4-(4-methoxyphenyl)-5-oxo-4H-1,3,4-oxadiazin-2-yl]methyl] O-ethyl O-methyl ester (9CI) (CA INDEX NAME)




RN 135588-41-9 CAPLUS

CN Phosphorotrichthioic acid, S-[5,6-dihydro-4-phenyl-4H-1,3,4-oxadiazin-2-yl]methyl] O-ethyl S-propyl ester (9CI) (CA INDEX NAME)




RN 135588-42-0 CAPLUS

CN Phosphorotrichthioic acid, S-[5,6-dihydro-4-phenyl-4H-1,3,4-oxadiazin-2-yl]methyl] O-ethyl S-(1-methylpropyl) ester (9CI) (CA INDEX NAME)




RN 135588-43-1 CAPLUS

CN Phosphorotriothioic acid, S-[(5,6-dihydro-5-oxo-4-phenyl-4H-1,3,4-oxadiazin-2-yl)methyl] O-ethyl S-(2-methylpropyl) ester (9CI) (CA INDEX NAME)




RN 135588-44-2 CAPLUS

CN Phosphorodithioic acid, S-[[5,6-dihydro-5-oxo-4-[2-(trifluoromethyl)phenyl]-4H-1,3,4-oxadiazin-2-yl]methyl] O,O-diethyl ester (9CI) (CA INDEX NAME)




RN 135588-45-3 CAPLUS

CN Phosphorotriothioic acid, S-[(4-[1,1'-biphenyl]-2-yl-5,6-dihydro-5-oxo-4H-1,3,4-oxadiazin-2-yl)methyl] O-ethyl S-propyl ester (9CI) (CA INDEX NAME)




RN 135588-46-4 CAPLUS


CN Phosphorodithioic acid, S-[(4-[1,1'-biphenyl]-2-yl-5,6-dihydro-5-oxo-4H-1,3,4-oxadiazin-2-yl)methyl] O,O-diethyl ester (9CI) (CA INDEX NAME)




RN 135588-47-5 CAPLUS
CN Phosphorotritioic acid, S-[{(4-[1,1'-biphenyl]-2-yl)-5,6-dihydro-5-oxo-1,3,4-oxadiazin-2-yl}methyl] O-ethyl S-(2-methylpropyl) ester (9CI) (CA INDEX NAME)




RN 135616-94-3 CAPLUS
CN Phosphorotritioic acid, S-[{[5,6-dihydro-5-oxo-4-[2-(trifluoromethyl)phenyl]-4H-1,3,4-oxadiazin-2-yl}methyl] O-ethyl S-propyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 37 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1991:76982 CAPLUS
 DN 114:76982
 TI Quantitative structure-activity relationships in acaricidal
 4H-1,3,4-oxadiazin-5(6H)-ones
 AU Dekeyser, Mark A.; Borth, David M.; Moore, Richard C.; Mishra, Anupama
 CS Res. Lab., Uniroyal Chem. Ltd., Guelph, ON, N1H 6N3, Can.
 SO J. Agric. Food Chem. (1991), 39(2), 374-9
 CODEN: JAFCAU; ISSN: 0021-8561
 DT Journal
 LA English
 OS CASREACT 114:76982
 AB A series of 37 2,4-diphenyl-1,3,4-oxadiazin-5-one acaricides were
 synthesized. Their acaricidal activity was related to their
 physicochem.
 properties by using a Hansch-type regression equation. The initial
 equation developed was validated by predicting the activity of an addnl.
 9
 compds. which were subsequently synthesized and tested. The QSAR study
 was carried out to optimize activity, resulting in a 6-fold increase in
 activity over the lead compd. Two novel aspects of the study were the
 use
 of a new technique for selecting the compds. in the original set, so as
 to
 maximize the information obtained for a given amt. of synthesis effort,
 and the use of a statistical technique called censored data regression
 to
 make use of information from compds. that were insufficiently acaricidal
 to allow detn. of an ED50.
 IT 109462-78-4 109463-19-6 109463-23-2
 109491-76-1 109491-77-2 109491-78-3
 109491-79-4 109491-80-7 109491-81-8
 109491-86-3 109491-87-4 109491-88-5
 109491-89-6 109491-94-3 109491-97-6
 109492-00-4 109525-24-8 109551-08-8
 129786-74-9 129786-75-0 129786-76-1
 129786-77-2 129786-78-3 129786-79-4
 129786-80-7 129786-81-8 129786-82-9
 129786-83-0 129786-84-1 129786-85-2
 129786-86-3 129786-87-4 129786-88-5
 129786-89-6
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except
 adverse); BIOL (Biological study); USES (Uses)
 (acaricidal activity of, synthesis difficulty and efficiency data
 for)
 RN 109462-78-4 CAPLUS
 CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-phenyl- (9CI) (CA
 INDEX NAME)




RN 109463-19-6 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2,4-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 109463-23-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-methylphenyl)-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 109491-76-1 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-methoxyphenyl)-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 109491-77-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-methoxyphenyl)-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 109491-78-3 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-bromophenyl)-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 109491-79-4 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-fluorophenyl)-2-(4-methylphenyl)- (9CI)


(CA INDEX NAME)



RN 109491-80-7 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-fluorophenyl)-2-(4-methylphenyl)- (9CI)


(CA INDEX NAME)



RN 109491-81-8 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-bromophenyl)-2-(4-methylphenyl)- (9CI)

(CA INDEX NAME)




RN 109491-86-3 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-[2-(phenylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 109491-87-4 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[1,1'-biphenyl]-2-yl-2-(4-methylphenyl)-
(9CI) (CA INDEX NAME)




RN 109491-88-5 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 109491-89-6 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-ethylphenyl)-2-(4-methylphenyl)-
(9CI) (CA INDEX NAME)




RN 109491-94-3 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-(4-nitrophenyl)-
(9CI) (CA INDEX NAME)




RN 109491-97-6 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 109492-00-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-aminophenyl)-2-(4-methylphenyl)-
(9CI)
(CA INDEX NAME)




RN 109525-24-8 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-fluorophenyl)-2-(4-methylphenyl)-
(9CI)
(CA INDEX NAME)




RN 109551-08-8 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-[3-(phenylmethoxy)phenyl]-
(9CI) (CA INDEX NAME)



RN 129786-74-9 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-methylphenyl)-2-(4-methylphenyl)-
(9CI)
(CA INDEX NAME)




RN 129786-75-0 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-cyclohexylphenyl)-2-(4-methylphenyl)-
(9CI) (CA INDEX NAME)




RN 129786-76-1 CAPLUS

CN Benzenaminium, 3-[5,6-dihydro-2-(4-methylphenyl)-5-oxo-4H-1,3,4-oxadiazin-4-yl]-N,N,N-trimethyl- (9CI) (CA INDEX NAME)




RN 129786-77-2 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 129786-78-3 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-aminophenyl)-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 129786-79-4 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-hydroxyphenyl)-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 129786-80-7 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-chlorophenyl)-2-(4-methylphenyl)- (9CI)


(CA INDEX NAME)



RN 129786-81-8 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(2-ethoxyphenyl)-2-(4-methylphenyl)-
(9CI)


(CA INDEX NAME)



RN 129786-82-9 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-ethylphenyl)-2-(4-methylphenyl)-
(9CI)


(CA INDEX NAME)



RN 129786-83-0 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-[3-(methylthio)phenyl]-
(9CI)


(CA INDEX NAME)




RN 129786-84-1 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[1,1'-biphenyl]-4-yl-2-(4-methylphenyl)-
(9CI)


(CA INDEX NAME)




RN 129786-85-2 CAPLUS
CN Benzoic acid, 4-[5,6-dihydro-2-(4-methylphenyl)-5-oxo-4H-1,3,4-oxadiazin-4-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 129786-86-3 CAPLUS
CN Benzoic acid, 4-[5,6-dihydro-2-(4-methylphenyl)-5-oxo-4H-1,3,4-oxadiazin-4-yl]- (9CI) (CA INDEX NAME)




RN 129786-87-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-[3-(phenylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 129786-88-5 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[1,1'-biphenyl]-3-yl-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 129786-89-6 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-[4-[[methylamino]carbonyloxy]phenyl]-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)



IT 109463-24-3P 109491-99-8P 129786-95-4P


RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. and acaricidal activity of, synthesis difficulty and efficiency

data for)

RN 109463-24-3 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-[2-(phenylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 109491-99-8 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(3-aminophenyl)-2-(4-methylphenyl)- (9CI)


(CA INDEX NAME)



RN 129786-95-4 CAPLUS

CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-(4-methylphenyl)-4-(3-nitrophenyl)- (9CI)

(CA INDEX NAME)




IT 129786-91-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 129786-91-0 CAPLUS


CN Benzenaminium, 3-[5,6-dihydro-2-(4-methylphenyl)-5-oxo-4H-1,3,4-oxadiazin-

4-yl]-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)




● I-

L4 ANSWER 38 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1990:118743 CAPLUS
 DN 112:118743
 TI Synthesis and reactions of phthalazine derivatives. Part III.
 Synthesis
 of heterocyclic compounds containing the 4-phenylphthalazin-1-yl moiety
 as
 fungicidal agents
 AU El-Gendy, Z.; Abdel-Rahman, R. M.; Abdel-Malik, M. S.
 CS Fac. Educ., Ain-Shams Univ., Cairo, Egypt
 SO Indian J. Chem., Sect. B (1989), 28B(6), 479-85
 CODEN: IJSBDB; ISSN: 0376-4699
 DT Journal
 LA English
 OS CASREACT 112:118743
 GI




AB A no. of heterocyclic systems bearing 4-phenylphthalazin-1-yl moiety have been synthesized by interaction of 1-(4-phenylphthalazin-1-ylamino)guanidine and thiosemicarbazide with .alpha.,.beta.-bifunctional compds. in neutral or alk. medium. Some of them, e.g. I [R = NHN:C(NH₂)₂, NHNHCSNH₂] or dihydrotiazines II (R₁ = 4-phenylphthalazin-1-yl, R₂ = 2-O₂NC₆H₄, Et, PhCH₂), have been evaluated for their antifungal activity against *Aspergillus niger* and *Penicillium oxalicum*.

IT 125706-95-8P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation (prepn. and fungicidal activity of))
 RN 125706-95-8 CAPLUS
 CN 4H-1,3,4-Thiadiazin-5(6H)-one, 2-[(4-oxo-3-phenyl-2-thiazolidinylidene)amino]-4-(4-phenyl-1-phthalazinyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 39 OF 61 CAPLUS COPYRIGHT 2002 ACS
 AN 1990:7457 CAPLUS
 DN 112:7457
 TI Radical reactions on N-heterocyclic compounds. IX. Oxidation reactions
 of cyclic amidrazone
 AU Schulz, Manfred; Kluge, Ralph; Hoell, Bernd Volker; Drewelies, Juergen
 CS Sekt. Chem., Tech. Hochsch. "Carl Schorlemmer" Leuna-Merseburg,
 Merseburg,
 DDR-4200, Ger. Dem. Rep.
 SO Chem. Ber. (1989), 122(10), 1983-7
 CODEN: CHBEAM; ISSN: 0009-2940
 DT Journal
 LA German
 OS CASREACT 112:7457
 GI




AB The cyclic amidrazone derivs. I and II were oxidized with dibenzoyl peroxide or bromine to give the dehydro derivs. III and IV, resp.
 Oxidn.
 of II or IV by Fremys salt yields the quinone imine deriv. Treatment of the cyclic amidrazone V with Ag₂O afforded, via an isolable silver complex, which was decompd. by nitric acid, 1,3-diphenyl-1,2-dihydro-1,2,4-triazine-5,6-dione and 1,3-diphenyl-1,6-dihydro-1,2,4-triazin-5(2H)-one. From V the dimer bis(1,3-diphenyl-1,4,5,6-tetrahydro-4-nitroso-1,2,4-triazine) VI is formed in the usual manner. On irradn. or thermal treatment VI yields the 1-(p-nitrophenyl) deriv. of V. Photolysis of VI in the presence of O₂ leads to the hydroperoxides. 2,5-Dihydro-1,3-diphenyl-1,2,4-triazin-6(1H)-one reacts with three equiv. of the stable 2,4,6-tris-tert-butylphenoxy radical to form hippuric acid and phenyldiimide.

IT 82059-55-0
 RL: RCT (Reactant)
 (oxidative ring cleavage of)
 RN 82059-55-0 CAPLUS
 CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1,3-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 40 OF 61 CAPLUS COPYRIGHT 2002 ACS
AN 1989:192785 CAPLUS
DN 110:192785
TI Inhibition of monoamine oxidase types A and B by 2-aryl-4H-1,3,4-oxadiazin-5(6H)-one derivatives
AU Mazouz, Fathi; Lebreton, Luc; Milcent, Rene; Burstein, Claude
CS Fac. Med. Xavier-Bichat, Univ. Paris 7, Paris, F-75018, Fr.
SO Eur. J. Med. Chem. (1988), 23(5), 441-51
CODEN: EJMCA5; ISSN: 0223-5234
DT Journal
LA English
OS CASREACT 110:192785
GI



AB MAO assay specificity based on substrate specificity was investigated by substrate competition expts. and 10 .mu.M serotonin and 5 .mu.M PhCH2CH2NH2 were found to ensure total substrate specificity for MAO types

A and B, resp. Twenty-five 2-aryl-4H-1,3,4-oxadiazin-5(6H)-one derivs.

I

[R = H, OMe, NO₂, Ph; R1 = H, Me; R2 = (CH₂)_nCN, (CH₂)_nBr, (CH₂)_nCO₂Me, CH₂CH₂OH, Et, Pr; n = 1-4] were synthesized and tested in vitro for their

inhibitory effects on MAO A and B. Most of them preferentially inhibited

MAO B. I (R = Ph, R1 = H, R2 = CH₂CH₂CN) was the most efficient MAO B inhibitor and acted as a competitive inhibitor on the two enzymes. Its Ki

values for MAO A and B were 11 and 0.15 .mu.M, resp. Structure-activity relationships suggest that I should interact with a hydrophobic site and nucleophilic site on MAO B for binding, while the functional group of the

N-4 substituent should compete with the substrate for the active site of the enzyme.


IT 120354-45-2P 120354-46-3P 120354-47-4P
120354-48-5P 120354-49-6P 120354-50-9P
120354-51-0P 120354-52-1P 120354-53-2P
120354-54-3P 120354-55-4P 120354-56-5P
120354-57-6P 120354-58-7P 120354-59-8P
120354-60-1P 120354-61-2P 120354-62-3P
120354-63-4P 120354-64-5P 120354-65-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and monoamineoxidase-inhibiting activity of)

RN 120354-45-2 CAPLUS


CN 4H-1,3,4-Oxadiazine-4-propanenitrile, 5,6-dihydro-5-oxo-2-phenyl- (9CI)

(CA INDEX NAME)




RN 120354-46-3 CAPLUS

CN 4H-1,3,4-Oxadiazine-4-pentanenitrile, 5,6-dihydro-5-oxo-2-phenyl- (9CI)
(CA INDEX NAME)




RN 120354-47-4 CAPLUS

CN 4H-1,3,4-Oxadiazine-4-propanenitrile, 5,6-dihydro-2-(4-methoxyphenyl)-5-oxo- (9CI) (CA INDEX NAME)




RN 120354-48-5 CAPLUS

CN 4H-1,3,4-Oxadiazine-4-pentanenitrile, 5,6-dihydro-2-(4-methoxyphenyl)-5-oxo- (9CI) (CA INDEX NAME)




RN 120354-49-6 CAPLUS

CN 4H-1,3,4-Oxadiazine-4-propanenitrile, 5,6-dihydro-2-(4-nitrophenyl)-5-oxo- (9CI) (CA INDEX NAME)




RN 120354-50-9 CAPLUS

CN 4H-1,3,4-Oxadiazine-4-propanenitrile, 5,6-dihydro-6-methyl-2-(4-nitrophenyl)-5-oxo- (9CI) (CA INDEX NAME)




RN 120354-51-0 CAPLUS

CN 4H-1,3,4-Oxadiazine-4-pentanenitrile, 5,6-dihydro-2-(4-nitrophenyl)-5-oxo- (9CI) (CA INDEX NAME)




RN 120354-52-1 CAPLUS

CN 4H-1,3,4-Oxadiazine-4-pentanenitrile, 5,6-dihydro-6-methyl-2-(4-nitrophenyl)-5-oxo- (9CI) (CA INDEX NAME)




RN 120354-53-2 CAPLUS


CN 4H-1,3,4-Oxadiazin-5(6H)-one, 4-(4-bromobutyl)-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 120354-54-3 CAPLUS
CN 4H-1,3,4-Oxadiazine-4-pentanoic acid, 5,6-dihydro-2-(4-nitrophenyl)-5-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 120354-55-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[1,1'-biphenyl]-4-yl-4-ethyl- (9CI) (CA INDEX NAME)



RN 120354-56-5 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[1,1'-biphenyl]-4-yl-4-propyl- (9CI)
(CA INDEX NAME)




RN 120354-57-6 CAPLUS
CN 4H-1,3,4-Oxadiazine-4-acetonitrile, 2-[1,1'-biphenyl]-4-yl-5,6-dihydro-5-oxo- (9CI) (CA INDEX NAME)




RN 120354-58-7 CAPLUS
CN 4H-1,3,4-Oxadiazine-4-propanenitrile, 2-[1,1'-biphenyl]-4-yl-5,6-


dihydro-5-
oxo- (9CI) (CA INDEX NAME)




RN 120354-59-8 CAPLUS
CN 4H-1,3,4-Oxadiazine-4-butanenitrile, 2-[1,1'-biphenyl]-4-yl-5,6-dihydro-
5-
oxo- (9CI) (CA INDEX NAME)




RN 120354-60-1 CAPLUS
CN 4H-1,3,4-Oxadiazine-4-pentanenitrile, 2-[1,1'-biphenyl]-4-yl-5,6-
dihydro-5-
oxo- (9CI) (CA INDEX NAME)




RN 120354-61-2 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[1,1'-biphenyl]-4-yl-4-(2-bromoethyl)-
(9CI) (CA INDEX NAME)




RN 120354-62-3 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[1,1'-biphenyl]-4-yl-4-(3-bromopropyl)-
(9CI) (CA INDEX NAME)




RN 120354-63-4 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[1,1'-biphenyl]-4-yl-4-(4-bromobutyl)- (9CI) (CA INDEX NAME)




RN 120354-64-5 CAPLUS
CN 4H-1,3,4-Oxadiazine-4-propanoic acid, 2-[1,1'-biphenyl]-4-yl-5,6-dihydro-5-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 120354-65-6 CAPLUS
CN 4H-1,3,4-Oxadiazin-5(6H)-one, 2-[1,1'-biphenyl]-4-yl-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 41 OF 61 CAPLUS COPYRIGHT 2002 ACS
AN 1988:602024 CAPLUS
DN 109:202024
TI Structure of 1,3-diphenyl-4,5-dihydro-1H-1,2,4-triazin-6-one
AU Hajjem, Bechir; Baccar, Belgacem; Kallel, Ahmed
CS Fac. Sci., Campus Univ. le Belvedere, Tunis, 1060, Tunisia
SO Acta Crystallogr., Sect. C: Cryst. Struct. Commun. (1988), C44(8),
1440-2 CODEN: ACSCEE; ISSN: 0108-2701
DT Journal
LA English
AB The title compd. is orthorhombic, space group P212121, with a 11.511(3),
b 17.96(1), and c 6.118(1) .ANG.; dc = 1.32 for Z = 4. The final R =
0.032 for 960 reflections. At. coordinates are given. The 6-membered
triazine ring is not planar. The Ph ring in position 3 is nearly
coplanar with the mean plane of the heterocycle; the other Ph ring is
twisted 57.degree. out
of that plane. Weak N-H...O intermol. H bonds of 3.004(4) .ANG.
contribute towards the crystal packing.
IT 82059-55-0, 1,3-Diphenyl-4,5-dihydro-1H-1,2,4-triazin-6-one
RL: PRP (Properties)
(crystal structure of)
RN 82059-55-0 CAPLUS
CN 1,2,4-Triazin-6(1H)-one, 2,5-dihydro-1,3-diphenyl- (9CI) (CA INDEX
NAME)





Creation date: 02-27-2004
Indexing Officer: TLAM2 - THY LAM
Team: OIPEBackFileIndexing
Dossier: 09913444

Legal Date: 02-08-2002

No.	Doccode	Number of pages
1	CTNF	9
2	892	1
3	1449	1

Total number of pages: 11

Remarks:

Order of re-scan issued on